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I Abstract
Large conductance voltage-activated calcium-sensitive potassium channels (BKca) 
are fundamental in the control of cellular excitability which is critical in the 
regulation of many physiological processes. Agents that activate the channel 
(openers) have been proposed to be potential therapeutics for a number of un-met 
clinical conditions. Several heterogeneous classes of compounds have been 
described as BKCa channel openers and preliminary pharmacophore data has 
arisen for synthetic molecules based on the structure of benzimidazolones.
The project aimed to explore a series of novel compounds based on a benzanilide 
template for BKca channel opener properties and to further probe the 
pharmacophore of BKCa channel openers. This was achieved by the validation and 
optimisation of a medium through-put, non-radioactive, rubidium (Rb+) efflux assay 
using recombinant HEK293 cells expressing BKCa channel subunits. From which 
novel benzanilides have been identified as BKCa channel openers that display 
varying degrees of potency, efficacy and co-operativity. The Rb+ efflux stimulated 
by each compound was blocked by use of the BKCa channel blockers paxilline and 
iberiotoxin demonstrating specificity to BKCa channels in the cell lines studied. 
Furthermore initial data demonstrates that some of these compounds showed 
selectivity for the BKCa channel a-subunit.
The benzanilide compounds were also examined using whole cell 
electrophysiology; all compounds tested, relative to control, produced shifts in V50 
values in the hyperpolarising direction, indicative of BKca channel activation. The 
benzanilides did not affect the kinetics of activation or deactivation. Furthermore, 
the order of effectiveness determined using whole cell electrophysiology showed 
good correlation with that obtained using the Rb+ efflux assay. Using both the 
electrophysiology and Rb+ efflux techniques BKOEtl was identified as a novel and 
potent BKCa channel opener and selected as a lead compound.
In single channel electrophysiology recordings of cloned cell lines expressing BKca 
channel subunits application of BKOEtl promoted significant, paxilline sensitive, 
BKCa channel activation. BKOEtl increased open pore probability rapidly for small 
changes in voltage and increased the voltage-sensitivity of the channel. In addition, 
BKOEtl did not affect single channel conductance. BKOEtl activated BKCa 
channels in the near absence of intracellular calcium and its effects were not 
additive. Furthermore, the compound did not affect the level of intracellular calcium. 
It was concluded that BKOEtl acts directly on the channel at a site located on the 
a-subunit. A Hill slope of unity suggested one binding site per tetrameric channel 
complex and either an intracellular or transmembrane site of interaction was 
proposed. BKOEtl also stimulated paxilline sensitive Rb+ efflux from rat bladder 
myocytes and initial Rb+ efflux studies demonstrated that BKOEtl could activate Kv 
and SK channels.
Molecular modelling of the series of benzanildies provided clues as to the chemical 
or structural features required, in particular for BKOEtl, to retain potent channel 
opener properties. In addition, physicochemical properties were determined and 
revealed commonalities for compounds to retain potent BKca channel opener 
properties. A confirmatory pharmacophore was proposed with compounds requiring 
two substituted phenyl rings, the presence of an oxygen containing group, an 
amide group provided by the linker region and hydrophobic moieties.
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Chapter 1
Introduction
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1.1 Potassium channels
Potassium (K+) selective ion channels are a diverse group of membrane 
spanning proteins of which there are at least 100 different types (Seebohm 
2005). K+ channel activation leads to the efflux of K+ ions out of the cell 
resulting in hyperpolarisation of the cell membrane or returning the membrane 
potential towards the equilibrium potential of K+ (Ek), this provides a powerful 
means of controlling the level of cellular excitability following a depolarisation 
stimulus (Figure 1.1). Opening of K+ channels by endogenous mediators (ions, 
hormones, neurotransmitters etc) provides a negative feedback mechanism 
leading to the inhibition of several physiological functions including muscle 
contraction and action potential propagation (Lawson 2000a,b; Lawson and 
Dunne 2001; Lawson and McKay 2006).
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Figure 1.1: Effect of potassium channel opening on membrane potential
Potassium channel opening leads to efflux of K+ ions resulting in 
hyperpolarisation of the membrane of the cell dampening or decreasing cell 
excitability as a consequence of depolarisation. RMP=resting membrane 
potential, E=equilibrium potential for the specified ion. Modified from Lawson 
(2000a).
Due to their critical role in physiology there have been many rapid advances in 
the investigation of K+ channels and the development of potassium channel 
openers (KCO) during the past decade (Coghlan and Carroll 2001).
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A sub-group of the K+ channel family are the calcium (Ca2+) activated potassium 
channels (Kca). They were first postulated by Gardos et al (1958) following 
observations that changes in potassium permeability across the plasma 
membrane of erythrocytes occurred in response to minor changes in 
intracellular calcium. Since then three groups of Kca channels have been 
identified that differ in their voltage-dependence and calcium sensitivity and are 
classified based on their single channel conductance (Garcia and Kaczorowski 
1992); large-conductance voltage-activated calcium-sensitive potassium 
channels (BKCa), intermediate conductance K+ channels (IK) and small 
conductance K+ channels (SK).
BKca channels have received the most attention for their physiological roles and 
as a potential pharmacological target for un-met clinical conditions.
1.2 Large conductance voltage-activated calcium-sensitive 
potassium channels (BKCa)
Single channel recordings of BKca channel currents were first reported in 
chromaffin cell membranes (Marty et al 1981), cultured nerve cells (Pallota et al
1981) and membrane preparations of skeletal muscle t-tubules (Latorre et al
1982). BKca channels are unique among K+ channels in demonstrating a large 
single channel conductance of around 200-300pS in symmetrical 0.1M 
potassium chloride (KCI), (Marty et al 1981; Pallota et al 1981; Latorre et al 
1982). BKca channels display a high degree of potassium selectivity with a 
permeability ratio >50 relative to sodium (Na+) and to rubidium (Rb+) and >200 
for caesium (Cs+), (Blatz and Magleby 1984; Latorre et al 1989; Gutman et al 
2003).
BKca channels have been characterised pharmacologically by their specific 
sensitivity to block by the peptide iberiotoxin (IbTX) and the tremorgenic 
mycotoxin paxilline (pax). Other non-specific blockers of BKca channels include 
tetraethylammonium (TEA) and 4-aminopyridine (4-AP), (Gutman et al 2003). 
The unique feature of BKca channels is its ‘dual’ ability to be activated by both 
changes in intracellular Ca2+ and plasmalemmal membrane voltage.
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BKca channels are present in many different species such as nematodes and 
insects (Ghatta et al 2006) and the gene was first identified from the slopoke 
locus (dSlo) of Drosophila melanogaster (Atkinson et al 1991) from which 
subsequent homologues were cloned from human brain (hSlo), mouse (mSlo) 
and skeletal muscle (Butler et al 1993; Dworetsky et al 1994).
BKCa channels have since been shown to be ubiquitously expressed in nearly 
all excitable and non-excitable cell types (Korovkina et al 2002). Expression has 
been reported in various brain regions and within axons, nerve terminals, 
glioma cells (Tseng-Crank et al 1996; Knaus et al 1996; LiU et al 2002) and 
within the inner mitochondrial membrane of neurons and cardiomyocytes 
(Douglas et al 2006). BKca channels have also been shown to be expressed in 
smooth muscle of the vasculature (Tanaka et al 1997), uterus (Khan et al 2001), 
stomach and bladder. Skeletal muscle (Tseng-Crank et al 1994; Tanaka et al 
1997; Jiang et al 1999), epithelial cells (Grunnet et al 2005), endothelial cells 
(Nilius and Droogmans 2001), endocrine cells (Xie and Mccobb 1998; Prakriya 
and Lingle 1999), neutrophils and eosinophils (Ahluwalia et al 2004) also 
express BKca channels.
1.3 BKCa channel structure
Cloning revealed BKca channels to be members of the S4 superfamily of 
voltage activated ion channels similar to voltage dependent K+ (Kv), Na+ (Nav) 
and Ca2+ (VDCC), (Diaz et al 1998). Structurally BKca channels consist of a 
pore forming a-subunit and a regulatory p- subunit. Functional channels can be 
formed by a tetrameric complex of four a-subunits alone or found in a 1:1 
stoichometry associated with four p-subunits (Garcia-Calvo et al 1994; Toro et 
al 1998), (Figure 1.2).
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Figure 1.2: Topological structure of BKCa channels
Proposed topological structure of BKca channels highlighting the 1:1 
stoichometry of the a and p-subunit. The channel is arranged with the pore 
formed at the centre by four a-subunits. Modified from and Lu et al (2006) and 
Cox (2007).
1.3.1 BKCa channel p-subunit
Currently one group of p-subunits (p i-p4) have been identified from mammalian 
tissues with each subunit encoded by a separate gene (KCNMB1-4), (Uebele et 
al 2000). p-subunits expressed on their own cannot form functional channels 
(Knaus et al 1994a; McManus et al 1995) but when co-expressed with BKca 
channel a-subunits have a diversity of regulatory effects on channel function as 
described in Table 1.1 (Dworetsky et al 1996; Meera et al 1996; Nimingean and 
Magleby 1999; Orio et a /2004; Orio and Latorre 2005).
P-subunits are smaller than a-subunits and are composed of two 
transmembrane segments of between 191-270 amino acids and are arranged 
with intracellular N- and C-termini (Figure 1.3). The two transmembrane 
segments are linked by a long (116-128 amino acid) extracellular loop 
containing four putative glycosylation sites and four cysteine residues enabling 
disulphide bridge formation (Knaus et al 1994a; McManus et al 1995).
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Table 1.1: The pharmacology and physiology of p-subunits
ChTX=Charybdotoxin, STOC=Spontaneous transient outward currents
The presence of p2 subunit and some splice variants of the p3 subunit impart 
rapid inactivation properties to BKCa channels; this is conferred by the presence 
of an inactivation peptide at the NH2 terminal of subunits. The inactivation 
peptide is a hydrophobic domain followed by a region of positive charged 
residues and is similar to that of Shaker channels. The removal of the NH2 
domain eliminated inactivation properties of these subunits (Zeng et al 2001; 
Orio et al 2002). Inactivation has been proposed to occur by the entry of the first 
2-4 residues of the cytosolic NH2 terminus into the pore occluding permeation of 
K+ ions (Xia et al 2003).
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1.3.2 BKCa channel a-subunit
The a-subunit is derived from a single gene (KCNMA-1) located on 
chromosome 10 at locus 10q22 that encodes an 1154 amino acid residue 
subunit. This forms a pore forming a-subunit composed of an exoplasmic N’ 
terminus sequence, a non-conserved linker sequence and eleven hydrophobic 
domains. These domains contain a voltage sensor, a p-loop pore region and 
form part of a large intracellular C’ terminus tail region (Meera et al 1997; 
Magleby 2003). The core region of the channel is composed of six 
transmembrane spanning domains (S1-S6) that exhibit high homology to the a- 
subunit of Kv channels (Toro et al 1998). However, BKCa channels have an 
additional S0 transmembrane domain that places the N’terminus extracellular 
(Wallner et al 1996; Meera et al 1997). The S0 domain forms a site for functional 
coupling with the (3-subunit and its consequent facility to modulate BKca channel 
activity (Meera et al 1997; Toro et al 1998), (Figure 1.3).
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Figure 1.3: The structure of the BKCa channel a and p subunit
Schematic representation of the structure of a- and p-subunits highlighting 
major structural components, \j/= site of glycosylation. Re-drawn with reference 
to Magleby 2003 and Ghatta et al 2006.
7
The potassium selective pore is formed at the centre of four a-subunits from a 
motif that comprises the S5 and S6 domains and the p-loop domain. The p-loop 
from each subunit contains the characteristic K+ channel selectivity filter motif of 
the amino acid residues ‘TVGTG’ which provide carbonyl oxygen atoms 
arranged to form four binding sites for potassium (Latorre 1989; Orio et al 2002; 
Yellen 2002). The crystal structure of BKca channels remains as yet un-resolved, 
however the crystal structures of five different bacterial potassium channels 
(MthK, KirBac1.1, Kv1.2, KVAP) have been reported (Cox 2007). These 
channels have different transmembrane and cytosolic structures, yet they all 
share (structurally) identical selectivity filters that span about a third of the way 
through the bi-layer (MacKinnon 2003; Cox 2007). The large conductance of 
BKCa channels equates to ~90 million ions passing through the pore per second, 
these traverse in single file separated by a water molecule. The mechanism of 
large conductance is not fully known; although, two negatively charged rings of 
glutamate residues on the inner pore helix of BKca channels increase the local 
concentration of K+ from 150 to 500mM (Brelidze et al 2003; Cox 2007). 
Therefore due to the high conductance only a few BKca channels need to open 
to produce a major physiological response.
1.3.3 BKCa channel a-subunit: tail region
The a-subunit has a large intracellular C’terminus region whose structure is 
unique to BKca channels. This has approximately twice as many amino acid 
residues (~800) as present in the core region and consists of hydrophobic 
domains (S7-S10) and sites for regulation by calcium (Wei et a/'1994; Ghatta et 
al 2006), (Figure 1.4).
The C’termius contains a tetramerisation domain termed BK-T1 which is located 
near the S6 domain. The exact mechanism of tetramerisaton of BKca channels 
remains unknown (Quirk and Reinhart 2001). The C’terminus also contains 
sites for regulation by intracellular mediators in addition to binding sites for a 
number of protein partners. For example, binding of the protein cereblon results 
in suppression of ionic currents through a decrease in surface expression of the 
channel (Jo et al 2005). Furthermore, a dSlo binding protein, dSlipl expressed 
throughout the Drosophila nervous system can result in a decrease in BKca
channel currents (Lu et al 2006) although no mammalian equivalent has been 
identified. The carboxy terminus has multiple phosphorylation sites and a 
leucine zipper domain for interaction with other protein structures including 
protein kinases (Zhou et a /2001; Tian et a /2003).
1.3.4 Phenotypic diversity of BKCa channels
BKca channels display tissue specific expression of different a-subunit splice 
variants, moreover these can combine with different p-subunits to form homo or 
hetero oligomeric combinations of BKCa channels even within the same cell 
(Korovkina and England 2002). An example of this has been extensively studied 
in the avian tonotopic axis, where it was revealed that individual hair cells 
express multiple subsets of different splice variants of BKca channels that are 
different in composition to adjacent cells lining the cochlear (Fettiplace et al 
1999; Ramanathan et al 1999). Phenotypic variation also occurs as a result of 
multiple nuclear transcription promoters (Bohm et al 2000) and transcriptional 
regulatory elements such as Ca2+/calmodulin protein kinase and Ca2+ regulatory 
response elements (Xie and Black 2001).
Numerous cellular mechanisms contribute to changes in physical and 
physiological properties of the channel (Lu et al 2006), these include phenotypic 
variation that can occur at the post transcriptional level such as glycosylation 
(Hagen and Sanders 2006) and through mechanisms of alternative splicing of 
RNA (Shipston 2001). Over 10 different splice site variants have been identified, 
of which most occur within the intracellular C-terminus of the a-subunit 
(Shipston 2001; Qian et a12002) although only few have shown to have major 
physiological effects. The most widely characterised example is ‘stress axis’ 
regulated exon (STREX) which is a cysteine rich insert of 59 amino acids whose 
expression has been detected in a variety of excitable cells (Shipston et al 
1999). Inclusion of STREX leads to an increase in calcium and voltage 
sensitivity of the channel and confers inhibition on the channel by protein kinase 
A (PKA) phosphorylation. Investigation into the dynamic regulation of the 
inclusion of this splice variant in the channel and its regulation by hormones, 
protein kinases and response elements that have been described by Shipston 
et al (2001), Tian et al (1998) and Erxleben et al (1999).
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1.4 The functional role of BKCa channels
The unique feature of BKCa channels is its ‘dual’ ability to be activated by both 
changes in intracellular Ca2+ and plasmalemmal membrane voltage. Meech 
(1978) was the first to propose that Kca channels could provide a role in ‘linking 
cellular metabolism to electrical activity’. BKCa channels provide this via a 
negative-feedback mechanism to control the level of cellular excitability by 
returning the membrane to a hyperpolarising state reducing the activity of 
voltage dependent Ca2+ channel activation (VDCC), (Figure 1.4), (Latorre et al 
1989; Lawson 2001a; Lawson 2001b; Latorre and Brauchi 2006). BKCa 
channels lend themselves to facilitating this process due to their large 
conductance.
Further it has been identified that BKca channels co-localise with VDCC (L-type, 
N-type, P/Q type) in rat brain forming a Ca2+ nanodomain, where Ca2+ influx 
through VDCC activates BKCa channels in a physiological voltage range with 
sub-millisecond kinetics (Prakriya and Lingle 1999; Berkefeld et al 2006; Loane 
e ta ! 2007).
An increase in BKCa channel activity can be induced by the localised release of 
Ca2+ from the sarcoplasmic reticulum (Ca2+ sparks) that produce spontaneous 
transient outward currents (STOC) generated by BKCa channel activation. This 
then leads to hyperpolarisation of the membrane and prevention of influx of 
Ca2+ (Benham and Bolton 1986; Brenner et al 2000; ZhuGe et al 2000), (Figure 
1.4).
Therefore, BKCa channel function is important in the regulation of depolarisation 
and firing patterns in neurons (Gribkoff et al 2001a; Sah and Faber 2002; 
Berkefeld et al 2006), neurotransmitter release (Robitaille et al 1993; Gribkoff et 
al 2001a; Wang et al 2001), chemosensing control in the vasculature (Brayden 
and Nelson 1992; Neslon and Bonev 2004), smooth muscle contraction 
(Giangiacomo et al 1995; Korovkina et al 2002) and electrical tuning of non­
spiking properties of inner ear hair cells (Ramanathan et al 1999). Also BKCa 
channels are important in regulating steroidogenesis (Kunz et al 2002), 
hormone secretion and phagocytic killing in neutrophils (Ahluwalia et al 2004).
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Figure 1.4: BKCa channel as a regulator of cellular excitability
Schematic representing pathways of BKCa channel activation in smooth muscle. 
Depolarisation activates VDCC that leads to Ca2+ entry in the cell and resultant 
physiological effect. Intracellular Ca2+ build up via VDCC activation or from Ca2+ 
sparks activates BKca channels leading to efflux of K+ resulting in 
hyperpolarisation and inhibition of cellular excitability. Re-drawn and modified 
from Nelson and Bonev (2004).
The physiological importance of BKCa channels has been highlighted through 
the use of genetically modified (knock-out) animals by removing particular BKca 
channel subunit genes (Magleby 2003). The effect of deleting the p-subunit 
gene has been widely studied in smooth muscle of the vasculature, p i subunit 
knock-out mice demonstrate a decreased level of STOC's with functional 
coupling of calcium sparks to STOC's shifted to more depolarised potentials, 
that consequently resulted in hypertension in the animal models (Brenner et al 
2000; Pluger et al 2007), (Table 1.1). Thus the p i subunit is critical to the 
negative-feedback regulation of vascular tone. This coupled to recent evidence
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that p i subunit expression becomes decreased with age (Marijic et al 2001; 
Nishimaru et al 2004) has identified BKca channel modulation as a therapeutic 
approach for hypertension.
Human genetic studies have also implicated the pi subunit in hypertension; 
Fernandez-Fernandez et al (2004) in a larger human study showed that a 
single-nucleotide substitution (G352A) in the pi subunit gene (KCNMB1) 
resulted in an E65K gain of function mutation. The frequency of the E65K 
mutation decreased with increasing diastolic blood pressure leading to a low 
prevalence of moderate to severe diastolic blood pressure. In a recent larger 
term study the gain-of-function mutation reduced the incidence of stroke and 
myocardial infarction in women (Senti et al 2005).
1.5 Modulation of BKCa channel function
Sequence analysis and topological determination of the BKca channel revealed 
that certain structural motifs could account for regulation of the channel by 
voltage and calcium. As a result there has been an increased interest into the 
regulatory effects of voltage and calcium on BKca channel activation (Magleby 
2003; Cox 2007). Recent research has also highlighted a number of different 
classes of endogenous physiological stimuli that can modulate BKca channel 
function.
1.5.1 Voltage sens itivity
The S4 subunit has shown to confer the channel with its intrinsic voltage 
sensitivity (Stefani et al 1997), with partial contribution by acidic residues 
present in the S2 domain (Seoh et al 1996) and S3 domain (Papazain et al 
1995). Voltage sensitivity is imparted by a repeated triple sequence of positively 
charged amino acids (either argenine or lysine) separated by two hydrophobic 
residues (Stefani et al 1997; Diaz et al 1998). The exact molecular mechanism 
of voltage dependent activation of BKca channels is thought to be similar to that 
of other K+ channels. Depolarisation results in the movement of the charged 
residues that provide gating currents that result in a conformational change 
causing a bend in the inner helix lining the pore at a conserved glycine gating 
hinge point (Stefani et al 1997; Ghatta et al 2006). The possession of a voltage 
sensor domain confers BKca channels with an ability to open in the absence of
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calcium but only at high depolarising voltages (Toro et al 1998; Cui and Aldrich 
2000). It has been proposed that calcium acts to decrease the intrinsic 
configuration energy difference that separates the closed from the open state 
(Diaz et al 1998).
1.5.2 Calcium sens itivity
Wei et al (1994) showed that cutting the channel of mSlo and dSlo at a non­
conserved linker region between S8 and S9 domains yielded two molecular 
regions, a core (So-S8) and tail (S9-S10), that when expressed together produced 
identical calcium sensitivity to wild type channels. This led to the identification of 
a site of calcium regulation in the intracellular C-terminus of the channel. This 
was confirmed by the work of Schreiber and Salkoff (1997), in that the intrinsic 
sensitivity to activation by intracellular calcium ions was conferred upon the 
channel by a characteristic calcium binding EF hand motif in the cytoplasmic tail. 
This “calcium bowl” region contained high affinity calcium regulatory sites. The 
calcium bowl region occurs prior to the hydrophobic S-|0 subunit and consists of 
ten negative charges, five of which are derived from five consecutive aspartate 
residues (Schreiber and Salkoff 1997), (Figure 1.5). This sequence is 
conserved (except residue 889) between nematode, mouse, fly and humans. 
Removing or replacing negative charges within the calcium bowl greatly 
decreased calcium sensitivity (Magleby 2003). Additionally binding experiments 
confirmed that the calcium bowl was a high affinity calcium binding site and that 
each functional calcium bowl (of the tetrameric channel) added a stepwise 
increase to the Hill co-efficient, (a measure of co-operativity in ligand binding) 
for calcium binding of 0.3-0.8 (Schreiber and Salkoff 1997; Schreiber et al 1999; 
Niu and Magleby 2002).
883 TELVNDTNVQFLDQDDDDDPDTELYTQ
Figure 1.5: The primary amino acid structure of the Ca2+ bowl 
Sequence shows the highly conserved calcium bowl amino acid sequence. Bold 
letters Indicate negative charged residues. E=gluatmic acid, D=aspartic acid. 
Re-drawn and adapted from Magleby 2003.
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BKca channels can respond to calcium over four fold orders of magnitude from 
500nM to 50mM (Schreiber et al 1999; Xia et al 2002; Magleby 2003); this 
would support more than one site of Ca2+ regulation of the channel. Schreiber 
et al (1999) replaced the tail of BKca channel a-subunit (S!o1) with the tail of the 
Slo3 channel (that lacks a calcium bowl), the chimeric channel was insensitive 
to low calcium concentrations, however was activated at higher levels of 
calcium (>300pM) suggesting that sites separate from the calcium bowl 
contribute to the broad sensitivity of BKca channels to Ca2+ (Schreiber et al 
1999). The mechanisms of calcium regulation of BKca channel remain unknown; 
in an attempt to further understand calcium regulation of the BKca channel, site 
directed mutagenesis has been extensively used and has revealed different 
types of calcium sensors that act independently from one another to increase 
the activity of BKca channels. In addition to the calcium bowl other high affinity 
sensors include the D36S/D367 and D81E374/E399 in addition to low affinity 
calcium/magnesium site (E374/E399), (Figure 1.3), (Magleby 2003).
A second region to the calcium bowl the ‘regulator of conductance’ for 
potassium (RCK) domain was identified by Jiang et al (2001) following 
alignment of C’ terminal sequences of BKca channels to that of different 
bacterial K+ channel sequences. The RCK domain adopts a Rossmann fold 
structure that is conserved among BKca channels of eukaryotic and prokaryotic 
potassium channels (Hu et al 2003). Xia et al (2002) showed that the RCK 
domain contained residues that enable two sites of regulation of the BKca 
channel, the first site in association with the calcium bowl accounts for the 
physiological regulation of BKca channels by calcium and the second site 
contributed to the effects of other divalent cations particularly milli-molar 
magnesium on channel activation (Niu and Magleby 2002), this site has been 
shown to include the E374 and E399 low affinity regulation site (Magleby 2003), 
(Figure 1.3).
Therefore, the calcium bowl has a high-affinity (<10pM) for calcium and the 
RCK site has a low affinity for calcium and magnesium (>100pM), it is thought 
that regulation of these channels over many sites enables BKca channels to 
respond to a broad range of calcium concentrations. Hill co-efficient of 2-5 for 
BKCa channels indicate that calcium acts in a co-operative manner and
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suggests that 2-5 calcium ions must be bound to allosteric activators to 
maximally activate the channel (Niu and Magleby 2002). In complete contrast to 
the extensive work on sites of Ca2+ regulation of channel function, Piskorowski 
and Aldrich (2002) showed that when the whole cytoplasmic tail is deleted Ca2+ 
and voltage dependence is unaltered implying Ca2+ sensitivity is located within 
the ‘core’ S0-S6 region. Therefore, a lack of understanding still remains in the 
mechanism of Ca2+ activation of the channel, this is in part down to a lack of 
crystal structure of BKca channels in particular of the Ca2+ bowl region 
(Moczydolowski 2004).
Cui and Aldrich (2000) propose that calcium and voltage have additive effects 
upon channel stimulation and opening. It has been proposed that the calcium 
binding sites and voltage sensors do not directly interact and that an allosteric 
mechanism of channel opening occurs that could facilitate the open and closed 
conformations of the pore (Cui and Aldrich 2000; Moss and Magleby 2001).
1.5.3 Biochem ical and phys iological mediators
BKca channels can be modulated by a plethora of other physiological stimuli 
including sulphatides (Chi and Qi 2006), glucocorticosteroids (Tian et al 1998), 
17p-oestradiol (Valverde et al 1999), insulin (O’Malley and Harvey 2004), 
nitrous oxide (NO), (Gruhn et al 2002), bile acids (Dopico et al 2002), fatty acids 
(Clarke et al 2003) the inhibitory amino acid y-aminobutyric acid (GABA) 
(Baragatti et al 1999), ethanol (Brodie et al 2007) hypoxia (Lewis et al 2002), 
cannabinoids (Sade et al 2006). More recently numerous protein partners to 
BKCa channels have been identified (Lu et al 2006) and include calveolin-1 
(Wang et al 2005) and haemoxygenase (Williams et al 2004). BKca channels 
have also shown to form macromolecular complexes with p2 adrenergic 
receptors in smooth muscle (Liu et al 2004; Lu et al 2006).
BKCa channels have shown diversity in their sensitivity to protein 
phosphorylation (Schubert and Nelson 2001) and with association of G-proteins 
and intracellular signalling pathway intermediates such as cyclic AMP and cyclic 
GMP (Zhou e fa /2001 ) and protein kinases (Shubertand Nelson 2001).
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The function of BKca channels can also be governed by metabolic regulation in 
that vasoconstrictors such as angiotensin II and thromboxane A2 have shown to 
inhibit BKca channels via src tyrosine kinase phosphorylation of the channel 
(Alioua et al 2002; Lu et al 2006). Whereas smooth muscle vasodilators such as 
prostaglandin, NO and arachdonic acid induce Ca2+ sparks that activate BKca 
channels (Schubert and Nelson 2001; Lu e ta l 2006), (Figure 1.4).
1.6 BKCa channels: A therapeutic target for clinical conditions
Rapid progress into the pharmacology of potassium channels has been 
facilitated by the introduction of modern ion channel research technologies. This 
coupled with advances in bioinformatics and molecular biology has enabled 
better characterisation of ion channel structure, distribution and the regulatory 
mechanisms involved in the modulation of gating and physical properties. This 
in turn has enabled the development of improved pharmacological tools to study 
ion channels (Calderone 2002).
Over the last couple of decades there has been rapid progress in the 
development of therapeutic ion channel modulators. Ion channel drugs 
represent 15 of the top 100 selling drugs world-wide totalling $5 billion in global 
sales (England 1999; Cox et al 2002). Examples include sodium channel 
blockers used as local anaesthetics or class I antiarrhythmic agents including 
lidocaine and disopiramide. Calcium channel blockers such as verapamil and 
nifedipine have been used as major drugs in the treatment of hypertension and 
angina. In addition, GABA-activated channels are the targets for barbiturates 
and benzodiazepines and are utilised in the treatment of conditions associated 
with excitability of the nervous system (Kazic et al 1999).
The structural diversity of BKca channels coupled with their response to a 
plethora of physiological stimuli and their central role in physiological processes 
has highlighted them as potential ‘tissue specific’ targets. Numerous reports 
have suggested that synthetic openers of the BKca channel could provide 
therapeutic agents in a number of pathophysiological conditions including 
several un-met clinical conditions. These are stroke (Gribkoff et al 2001b; 
Jensen e ta l 2002), coronary artery spasm (Marijic et al 2001), epilepsy (Graves 
2006), progressive hearing loss (Ruttiger et al 2004), bladder over-reactivity and
16
urinary incontinence (Hewawasam e ta l 2002d; Turner et al 2003; Meredith et al 
2004), asthma (Ise et al 2003), chronic cough (Fox et al 1996; Belvisi and 
Geppetti 2004), hypertension (Korovkina et al 2002; Nelson and Bonev 2004), 
erectile dysfunction (Hewawasam et al 2004; Boy et al 2004), colonic and 
gastric hypermotility (Sivarao et al 2005), dup(3q) syndrome (Riazi et al 1999), 
hypokalemic periodic paralysis (hypoPP) (Tricarico et al 2004) and psychoses 
(Kaczorowski e ta l 1996; Coghlan and Carroll 2001; Gribkoff et al 2001b).
Paroxymal dyskinesia was recently identified as the first BKca channelopathy 
and is caused by single missense mutation in the regulator of conductance 
(RCK) domain of the channel protein (Du e ta l 2005). BKca channel function has 
been implicated in the pathology of schizophrenia (Zhang et al 2006), 
Alzheimer's disease (Chi et al 2000) and age related disease in the 
cardiovascular system (Marijic et al 2001; Nishimaru et al 2004).
Christ and colleagues have investigated the use of delivering cDNA encoding 
BKCa channels as a gene therapy technique (Christ et al 2001; Christ 2002). 
Examining the streptozotocin induced diabetes rat model it was observed that a 
decline in BKca channel expression occurred in corporal tissue with age and 
that it was associated with the development of erectile dysfunction (ED). Further, 
that gene transfer of cDNA encoding hSlo fully restored age or diabetes induced 
ED with relatively low levels of hSlo transfection rates. The BKca channel was 
thought to produce enhanced hyperpolarising ability of corporal smooth muscle 
in response to cellular activation by neurotransmitters (Christ 1998; Christ 2002). 
Christ et al (2001) also showed that injection of hSlo cDNA ameliorated 
obstruction-associated bladder hyperactivity. Therefore, gene transfer of BKca 
channel subunits could offer a therapeutic strategy for treatment of bladder 
ovaeractivity and urinary incontinence (Christ et al 2001; Christ 2002).
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a Bristol Mayer Squib 
BMS- 
204352/MaxiPost
post stoke 
neuroprotection
Discontinued (2001) after 
phase III
Nippon Shinyaku and 
Apogepha Arznemittel 
NS-8
Overactive Bladder Discontinued (Jan 2007) after completion of phase I
c Tanabe and 
GlaxoSmithKline 
! TA-1702
Overactive Bladder Phase I
d Rottapharma
CR-2039/Andolast
Bronchial Asthma 
Allergic Rhinitis 
COPD
Phase II allergic rhinitis and 
COPD
and Phase III for Bronchial 
Asthma
1 1
Table 1.2: BKCa channel opener compounds subm itted for clinical trials
(a) Jensen (2002), (b) Japan Corporate News (2007), (c) Mitsubishi Tanabe 
Pharma (2007), (d) Rottapharm (2007).
The development of medium to high throughput pharmacological screening 
assays including rubidium efflux, membrane potential and binding assays, 
(Bennett and Guthrie 2003) has facilitated industry led developments in the 
identification of synthetic potassium channel openers (KCO) with a recent focus, 
over the past decade, into the development of BKCa channel openers (BKCaCO). 
As a consequence a few synthetic BKCa channel openers have been advanced 
to clinical trials for the treatment of stroke, bladder over-activity and asthma 
(Table 1.2). Neurosearch A/S and TopoTarget have developed the therapeutic 
use of BKCaCO to enhance the transport of anti-cancer drugs into brain tumours 
and are testing certain a compound termed NSD-551 (structure undisclosed) to 
pre-clinical testing (Neurosearch A/S 2005).
The most well known compound advanced to clinical trail as a BKCaCO was 
Maxipost (BMS-204352) developed by the work of Gribkoff and colleagues at 
Bristol Myers Squibb (BMS) for use in post-stroke neuroprotection. In the middle 
cerebral artery occlusion (MCAO) rat stroke model Maxipost was able to reduce
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cerebral oedema and improve neuromotor function by preventing toxic Ca2+ 
build up within the cell that is associated with the pathogenesis of this condition 
(Gribkoff et al 2001a; Gribkoff et al 2001b). However, following phase II I clinical 
trials Maxipost was withdrawn because of a lack of clinical efficacy (Jensen 
2002), although a second phase III study is being considered (Davis 2006). 
There has been a lack of published in-vivo work studying the potential of 
BKCaCO to provide therapeutic benefit in different animal models, this in part is 
preventing the potential therapeutic benefits of BKcaCO from being realised 
(Lawson and McKay 2006).
1.7 BKCa channel openers (BKcaCO’s)
A number of BKcaCO’s have been discovered through an empirical approach; 
where compounds are selected from a large pool of molecules such as found in 
fermentation broths and plant extracts or identified through serendipitous means 
(Lawson 2001 a,b). The advent of structure based ligand/drug design has led to 
a decline in the empirical selection of pharmacological agents. However, Van 
Regenmortel (2000) argues that design and empirical selection should not be 
seen as separate but should be complimentary. For example, molecules 
identified as BKcaCO’s, using an empirical approach, could be used as 
templates to guide the design of other compounds. Further, using similar 
structured compounds the requirements of a particular compound to be BKca 
channel opener can be determined. Due to the lack of 3D structural information 
of BKCa channel function ligand-protein modelling has been limited (Li and Harte 
2002). One such approach for the elucidation of BKcaCO's is to define and 
develop pharmacophores. Langer and Wolber (2004) define a pharmacophore 
as ‘an ensemble of steric and electrostatic features of different compounds 
which are necessary to ensure optimal supramolecular interactions with a 
specific biological target structure to trigger or block a biological response’
Therefore, the ability to develop subtype specific BKca channel openers through 
pharmacophore identification will be useful in understanding the basic 
pharmacology of these specific subsets and could provide selective tissue 
specific therapeutics in numerous diseases. This approach has been used to 
guide the design and development of a number of novel heterogeneous classes
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of compounds. The development of pharmacophores through rationale design 
could infer knowledge about the structure of BKca channels and provide further 
understanding of the function of BKca channels at the molecular level.
The development of high throughput screening technology as alternative to 
functional tests in combination with developments in combinatorial chemistry 
libraries has enabled rapid development in drug discovery of ion channel 
modulators. The progress in the identification and the elucidation of BKcaCO 
has lagged behind that of the development of K a tp  channel modulators (Lawson 
and Dunne 2001) where detailed descriptions of pharmacophores and 
differential specificity profiles of different K a tp  channel openers including 
cromakalim, pinacidil and nicorandil has been described (Lawson 2000; 
Coghlan and Carroll 2001).
Compounds identified as BKCaCO can be grouped broadly based on the source 
of their discovery. For example compounds have been discovered through 
empirical selection from natural sources including plant extracts and 
fermentation broths or identified as ancillary effects of other drugs and 
pharmacological agents, but over the past decade there have been many rapid 
advances in the development of novel synthetic compounds as BKcaCO’s.
This thesis will review BKca channel openers discovered and disclosed to date. 
Furthermore, identify the synthetic pharmacophores being studied by different 
research groups and highlight the particular features of these compounds that 
are intrinsic to them displaying BKCaCO properties and describe issues 
concerned with the development and elucidation of BKcaCO’s.
Chemical structures displayed in the following figures have been drawn using 
Chemdraw version 10 software (Cambridgesoft, Cambridge, U.K).
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1.8 BKcaCO isolated from natural sources
A pharmacognosy approach has identified BKcaCO properties for a number of 
compounds isolated from natural sources that had historically been shown to 
treat symptoms that could be therapeutically relieved by BKca channel 
modulation (Wu e t a l2006).
1.8.1 Terpenes
Researchers from Merck Laboratories, using a ligand binding assay based on 
the use of the radiolabelled BKca channel blocker, charybdotoxin (125l-ChTX), 
were the first to isolate and identify compounds with BKcaCO properties from 
natural sources. The first example, dehydrosoyasaponin (DHS-1), (Figure 1.6) 
was isolated from the medicinal herb Desmodium adscendes that was 
traditionally used in Ghana as a powerful remedy against asthma (McManus et 
al 1993). Application of low concentrations of DHS-1 (10nM range) led to a 50- 
fold increase in open pore probability by stabilising the open state conformation 
of the channel (Giangiacomo et al 1998). Interestingly, DHS-1 only activated 
channels when applied to the intracellular aspect of the channel and could not 
activate the channel in the absence of intracellular calcium (McManus et al 
1993), (Figure 1.9). DHS-1 activation is dependent upon the co-expression of 
the [3-subunit as BKca channels composed of only four a-subunits were 
insensitive to DHS-1 up to concentrations of 500nM (McManus et al 1995).
McManus et al (1993) proposed that the binding site is probably as long as the 
length of the molecule and could be allosterically coupled between the a- 
subunit and to a region within the (3-subunit and suggested the rigid triterpene 
portion could bind to a hydrophobic site on the channel. Chemical modifications 
to the structure have showed that the first two sugar residues are required for 
maximal activation and proposed that the molecule aligns orthogonal to the 
plane of the membrane with the sugar molecules facing the hydrophillic 
cytoplasmic side (McManus et al 1993; Giangiacomo et al 1998). Furthermore, 
DHS-1 did not display any ancillary pharmacology to SK channels, Katp 
channels and L-type Ca2+ channels (McManus et al 1993).
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Another compound identified by researches at Merck was MaxiKdiol (1,2- 
dihydroxyisoprimane diterpenoid), (Figure 1.6) isolated from the fermentation 
broth of an unidentified coelomycete. Although structurally dissimilar to DHS-1, 
MaxiKdiol, like DHS-1, only activated BKCa channels when applied to the 
cytoplasmic side of the channel, however unlike DHS-1 it was less potent with a 
higher threshold of activation (1-1 OpM) and activation of BKca channels was not 
dependent upon the presence of a p-subunit (Singh et al 1994), (Figure 1.9).
OOH HO '
OH ['""Hi
HOOH
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DHS-1 L-735,334O H
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HO CAF-603
Diosgenin
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Figure 1.6: Terpinoids
Other terpene derivatives identified by Merck Research Laboratories using 125l- 
ChTX assay include isolation of the carotene sesquiterpene CAF-603 (Figure
1.6) from the fermentation products of Arthinium Phaesospermum whose 
structure was identical to a product with anti-fungal activity isolated from 
Trichoderma Virens. Although, CAF-603 caused significant displacement of 
radio-labelled ChTX it did not demonstrate BKcaCO effects (Ondeyka et al 
1995). However an oleic acid ester, L-735,334 (Figure 1.6) isolated from the 
same culture of T.Virens showed slow effects at activating BKca channels and 
was only effective, like maxiKdiol, when applied to the intracellular aspect of the 
channel (Lee et al 1995c), (Figure 1.9). Poor cell membrane permeability of this
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group of terpenoids limited their use as in-vitro experimental tools and as 
therapeutic agents (Nardi et al 2003).
Another terpenoid investigated for BKcaCO properties was diosgenin (3p- 
hydroxy-5-spirostene), (Figure 1.6). This a plant steroid isolated from the root of 
wild yam that can be enzymatically converted in-vivo into human steroid 
hormones progesterone and oestrogen and has been used to treat post­
menopausal symptoms. Wang et al (2006) investigated its effects on BKca 
channels in human cortical neuron cells (HCN-1A). Diosgenin failed to directly 
activate BKca channels when applied to the intracellular aspect of the channel 
during inside-out patch recordings. This coupled to it not having an effect on 
single channel conductance led them to conclude that it must activate BKca 
through an indirect mechanism. They showed that diosgenin increased P0 of 
BKCa channels in HCN-1A cells resulting from an increase of calcium within the 
cell, potentially as a consequence of VDCC activation (Wang et al 2006), 
(Figure 1.9).
1.8.2 Phenols
A number of BKca CO's have been discovered from plant extracts, in particular 
a number of phenolic based compounds (Figure 1.7). Magnolol isolated from 
the Chinese medicinal herb Magnolia officinalis is one of the active components 
in the herbal medicine Saiboku-to traditionally used to treat bronchial asthma 
(Wu et al 2002). Trans-resverstrol is a naturally occurring phytoalexin present in 
grapes and wine thought to have potent antioxidant and cardio-protective 
effects (Li et al 2000). These phenols activated BKca channels concentration 
dependency,by causing a shortening in the closed and a lengthening in the 
open time of the channel. In addition both compounds did not affect the affinity 
of Ca2+ binding or single channel conductance. Therefore, activation of BKca 
channels by these compounds may underlie their anti-asthmatic and potential 
cardio-protective effects (Li et al 2000; Wu et al 2002).
23
OH
HO
T rans-resverstol
OH
Thymol
.OH
Magnolol
Menthol
OH
OH
HO ' NDGA
OH
Figure 1.7: Phenolic compounds
The phenolic nordihydroguaiaretic acid (NDGA) is a natural product contained 
in the Creosote bush that is used as a natural antioxidant in fats and food oils 
and as a nutritional supplement (Figure 1.7). NDGA has been demonstrated to 
be an inhibitor of lipoxygenase and cyclooxyenase and at high concentrations 
will inhibit mitochondrial respiration. In smooth muscle cells NDGA directly 
activated BKca channels independent of its effects on lipoxygenase by 
association with the a-subunit increasing the channels sensitivity to calcium 
(Yamamura et al 2002). At higher concentrations, NDGA could release Ca2+ 
from caffeine/ryanodine sensitive Ca2+ storage sites, it affects on Ca2+ storage 
site were thought to be associated with its ability to inhibit mitochondrial 
respiration (Yamamura et al 2002), (Figure 1.9).
Thymol (2-isopropyl-5-methylphenol) is a phenolic monoterpene found in plant 
oil of Thymus Vulgaris (Thyme) and is used widely in medical and industrial 
applications in particular as a stabilising reagent for volatile anaesthetics (Figure
1.7). Thymol activated BKca channel currents from GH3 rat pituitary cells 
increasing P0 with an EC5o of 75pM. However, in cell attached recording, thymol 
applied to the bath was inhibited upon extracellular application of the Ca2+ 
chelator BAPTA, whether thymol affects Ca2+ binding on the channel remains 
unknown. However, application of thymol to the intracellular aspect of excised 
patches resulted in activation of BKca channels whereas the structurally similar 
menthol did not, therefore the underlying the mechanisms of thymol activation
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of BKca channels could be helpful in understanding neuronal or endocrine 
functions of the medicinal herb (Huang et al 2005).
1.9 BKCaCO identified as ancillary effects of other agents
As well as the identification of BKca channel openers from natural sources there 
has more recently been a number of synthetic enzyme inhibitors, cell signalling 
activators and therapeutic agents reported as BKcaCO's.
1.9.1 The effect of enzyme inhibitors and cell s ignalling activators
A number of synthetic pharmacological agents used in the study of intracellular 
signalling enzymes and pathways have been determined as potential BKcaCO’s 
(Wu 2003; Wu et al 2006). These include xanthine and non-xanthine based 
phosphodiesterase (PDE) inhibitors, protein kinase activators and soluble cyclic 
guanylyl cyclase (sGC) activators (Table 1.3); all have shown differential effects 
on BKCa channel activation (Figure 1.9). These agents can act via direct 
association with the channel or as an indirect consequence of their effects on 
intracellular cell signalling enzymes and pathways that lead to BKca channel 
activation (see Figure 1.8). These ancillary agents activate BKca channels at 
concentrations similar to their primary pharmacological effect. Therefore these 
agents as therapeutic BKcaCO’s are disadvantageous as they display various 
ancillary pharmacology and are not specific to BKca channels.
SCA-40, an imidazopyrazine, was developed by Zeneca as a smooth muscle 
relaxant for the treatment of asthma (Lawson 1997). It was initially thought to 
exert its vasorelaxant effect via BKca channel activation in smooth muscle 
airways (Bonnet et al 1992; Cortijo et al 1997). However subsequent to this, 
SCA-40 has demonstrated differential IbTX sensitive effects in different tissues 
with organ bath experiments and when tested with electrophysiology or 86Rb 
efflux it did not activate BKca channels (MacMillan et al 1995; Cook et al 1995; 
Lawson 1997). Around the same time it was demonstrated that like structurally 
related theophylline, SCA-40 was a potent PDE inhibitor. Inhibition of PDE and 
consequent elevation of cyclic nucleotides could lead to BKca channel activation 
without SCA-40 having direct effects upon channel activation (Lawson 1997; 
Cortijo et al 1997).
25
YC-1 sGC activator
Initially developed for 
treatment o f circulatory 
disorders
Wu et al 2000 3
BAY-41-2272 sGC activator
Initially developed for 
treatment of erectile 
dysfunction
Liu and Wu 2005
KMUP-1 PDE Inhibitor none Wu et al 2005
Theophylline PDE Inhibitor Bronchodilator Treatment of COPD Ise et al 2003
Vinpocetine PDE Inhibitor
Isolated from leaves of 
Vinca minor used as 
for its neuroprotective 
properties
Wu et al 2000b
Cilostazol PDE Inhibitor
Treatment of symptoms 
of intermittant 
claudation
Wu et al 2004
LY-171883 Leukotriene D4 antagonist
Initially proposed as a 
bronchodilator Li e t a l2002
Rottlerin/Mallotoxin PKC8 inhibitor
Patent filed as a 
BKCaCO for treatment 
of hypertension
Zakharov e t a l2005 
Marx and Zakharov 2006 
Wu et al 2007
I I
Table 1.3: Synthetic cell signalling enzyme activators and inhibitors 
identified as BKca channel openers.
COPD=Chronic obstructive pulmonary disease
Chloroxazone
modulation of 
polysynaptic reflexes 
in spinal cord
Centrally acting muscle 
Relaxant Liu e f al 2003 j
Zonisamide
Potential block of 
Nav channels or 
GABA interaction
Antiepileptic Huang et al 2007
Amiodarone 
derivative KB130015
Multiple actions on 
ion channels Cardiac anti-arrhythmic Gessner et al 2007
Unoprostone FP receptors in trabecular network
Glaucoma: reduction of 
intraoccular pressure Cuppoletti et al 2007
Evans Blue Associates with albumin in circulation
Dilution indicator for 
measurement o f blood 
volume and vascular 
permeability
Hollywood e ta l 1998 
Yamada et al 2002
Fenamates Inhibition o f cyclo- oxygenase
Common non steroidal 
anti Inflammatory drugs
Ottolia and Toro 1994 
Wu et al 2001
Tamoxifen Oestrogen receptor modulator Anti cancer drug
Dick et al 2001 
Duncan 2005 
Coiret et al 2007
ICI-187,780 Oestrogen receptor 
antagonist Anti cancer drug Dick 2002
I _ . _ l
Table 1.4: Therapeutic agents identified as having BKCaCO properties
FP= prostaglandin F receptor
1.9.2 Ancillary effects of therapeutics and agents
There have been a few reports of currently used therapeutics for a number of 
different conditions that have also shown to be able to activate BKca channels. 
Further that BKCa channel activation could account for the mechanism of action 
of these drugs in relieving symptoms, such as zonisamide and chloroxazone 
(See table1.4). In addition, certain drugs such as tamoxifen and fenamates 
have shown to also activate BKCa channels as a secondary effect to their 
primary site of action and that activation of BKca channels may underlie the 
clinical benefit or adverse effects of these drugs. The mechanism of actions of 
these BKCaCO isolated or identified from natural sources or as ancillary effects 
have been well characterised and is summarised in Figure 1.8 and Figure 1.9.
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MTX/Rottlerin
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Figure 1.8: The mechanisms of BKCa channel activation by cell signalling 
enzyme activators and inhibitors
Solid arrows represents that particular compound/intracellular intermediate 
having an activating effect on the other; Dashed arrows represent an inhibitory 
effect. ?=unknown thought may involve activation of cyclic nucleotide gated 
channels or the phosphorylation effects of PKG on VDCC the effects of these 
molecules are independent of intracellular Ca2+ release from stores. Note; 
PKC5 phosphorylation inhibits BKca channels.
27
Intracellular specific site
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of intracellular Ca2+
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BKcaCO
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2272, MTX/Rottlerin, 17-3 
estradiol, YC-1
Activation via phosphorylation
Compounds that activate 
resulting from an increase in 
intracellular Ca2+
diosgenin, thymol, NDGA, 
YC-1, vinpocetine, BAY 41- 
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Diosgenin,MTX/Rottlerin 
ethylbromide tamoxifen, 
tamoxifen, ICI-187,780
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187,780
Modulate channel with site 
on the pi-subunit
Figure 1.9: BKCaCO properties of compounds identified from natural 
sources, therapeutic agents or enzyme inhibitors
1.9.3 Fenamates
The first BKcaCO's identified as an ancillary effect of a therapeutic were the 
fenamates (Figure 1.10). These are derivatives of N-phenylanthrancilic acid that 
are used therapeutically as non-steroidal anti-inflammatory drugs (NSAID) 
whose primary mechanism of action is via the inhibition of cyclo-oxygenase. In 
a study by Ottolia and Toro (1994) the effects of niflumic, flufenamic and 
mefenamic acid were assessed. Niflumic acid (EC50 2 O3 M) activated the 
channel by increasing its affinity for Ca2+ and by causing a decrease in the time 
the channel remains in the closed state. An external binding site was proposed 
that was not associated with TEA or ChTX and a decrease in potency was 
observed when it was applied to the intracellular aspect of the channel.
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Figure 1.10: Fenamates
The shift in voltage sensitivity was proposed to be due to the anionic form of 
niflumic acid having non-specific surface charge effects on the external side of 
the membrane resulting in local depolarisation and an increase in channel 
activity; however at higher concentrations niflumic acid (1mM) did not activate 
VDCC. Further a rank order of potency was achieved; Niflumic acid=Flufenamic 
acid»Mefenam ic acid (Ottolia and Toro 1994), this order of potency and a 
similar EC50 for niflumic acid was calculated for the effect of these fenamates on 
BKCa currents in MG-63 osteoblast like cells (Wu et al 2001). If these 
compounds were causing non-specific membrane effects resulting in BKca 
channel activation then the increased hydrophobicity of mefenamic acid (di­
methyl groups) relative to niflumic and flufenamic acid would result in this being 
the most active compound. However the amphipathic nature of niflumic and 
flufenamic acid and the commonality of the presence of a trifluoromethyl group 
(CF3) group supported the hypothesis that these two compounds bind the 
channel at a receptor confined to a hydrophobic pocket with the rest of the 
molecule facing the aqueous phase (Ottolia and Toro 1994).
1.10 Development of synthetic BKCa channel openers: 
Benzimidazolones
The breakthrough in the discovery of synthetic BKca channel openers was the 
development of NS004 (5-trifluoromethyl-1- (5-chloro-2-hydroxyphenyl)-1,3- 
dihydro-2H-benzimidazole-2-one) and NS1619 (1-(2’-hydroxy-5’-
trifluoromethylphenyl)-5-trifluoromethyl-2(3H) benzimidazolone) (Olesen et al 
1994a; Olesen et al 1994b), (Figure 1.11). Since then their use has been
reported in over 100 published articles (Nardi et al 2006). These compounds 
have also formed the basis for the generation of several novel pharmacophores 
(Coghlan and Carroll 2001; Lawson and Dunne 2001).
1.10.1 NS1619 and NS004
NS1619 has been extensively studied in many different tissues including the 
myometrium, trachea, smooth muscle, vascular tissues and neurons (Edwards 
et al 1994; Olesen et al 1994a; Olesen et al 1994b; Lee et al 1995; Holland et al 
1996; Hu and Kim 1996; Sheldon e ta l 1997; Huang et al 1997; Khan e ta l 1998; 
Zhang et al 2003; Malysz et al 2004).
NS1619 has been shown to hyperpolarise cells moving the membrane potential 
close to the equilibrium potential for K+ (Ek), a common feature for BKca channel 
openers. NS1619 activated BKca channels equi-effectively when applied to 
either side of the channel (Olesen et al 1994b; Holland et al 1996) with an EC50 
of around 10-30|liM, the responses to NS1619 were eliminated by co-application 
of IbTX (Olesen et al 1994b). NS1619 is thought to associate with a binding site 
on the a-subunit, and due to its differential effects with time to activate BKca 
channels in whole cell vs excised inside-out patches suggested an intracellular 
binding site (Edwards et al 1994; Olesen et al 1994b; Holland et al 1996), a 
similar mechanism has been proposed for NS004 (McKay et al 1994).
NS1619 affected the open channel properties (Olesen e ta l 1994a,b; Sheldon et 
al 1997) in cell-attached patches at the single channel level by increasing the 
number of open channels within the patch but not affecting the open time (Lee 
et al 1995b) or unitary conductance. Whether NS1619 can activate BKca 
channels in the absence of calcium has not been fully determined as Edwards 
et al (1994) showed that in a calcium free system NS1619 resulted in activation 
of BKCa channels from whole cell recording of rat portal vein suggesting that 
NS1619 could substitute for intracellular calcium. Whereas it has been shown 
that removal of calcium from inside out patch configurations reversed the effects 
of channel activation in the presence of NS1619 (Olesen et al 1994b; Holland et 
al 1996). NS1619 effects were independent of channel phosphorylation as 
application of protein kinases, guanosine-5-triphosphate (GTP) and the un-
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coupling of G-proteins using pertussis toxin did not affect the NS1619 response 
(Olesen et al 1994b; Edwards et al 1994). However, Yammamura et al (2001) 
showed that NS1619 effects could be mediated by stimulating an increase in 
intracellular calcium release from the sarcoplasmic reticulum.
A number of ligand binding assays had suggested that NS1619 was specific to 
BKCa channels as it did not show interaction with 38 different binding sites of 
neurotransmitters and autocoids (Olesen et al 1994b). Further, to confer 
specificity, application of an array of potent ion channel inhibitors such as 
glibenclamide (K a t p )  and apamin (SK) did not affect the hyperpolarisation 
induced by NS1619 (Edwards et al 1994; Olesen et al 1994b).
NS004 was equally effective at activating B K Ca channels when applied to either 
aspect of the channel and has an effective concentration of 0.1-0.4pM (McKay 
et al 1994; Hu et al 1995). NS004 caused an increase in whole cell B K c a 
channel currents in porcine coronary artery cells by 3-4 fold (Hu et al 1995) and 
by 2-5 times in Xenopus oocytes expressing B K c a channel subunits (McKay et 
al 1994). NS004 (30jiM) has shown to induce an 24-fold increase in P 0 in 
cerebellar granule cells and 7-8 fold in channels reconstituted lipid bilayers 
(McKay et al 1994; Olesen et al 1994b).
The first problems with the use of NS1619 as a selective B K c a channel opener 
were reported by Edwards et al (1994) who showed that NS1619 could inhibit 
Kv channels. This was subsequently reported by Holland et al (1996) where 
under conditions that minimised B K ca channel activation and optimised Kv 
channel opening NS1619 was able to produce a concentration-dependent 
reduction in K v current. In addition, Edwards et al (1994) and Holland et al (1996) 
determined that NS1619 was able to block Ca2+ currents from rat portal vein 
and basilar artery cells respectively. A similar effect has been observed with 
NS004 (Sargent et al 1993).
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Figure 1.11: Benzimidazolone compounds
Further, the prolongation of action potentials observed in dorsal root ganglion 
upon application of NS1619 could be due the ability of NS1619 to inhibit 
delayed rectifier channels and through mobilisation of intracellular Ca2+ release 
rather than through direct BKca channel activation (Yamamura et al 2001; 
Zhange et a /2003).
Furthermore, NS004 and NS1619 have shown ancillary pharmacology with the 
cystic fibrosis transmembrane conductance regulator (CFTR) whereby after pre­
treatment with forskolin NS1619 and NS004 activated both the wild-type and 
the most common mutation observed in cystic fibrosis; a deletion of a 
phenyalanine residue (AF508) (Al Nakkash et al 2001). These compounds 
could be used in the development of therapeutics targeting the CFTR-CI' 
channel in cystic fibrosis (Gribkiff et al 1994; Al Nakkash et al 2001).
1.10.2 NS1608
The first modification to the benzimidazolone structure was the introduction of a 
biaryl urea linker opening up the heterocycle of NS1619. This compound termed 
NS1608 (Figure 1.11) has been characterised for its BKCaCO properties. 
NS1608 effects were additive with increases in intracellular calcium, in that
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responses in the presence of increasing calcium resulted in a 200mV shift in 
voltage required for channel activation. Where as in a calcium free system 
NS1608 alone produced a shift of 70mV in the hyperpolarising direction, a 
similar shift as that observed with NS1619. NS1608 was more potent than 
NS004 and NS1619 (Strobaek et al 1996; Siemer et al 2000).
1.11 Benzimidazolone derived BKCa channel openers
The first examination of the pharmacophore properties of benzimidazolone type 
compounds was performed by Meanwell and colleagues at Bristol-Myers 
Squibb (BMS). This has subsequently led to the development of a number of 
classes of novel BKcaCO compounds.
1.11.1 Benzyl-benzim idazol-2-ones
The first such structures were a series of benzyl-benzimidazol-2-ones based on 
the insertion of either a methyl or ethyl spacer separating the phenolic and the 
imidazolone ring system of NS004 by 1 or 2 carbon atoms and is represented 
by BMS-189269 (Figure 1.11). Different substitutions of the benzene rings 
surrounding the imidazolone nucleus were used to determine the aspects of 
these compounds that impart BKca channel opener properties. Compounds 
were assessed using two electrode voltage-clamp on Xenopus oocytes injected 
with mSlo. The potency of compounds was determined as the maximum 
percentage increase in iberiotoxin-sensitive outward currents (above control) 
across a +20 to +140mV voltage range.
A phenolic ring appeared be a definite requirement for compounds to retain 
BKcaCO properties and that chlorination in the para (p-) position to the hydroxyl 
(OH) was important for activating properties (this was supported by 
Hewawasam et al 1997 in that des-chloro analogues were less efficacious), 
(Meanwell et al 1996). Another important feature is the trifluoro-methylated 
benzene ring, substitutions at position 5 with other halogens (Cl, Br, I) and NO2 
promoted BKca channel opener properties quite considerably compared to 
substitution with hydroxyl, methyl or the un-substituted derivative. Interestingly, 
if chlorine or bromine is substituted at position 6 only weak BKca channel 
opening properties are displayed. However, di-chlorination in positions 5 and 7
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results in potency similar to that achieved in position 6 but di-chlorination in 
positions 5 and 6 resulted in B K Ca channel activation at levels similar to that 
observed with chlorination at position 5 alone (Meanwell et al 1996). The 
importance of the trifluro-methylated (CF3) benzene ring was further confirmed 
by substitution with an electron deficient pyridine ring system which was in 
effective. Therefore electron withdrawing groups (EWG), particularly halogens, 
appear to be important requirements in this molecules ability to activate B K ca 
channels, and that slight modifications in the positioning of substituents in 
particular chlorine, can have marked effects on potency and efficacy. This could 
provide clues on how the compound could potentially interact with the BKca 
channel protein (Meanwell et al 1996). Hewawasam et al (1997) also showed 
that NS004 adopted more of a planar network as a mimic of this compound in 
which the phenol and the benzimidazolone rings adopted an orthogonal 
relationship was unable to activate B K Ca channel currents.
It had been suggested that the amide NH of benzimidazolones acts as a weak 
acid and that this acidity is increased by the attachment of EWG to the 
heterocyclic nucleus. Furthermore, the amide NH together with the amide 
carbonyl oxygen is critical for activity and could act as a surrogate carboxylic 
acid (Li et al 1997). In addition, the phenolic OH and carbonyl oxygen were 
thought to act as a mimic of carboxylic acid as well (Meanwell et al 1996).
For a series of PDE inhibitors (heterocycle-phenyl-imidazole) molecular 
modelling has suggested that the imidazolone of the inhibitor could act/mimic a 
phosphate for the enzymes active site. Therefore, this ring system of NS1619 
could act at a complementary site to the phosphate on the channel (Li et al 
1997).
1.11.2 Identification of flavanoids as BKCaC O ’s
The similarity in NS004 and benzylated benzimidazol-2-one at activating BKca 
channels indicated flexibility between these two bioisosteres. A three 
dimensional database search using the essential pharmacophore properties of 
NS004 was performed by Li et al (1997) at BMS. A pharmacophore was 
constructed involving the presence of a carbonyl O as a hydrogen bond (H- 
bond) acceptor, a H-bond donor site and an aromatic group located within a 3-
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5A distance of the amide carbonyl oxygen. Furthermore, the torsional angle of 
the H-bond donor was further constrained (HX...C=0 ±30°). These criteria were 
queried against the 3-D CSDS database of 120,000 crystal structures, from 
which 300 hits were obtained (Li et al 1997). A particular chemotype identified 
was KAMJUD01 similar to the flavone quercetin that contains a hydroxyl and 
ketone phenol moiety that has been shown to mimic carboxylic acid of L-DOPA 
(Figure 1.12). Therefore, similar flavanoid compounds were studied, cyclic 
flavanoids were found to be more efficacious than acyclic; of those studied 
apigenine and kaempferol produced the greatest BKca channel current. These 
compounds had hydroxyl at carbon 5 (C5) position located adjacent to the 
ketone and demonstrated greater activation than NS004; this difference in 
potency was thought to involve the OH at the C5 position providing a more 
acidic function than the equivalent amide NH in NS004 (Figure 1.12).
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Figure 1.12: Flavonoids
Further, meta-OH substitution in the R2 group at position C7 of the same ring 
enhanced the activation properties but substitution with methoxy groups were 
less active (Li et al 1997). The work of Calderone et al (2004) revealed other 
flavanoids as potent BKcaCO’s including naringenine, hesperetin and luteolin 
(Figure 1.12). The hydroxyl group in carbon position 5 of these compounds was 
essential for flavonoids to display specific BKca channel mediated vasorelaxant 
responses as 5-methoxyflavone could not induce IbTX sensitive vasorelaxation 
(Nardi et al 2003; Calderone et al 2004). In addition, a wider study of vascular 
relaxation of porcine coronary artery by flavanoids confirmed that the OH 
function in C5 and also in C7 position was important and that the presence of a 
double bond between C2 and C3 were important for vasorelaxant responses. 
Hydroxylation of the phenyl ring weakened the potency, although whether 
relaxation was specific to any type of K+ channel including BKca channels was 
not tested (Xu et al 2007).
This data supports the idea that the ketone oxygen and hydroxyl group at 
position C5 could act as a surrogate carboxylic acid imparting specificity to BKCa 
channels, this feature is also important to benzimidazolones.
1.11.2.1 Quercetin
Cogolludo et al (2007) demonstrated that quercetin, the most commonly eaten 
dietary flavanoid, found in most plant and vegetables could activate BKca 
channels and that its mechanism of activation was dependent upon the 
production of the reactive oxygen species hydrogen peroxide (H20 2). The 
production of H20 2 led to an increase in STOC frequency mediated by BKca 
channel activation. These effects were inhibited by application of IbTX and the 
reactive oxygen species scavenger catalase. The effects were independent of 
the release of substances from the endothelium although Khulmann et al 
(2005a) have demonstrated that quercetin can activate BKca channels in 
endothelial cells through the activation of NO/cGMP pathway. These actions 
may explain the beneficial effects of quercetin in rat hypertensive models 
(Cogolludo et al 2007).
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1.11.2.2 Phloreitin
Another flavanoid, phloretin had been independently studied for its BKcaCO 
activity on peroneal nerve fibres of the clawed toad Xenopus laevis (Figure 
1.12), (Koh et al 1994). Phloretin produced a 68mV hyperpolarising shift in 
activation curve and was equally effective when applied to either aspect of the 
channel, however, it had slow onset effects and slow wash-out effects. The 
mechanism of action of phloretin was proposed to occur via its absorption in 
neutral form into the membrane where it changes the gating properties of the 
channel. A decrease in the steepness of the activation curve (P0 Vs Voltage) 
accompanied by a shift to more hyperpolarised voltage was observed maybe 
due to dipole potentiation on the membrane and consequently affecting the 
gating charge and voltage sensitivity of the channel (Koh et al 1994).
1.11.2.3 Naringenin
Racemate (±) Naringenin (Figure 1.12) has been studied in further detail using 
electrophysiology in isolated rat tail artery myocytes. Using whole cell 
electrophysiology it induced a 22mV shift in V50 from control; interestingly 
potency was significantly reduced when the intracellular K+ concentration was 
reduced (from 90 to 14mM). Its effects were independent of the concentration of 
intracellular Ca2+ whereby naringenin activated BKca channels by affecting the 
voltage sensitivity of the channel as demonstrated by a change in slope of 
activation curve and by increasing the rate of channel activation (Saponara et al 
2006).
1.11.3 3-aryloxindoles
Further insights into the BKca channel opener characteristics of NS004 were 
addressed by replacing the nitrogen atom of the imidazolone bearing the phenyl 
ring with a carbon introducing a stereogenic centre at the 3’-position of the 
indole nucleus, this allowed for assessment of the 3D effects and 
stereochemistry (Hewawasam et al 1997) and the first example studied had the 
addition of a hydroxyl group at the carbon atom (Figure 1.13). Enantiomers of 
compounds were generated and tested either as racemate, optically active or 
inactive compounds. The trifluoro group was found to be essential (similar to 
NS004 and NS1619) and by substituting different groups on the C-phenyl ring it
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was shown that like NS004, chlorine in the para position to a hydroxyl group 
was essential for BKca channel activity although replacement of the hydroxyl 
with a methoxy group was tolerated. With regards to the chirality of the 
methoxy-chloro compound no particular enantiomeric composition displayed 
any significant advantage (Hewawasam et al 1997). However, 3-aryl-3- 
hydroxyindolones, displaying the same functional groups in the identical 
positions as NS004, the (-)-isomer was significantly more effective than the (±) 
or the (+)-isomer when compared to NS004 the eutomer was significantly more 
potent at 100pM, but not at 30pM, when tested on BKca channels expressed in 
Xenopus Oocytes (Hewawasam et al 1997; Hewawasam et al 2002a).
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Figure 1.13: Oxindoles
Further analysis of the structure-activity-relationships (SAR) of 3-aryloxindoles 
revealed that a des-hydroxy alternative was just as effective as the presence of
3-hydroxy group (Figure 1.13) and that an EWG (6'-CF3) was not essential for a 
compound to display BKcaCO properties. However its introduction greatly 
enhanced BKcaCO properties and its positioning on the ring affected potency 
(Hewawasam et al 2002a). Exploring the effect of different functional groups 
and chirality of the 3-aryl-3-hydroxyindolones could lead to the development of 
molecules that may show tissue specificity for neurons. Administration in the in- 
vivo MCAO rat model of stroke showed that the des-hydroxyl compound was 
able to reduce infarct size and block the release of the excitatory 
neurotransmitter glutamate, whereas the hydroxyindole was not able to reduce 
infarct size. This difference maybe due to the lipophilicity of the compounds and 
their relative abilities to penetrate the blood brain barrier. However the des-
hydroxyindole compound was considered not suitable for advancement to 
clinical trials de to its poor pharmacokinetic properties and metabolic instability 
(Hewawasam et.al 2002a).
1.11.4 BM S-204352 and 3-Fluorooxindoles
Due to the poor pharmacokinetic and metabolic properties of the aryloxindoles a 
similar series of related 3-fluorooxindoles was further investigated by BMS 
(Figure 1.13). A fluorine atom substituted at the 3-hydroxyl site led to the 
development of a new template for BKcaCO (Hewawasam et al BMS 1996; 
Hewawasam et al 2002b). From this set a compound bearing a 5-chloro-2- 
methoxy moiety at C3 position and a 6-substituted trifluoromethyl oxindole 
group was the most potent and termed BMS-204352 (Gribkoff et al. BMS, 2002). 
Again the positioning of CF3 groups affected potency, also the solubility of BMS- 
204352 was low (<10pM). Examination of the chirality of this compound 
revealed that the (+) isomer produced the most robust and consistent increase 
in BKCa channel currents in cloned cell lines and demonstrated significant IbTX 
sensitive increase in current at 0.01 and 0.1 pM with an EC50 determined as 
0.35pM (Hewawasam et al 2002b; Gribkoff et al 2001b). Further it was found to 
be very brain permeable and the authors described a method for the 
stereospecific production of the (+) isomer. The compound was used as the 
lead in clinical trials for post stroke neuroprotection (MaxiPost) section 1.6 
(Gribkoff et al 2001b; Gribkoff et al. BMS, 2002).
The presence of the methyl ether moiety in place of the usual more polar 
hydroxyl function could account for the high prevalence of MaxiPost in the brain. 
It was proposed that it could be converted to a more active phenolic compound 
by metabolic O-demethylation by enzymes in the blood brain barrier and that 
this may account for its lack of side effect in vascular smooth muscle 
(Kiesewetter et al 2002). Recently researchers at Neurosearch A/S have 
shown that racemate BMS-204352 can activate KCNQ/KV7 channels expressed 
in HEK293 cells (Schroder et al 2003) and that different enantiomers of BMS- 
204352 had differential anxiolytic effects in animal models of anxiety and stress 
via activation of Kv7 channels (Korsgaard et al 2005).
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1.11.5 Substituted Quinolinones
Retaining the aryl elements of the indole compounds and enlarging the 5- 
membered imidazolone ring into a 6-membered heterocycle led to the reporting 
of quinolinones as BKca channel openers. These were investigated by altering 
the substituents in the 3' position and led to the reporting of several classes of 
quinolinone molecules by researchers at BMS (Figure 1.14).
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Figure 1.14: Substituted quinolin-2-ones
1.11.5.1 Amino and hydroxyl quinolin-2-ones
4-aryl-3-hydroxyquinolin-2-ones (Figure 1.14) were the first of this series to be 
evaluated and patented as BKcaCO’s for treatment in post stroke 
neuroprotection (Sit and Meanwell, BMS, 1998). Interestingly they also showed 
potent antibiotic activity (Sit and Meanwell, BMS, 1999). However, the optimised 
compounds did not display the ability to penetrate the blood brain barrier this 
was thought to be a result of the presence of an ionisable 3-hydroxyl group 
(Hewawasam et al 2002c). As a result replacement of the 3-hydroxyl moiety of
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quinolinone with a less ionisable amine group generated 4-aryl-3-aminoquinolin- 
2-one derivatives (Figure 1.14) that were tested (Hewawasam et al 2002c).
The substitution of the quinine nucleus demonstrated that the presence of 5- 
CF3 and 6-CF3 had the most pronounced effect on channel activation than in 
other positions of the ring and that removal of hydroxyl or chlorine from the 4- 
aryl moiety decreased potency. This is further evidence of the requirement of 
BKcaCO’s to contain a hydroxyl function with a concurrent halogen in p-position, 
and that the presence and positioning of EWG was essential for optimisation of 
BKcaCO structural properties. Also, compounds that contained (trifluoromethyl) 
sulphonamide in replacement of the 3-amine moiety produced even greater 
activation. However, unlike the 4-aryl-3-aminoquinolin-2-one it failed to 
demonstrate brain penetrability. Therefore, the effects of 4-aryl-3-aminoquinolin- 
2-one were tested in MCAO stroke model where application of the compound 
reduced infarct size by around 10% (Hewawasam et al 2002c).
1.11.5.2 Mercapto quinolin-2-ones
Furthermore, quinolin-2-one compounds bearing 3-mercapto (SH) groups were 
also investigated (Figure 1.14). Although these compounds showed significant 
increases in BKca channel current relative to NS004 they demonstrated poor 
aqueous solubility (<0.005mg ml'1). From this series a hydroxyethyl derivative of 
the mercapto group (S-(CH2)2)OH) produced significant potency (3 times more 
potentiation of current than NS004) but still lacked sufficient solubility for 
potential therapeutic and in-vivo testing (Hewawasam et al 2004). In an attempt 
to increase solubility derivatives were added to the SH group. The addition of an 
amino alcohol retained equivalent BKca channel activation while improving 
solubility 100 times. The amino alcohol compound demonstrated potent 
vasodilator response in pre-contracted corpus cavernosum tissue. Further, in a 
rat model of erectile dysfunction (ED), it demonstrated comparable in-vivo 
efficacy to phentolamine increasing intra-cavernosum pressure without 
adversely affecting blood pressure as demonstrated with phentolamine. 
Therefore, these structures may provide therapeutic tools in erectile dysfunction 
(Hewawasam et al 2004).
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Following the work on 4-aryl-3-(mercapto) quinolin-2-ones Boy et al (2004) 
investigated attaching various alky subsituents to the 3-thiol group to 
characterise further compounds for the treatment of ED (Figure 1.14). This 
involved the generation of over 60 compounds of four major classes, of which 
the most potent class of compounds were typified by the presence of a 3- 
amino-2-hydroxy thiol side chain. A variable length of the tether (n) could be 
tolerated and phenols were generally more active than methylesters. However, 
those that showed the most potent activating potential had a H-bond acceptor 
with a remote amino group on the side chain of compounds.
1.11.5.3 4-aryl-3-(hydroxyalkyl)quinolin-2-ones (BMS-223131)
Further probing of the quinolin-2-one nucleus was performed to determine the
optimal hydroxyl-alkyl group by varying the number of bonds between the 
hydroxyl and C3 position (Hewawasam et al 2003a). These compounds had 
either a 4-aryl moiety of p-chlorophenol or p-chloroainsole both previously 
shown to have beneficial effects to derivatives of hydroxyquinolin-2-ones and 
aminoquinolin-2-one compounds. Here p-chlorophenol derivatives were more 
effective than p-chloroainsole derivative at relaxing pre-contacted corporal 
tissue and activating whole cell BKca channel currents. Compounds with 
variable length (1-3 carbons) all demonstrated BKcaCO properties with a trend 
for increasing potency with increasing bond separation. However, the most 
potent hydroxyalkyl termed BMS-223131 (Figure 1.14) was examined in rat 
model of ED. Interestingly the order of potency of these compounds 
determined using electrophysiology did not correlate well in relation to the order 
of potency determined by testing their vasorelaxant effects in rabbit corporeal 
tissue. This indicated possible contribution of tissue specific BKca channel 
expression, other biochemical mediators and differences in experimental setup 
(Hewawasam et al 2003a). A similar discrepancy was observed with 3- 
thioquinoline compounds (Boy et al 2004).
In a novel application for BKcaCO's, BMS-223131 demonstrated dramatic 
reduction of stress induced colonic motility and visceral noiception in rat in-vivo 
models, implicating a role for this compound in the treatment of diseases such 
as irritable bowl syndrome (Sivarao et al 2005). Whether the effects of BMS-
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224131 in the animal models used was specific to BKca channel activation was 
not determined. This was because antagonising the effects with BKca channel 
blockers could not be tested due to their high in-vivo toxicity. In addition, this 
series of quinolin-2-ones demonstrated potent cytochrome P450 (2C9 isoform) 
inhibition within a therapeutic range. This has resulted in the design of new 
synthetic routes generating new compounds that demonstrate a decreased 
cytochrome P450 profile while retaining BKcaCO properties (Vrudhula et al
2005). As the phenolic OH group is an essential element for BKcaCO properties 
Vrudhula et al (2007) investigated the addition of hydrophilic and hydrophobic 
subsituents ortho to the phenolic OH group of C ring of BMS-223131 with the 
most potent compound displaying decreased cytochrome P450 interation was 
the olefin derivative (Figure 1.14) although these derivatives were only half as 
potent as the parent BMS-223131 compound.
Further investigation of BMS-223131 included analysing the atropisomers of the 
compound, these were obtained by chiral separation of the molecule using high 
performance liquid chromatography. The atropisomers were not previously 
studied as it was assumed that the hydroxyethyl in the C3 position did not 
impose a strong rotational barrier between the phenolic and quinolinone rings 
and that under physiological conditions this would not have any consequences. 
However, the (-) isomer in all cases had the greater activating effect compared 
to the (+) isomer, suggesting stereoselective activation of BKca channels by 
these compounds (Vrudhula et al 2007). Therefore the atropisomeric effects 
should be considered when dealing with the development of chiral drugs; and 
that stereospecific drugs may also provide clues into sites of action on the 
channel.
1.11.6 Triazolones
Further exploration of the benzimidazolone derivatives included simplifying the 
structure by deanulation of the bicyclic benzimidazolone ring through the 
introduction of a heterocycle linker between the phenolic and electron deficient 
rings. The first example of these compounds including maintaining the p- 
chlorophenol ring and separating it from the other phenyl ring with a 1,2,4 
triazol-5-one heterocycle (Figure 1.15). These diaryl 1,2,4 triazol-5-ones were
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pioneered as a template structure for the treatment of urinary incontinence 
(Hewawasam et al 20026).
In this molecule the un-substituted phenyl analogue was ineffective but the 
addition of EWG to it induced activation properties similar to that observed for 
benzyl-benzimidazol-2-ones, aryloxindoles and quinolinones. Further, the 
positioning of the CF3 was important and increasing the electron deficiency by 
addition of 7,4 and 3,5 bisCF3 maintained BKcaCO ability. The effects of these 
compounds were studied in-vitro using pre-contracted bladder tissue strips and 
like with the quniolin-2-ones and 3-thioquinolinones the rank order of potency of 
inhibition of contraction did not correlate with electrophysiology. For example 
the phenyl analogue (no EWG attached) produced -90%  inhibition in 
contraction but did not activate BKca channels in electrophysiology. This 
highlights the need for representative functional in-vitro and in-vivo tests to 
assess the physiological effect of compounds (Hewawasam et al 2002d).
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Figure 1.15: Triazolones
A more in-depth SAR analysis of triazolone structure was examined by Romine 
et al (2002) via examination of a series of 4,5 diphenyltriazol-3-ones (Figure 
1.15). While retaining a 4-CF3 the positioning of the hydroxyl and chloro function 
of the N-phenyl ring was manipulated. Maintaining a 2-OH and 5-CI position 
was important as a 4-OH, 3-CI or 5-OH, 2-CI configuration resulted in inactive 
compounds. This highlighted the importance of the phenol ring and the 
positioning of a 2'-hydroxyl function as demonstrated for other benzimidazolone 
derived BKcaCO's. Further studies maintaining the 2-OH and 5-chloro groups 
and altering the positioning of the CF3 group demonstrated that it was preferred 
in either the para or meta position increasing the electron deficiency of the ring.
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Further bisCF3 groups potentiated BKca channels but replacement with the less 
electronegative fluorine led to a reduction in channel activation and the absence 
of a EWG altogether led to a loss of BKcaCO ability.
Introduction of flexibility into this template structure was not tolerated as addition 
of a methylene spacer between the triazol-3-one and the N-phenolic ring had 
deleterious effects. Insertion of a methylene linker between the phenolic ring 
and imidazolone nucleus of benzyl-benzimidazol-2-ones had previously shown 
to retain BKca channel activation (Meanwell et al 1996). Interestingly 
compounds that had a methylene spacer inserted between the electron 
deficient ring and the heterocycle triazol-3-ones retained activity (Figure 1.15). 
Romine et al (2002) suggested that the electron deficiency of the ring is not 
important for binding to the channel but rather the lipophilic nature of the 
aromatic ring imparted by the trifluoromethylated groups.
The carbonyl oxygen and its relation to phenol ring has been proposed to be 
important for quinolin-2-ones and benzimidazolone based compounds. However, 
for the deannulated triazoles the positioning of the carbonyl oxygen in the 
heterocycle ring and the different regioisomer forms did not have any effect on 
the overall BKcaCO ability of these compounds. Modelling studies revealed that 
the relationship between carbonyl group and the phenol was not important but 
the relationship and distance between the oxygen of phenol and the hydrogen 
of NH of the triazole ring important for compounds that activated the channel. 
Further removal of NH while retaining the carbonyl group led to inactive 
compounds, therefore an H-bond donor or protonated N in the heterocycle was 
thought to be essential for these compounds (Romine et al 2002). An amide NH 
group was also thought to be important for benzimidazolones and benzyl- 
benzimidazol-2-one derivatives (Meanwell et al 1996; Hewawasam et al 1997; 
Li ef a /1997).
1.11.7 Oxad iazolones/BMS-191011
Replacement of the triazolone heterocycle with oxadiazolone revealed a series 
of new compound typified by BMS-191011 (Figure 1.16). This compound was 
able to increase BKca channel currents by 26% at 1 jlxM and has been proposed 
as another target for the treatment of post stroke neuroprotection having shown
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efficacy in rat stroke models. However, like other BKcaCO structures its 
therapeutic potential is limited by poor solubility in aqueous buffer. This led the 
authors to guide the design and synthesis of pro-drug versions of BMS-191011 
resulting in the addition of deoxycarnitine to the phenolic hydroxyl. The pro-drug 
did not display BKca channel activity but was readily converted (>80%) to the 
active compound upon intravenous administration, by undetermined esterases 
in blood plasma. The converted form was able to potently reduce the effects of 
MCAO stroke in rats and was submitted for potential clinical development 
(Hewawasam et al 2003b).
More recently there have been reports of attempts to increase solubility of BMS- 
191011 through the appendage of different heterocycles such as piperizines 
and piperidines to the phenol or electron deficient rings. However, the simple 
addition of aniline yeilded sufficient solubility and increased BKca channel 
potentiation (Figure 1.16). The aniline derivative showed enhanced brain to 
plasma partitioning relative to BMS-191011, but had no significant effect in the 
rat MCAO stroke model (Romine et al 2007).
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Figure 1.16: Oxadiazolones
1.11.8 Triazoles
An extensive research program by V.Calderone, G.Biagi and I.Giorgi in Italy has 
led to the development of detailed SAR relationships for novel BKcaCO’s. Using 
triazole compounds as a starting point the 5-(4’-substututed-2’-nitroanilino)-4- 
carboxyamido-1,2,3-triazoles were examined (Figure 1.17). The addition of 
halogens or methoxy and methyl groups to the 4 ’ position of the nitroanilino ring 
gave compounds that retained similar activity to NS1619 but the presence of a
46
sec-butyl imparted the highest potency. Overlapping of the theoretical tri­
dimensional structure of NS1619 or NS004 with triazoles revealed that the nitro 
group was at a position mimicking the carbonyl oxygen of the benzimidazolones. 
Replacement of the nitro group resulted in inactive compounds no matter what 
groups were added to the 4-position, this implied a role for this oxygen in 
BKcaCO properties of these triazoles potentially acting as a H-bond acceptor 
(Biagi et al 2000).
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Figure 1.17: Triazoles I
Further exploration of triazoles included using them as intermediates in the 
synthesis of new compounds. These included 5-substituted triazolyl- 
benzimidazolones and 5-substituted triazolyl-benzotriazoles (Figure 1.17). 
Interestingly the former bearing the most structural resemblance to NS1619 
were not activators (except for a structure with a CH3 in 5’ position). Conversely 
the benzotriazoles, although not quite as potent as NS1619, showed activating 
properties that were dependent, like carboxyamido-1,2,3-triazoles on 
substitution with Cl, F and CF3. In contrast the methoxy group was deleterious 
but addition of methyl function resulted in a compound with greatest potency 
(Baragatti et al 2000). Therefore, as addition of methyl to both triazolyl -  
benzotriazoles or -benzimidazolones was advantageous. These structures were
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further examined by increasing steric hindrance and lipophilicity by addition of 
sec-butyl (Figure 1.17) or phenyl groups. These additions to the benzotriazole 
skeleton were tolerated and led to full relaxations of pre-contracted aortic rings, 
however, additions to the triazolyl-benzimidazolone were less potent (Biagi et al 
2001a) and opening up the benzimidazolone ring by replacement with an urea 
linker led to a decrease in activity. In addition, a series of benzotriazinone 
compounds (Figure 1.17) were found to be in effective BKcaCO’s suggesting 
that the molecular composition of the triazole ring was important to its 
pharmacophore (Biagi et al 2001 a).
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Figure 1.18: Triazoles I I  and related compounds
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Interestingly replacement of the 1,2,3 triazole ring with a 2-hydroxyphenyl group 
resulted in a benzotriazolyl phenol compound (Figure 1.18) that was 10-fold 
more effective than triazolyl-benzotriazoles (Biagi et al 2001a) providing further 
evidence to the importance of a 2-hydroxyphenyl ring for potent BKcaCO’s. 
Further to this work, salicylicbenzotriazoles were generated by introduction of a 
carbonyl group, found present on the imidazolone ring of benzimidazolones, as 
a linker between the 2-hydroxyphenyl ring and that of the benzotriazole. This
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introduced flexibility in the molecule of which salicylicbenzotriazoles with a 
methyl group in 5’ position (Figure 1.18) were the most potent and was 
preferred to phenyl or halogenated groups in this position. In addition, the 
carbonyl function was an essential feature as removal led to a decrease in 
potency (Biagi et al 2001b). The salicylicbenzotriazoles were the first of the 
triazoles to be tested in-vivo where they demonstrated cardio-protective 
properties against ischaemic injury. Worth mentioning are 2-nitro- 
salicylicanilides (Figure 1.18) a more open structured version of 5-(2’- 
nitroanilino)-1,2,3 carboxyamido triazoles (Figure 1.17) also with an amide 
linker. This demonstrated comparable potency to NS1619 and again the 
addition of methyl group in 5’positon of 2-nitro-salicylicanilides produced the 
most potent compound (Figure 1.18), (Biagi et al 2001b).
A series of 1,5-diarylsubstituted 1,2,3 triazoles were selected for investigation 
by Calderone and researchers (Figure 1.18). These compounds were derived 
from the bioisoteric replacement of the 1,2,4 triazol-3-ones heterocycle studied 
by researchers at BMS with a monocylic 1,2,3 triazole ring. The diaryl 
substituted 1,2,3 triazoles demonstrated similar potency to NS1619 but did not 
display full vasorelaxant properties, on the whole the 1,2,3 triazole cyclic linker 
was not as profitable as triazol-3-ones. This led to the conclusion that the 
presence of a hydrogen-bond donor site such as the NH group of the 1,2,4 
trizol-3-one heterocycle was important for activation. However, addition of a H- 
bond donor in the form of a secondary or tertiary alcohol near the 4-position of 
the 1,2,3 triazole ring caused a loss of activity (Biagi et al 2004a; Calderone et 
al 2005a). Another difference is the presence of a carbonyl group in triazol-3/5- 
ones, however, the lack of activity can not be fully attributed to lack of this group 
as triazoles tested demonstrated BKcaCO without this function (Biagi et al 
2004a; Calderone et al 2005a). In addition, the inclusion of methylene spacer 
was well tolerated but addition of a carbonyl linker was a deleterious 
requirement (Calderone et al 2005b).
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Further SAR work with this series highlighted the importance of hydroxyl group 
in 2-position, as compounds lacking this function or substituted with nitro or 
methoxy were inactive (Calderone et al 2005a). Further, addition of Cl in para 
position to hydroxyl group increased potency. Whether the Cl atom has 
electronic or steric effects upon triazoles remains undetermined (Calderone et 
al 2005b).
Flexibility of these molecules was investigated and it was identified that 1-N- 
benzyl substituted 1,2,3 triazoles (Figure 1.18) were much more potent than 
NS1619 and induced a near complete relaxation of pre-contracted aortic rings, 
and that the less flexible 1-N phenyl substituted analogue was ineffective. This 
demonstrated that flexibility with a benzyl group is more favourable than the 
phenyl and may effect the conformation and interaction with channel as phenyl 
groups bear a more co-planar conformation (Calderone et al 2005b).
These data support that the pharmacophore of these deannulated BKcaCO’s 
(triazoles and triazol-3/5-ones) requires two H-bond sites. In addition the pre­
requisites of BKcaCO’s having two phenyl rings one a hydroxy-para- 
chlorophenyl and the other containing an EWG is an important factor in the the 
design of deannulated BKcaCO’s. However, the composition of the linker/spacer 
region in particular placement of H-bond donating group in the series of triazol- 
3/5-ones and triazoles imparts a significant degree of biological activity.
Researchers at GlaxoSmithKline have recently reported in patents that a series 
of substituted thiazoles as BKcaCO for the treatment of urinary bladder 
conditions (Figure 1.18). However, compounds described also demonstrated 
COX -1 inhibition. In an attempt to develop further compounds with lower EC5o 
for BKCa channel activation than that required for COX inhibition various 
substitutions have been described that fit into pharmacophore patterns 
described for other activators and include the presence of EWG and H-bond 
donors (Marino and Haifeng, GSK, 2007).
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1.11.9 CGS-7181
The compounds CGS-7181 and CGS-7184 have been developed by 
researchers at Novartis Pharmaceuticals as BKcaCO’s. Structurally they are 
esters of indole-3-carboxylic acids and have shown to be far more potent than 
structurally related NS004 and NS1619 with similar potency to DHS-1 (<0.1 pM). 
It was hypothesised that the acidic NH of the urea moiety could act as a 
bioisoteric replacement for the 2-hydroxy function of NS004 and NS1619 (Hu et 
al 1997) which has been shown to be critical for BKca channel activation in 
these and related compounds (Meanwell et al 1996; Hewawasam et al 1997). 
CGS compounds were thought to act on a site located intracellular on the a- 
subunit of the channel; although when the compound was applied to either 
aspect of the channel it was able to activate BKca channels by increasing open 
pore probability. Specificity was investigated via the effect of CGS-7181 to 
inhibit binding assays for 26 other enzymes and receptors. The effects of CGS- 
7181 on BKCa channels from cells isolated from vascular and non-vascular 
tissue systems across different animal species (dog and rat) was tested, 
differences in sensitivity to different compounds within the series were found yet 
further SAR work and in-vivo testing has not been reported (Hu et al 1997; 
Coughlan et a /2001).
1.11.10 Sym m etrical b isphenols
The concept of a symmetrical pharmacophore of BKCa channel openers was 
explored by bioisoteric replacement of the amide of NS004 with phenolic 
hydroxyl groups to create symmetrical bisphenols. These compounds were 
assessed by substitutions with various halogens and separation of the two ring 
structures by a one or two bond linker (L) of either methylene or thiol bridges 
and by a four bond urea linker. Compounds of this description were obtained 
from BMS compound library and all compounds displayed C2 symmetrisation 
(Figure 1.19), (Li et al 2003). Different bond lengths (1, 2 and.4) were tolerated 
and introduced flexibility in the molecule and multiple substitutions of the ring 
systems with EWGs were essential for compounds to display enhanced BKca 
channel opener activity. It was shown that EWGs, in particular halogenations 
with chlorine, fluorine and bromine, increased the acidity of the phenolic OH 
(Figure 1.19).
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The pKa (logarithm of the acid dissociation constant) for the series of 
compounds was determined and those with a value of less than 8 produced 
significant increases of IbTX sensitive current. Selected compounds with 
chlorine or bromine R' group substitution (with one bond methylene separation) 
produced the greatest increase in activation of BKCa channels (up-to 3-fold) as 
demonstrated by bromo bisphenols and chloro bisphenols, (Li et al 2003). 
NS1608, an un-symmetrical BKca channel opener with a urea linker was less 
potent than the symmetrical bisphenols with a urea linker (Li et al 2003). The 
structure of magnolol can fit into the description of a symmetrical BKca channel 
modulator.
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Br. OH
Cl Cl
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Br HO Br ci HO Cl
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Figure 1.19: Symmetrical bisphenols
1.12 Non-benzimidazolone derived BKCaCO
A number of non-benzimidazolone derived compounds have been studied for 
BKcaCO properties. A pharmacophore approach has been used for some of 
these classes of molecules to understand the chemical features pertaining to 
those compounds bearing BKcaCO properties.
1.12.1 Pimaric acid derivatives
Further BKcaCO compounds based on terpenoids (section 1.8.1) were 
discovered by the work of the research groups of Imaziumi and of Ohwada in 
Japan. Investigating compounds bearing similar structure to maxiKdiol they 
identified a series of pimarane compounds and their isomers. These 
compounds were first isolated from pine tree gum resins and used as the basis
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to identify pharmacophore patterns using a membrane potential DiBAC4 
fluorescent assay and whole cell electrophysiology. From which pimaric acid 
(PiMA) was further characterised for its BKcaCO activity (Figure 1.20). PiMA 
increased the calcium and voltage sensitivity of the channel and activated BKca 
channels when applied to either side of the membrane unlike that observed with 
maxikdiol. However, the effect of PiMA was not dependent upon the presence 
of p-subunits similar to that observed with maxiKdiol (Imaizumi et al 2002). 
Interestingly abetic acid, a structural isomer of PiMA, could not activate BKca 
channels (Figure 1.20).
Structural alignment between PiMA, maxiKdiol and abetic acid revealed that the 
small difference in the extension and direction of the hydrophobic residues at 
C13 was similar in maxiKdiol and PiMA but different in abetic acid, and it was 
concluded that these alkyl groups could bind to a similar hydrophobic site of the 
oc-subunit. Another requirement of activation was the presence of a strong 
hydrogen bonding around the C4 region provided by carboxylic acid. PiMA was 
slightly more potent than maxiKdiol whose H-bond site was around position C5 
(Imaizumi et al 2002).
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Figure 1.20: Pimaric acid (PiMA) and related compounds
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Further structure activity studies revealed that dehydroabetic acid (DHAA), an 
aromatic form of abetic acid, showed BKcaCO properties similar to that of PiMA 
and that superimposition of these compounds revealed a close match in ring ‘A’ 
and ‘B’ but the aromatic ring ‘C’ of DHAA was different (Ohwada et al 2003). 
Therefore, a series of mono and di halogenations with Br or Cl of the ‘C’ ring 
were performed and it was shown that di-chlorination provided a compound, 12- 
14-dichlorodehydroabietic acid (di-CI-DHAA) that demonstrated marked 
increase in BKca channel current (Figure 1.20). The study also confirmed the 
importance of a carboxylic acid moiety in the C4 position as replacement with 
hydroxymethyl was deleterious, and adding an oxygen functionality to the ‘B’ 
ring was negated (Ohwada et al 2003). Therefore, an OH provided by the 
carboxylic acid moiety at this position was important for activity, a common 
feature among BKcaCO’s.
The properties of di-CI-DHAA were further assessed using electrophysiology 
and like PiMA and maxiKdiol it activated BKca channels equi-effectively when 
applied to either aspect of the channel. Moreover, its effects were not 
dependent on or affected by the presence of the p-subunit and it did not modify 
single channel conductance. However, unlike PiMA and maxiKdiol, di-CI-DHAA 
displayed marked potency with significant increases in BKCa channel current at 
concentrations <0.1 pM and is one of the most potent BKcaCO’s published to 
date (Sakamoto et a /2006). Furthermore, di-CI-DHAA was different to a number 
of other BKcaCO such as BMS-204352 in that its potentiation of BKca channel 
currents (relative to control) was much greater at more negative voltages and 
became diminished at more positive voltages. The mechanism of action was 
thought to decrease the time the channel remains in the closed state. Specificity 
was examined and at higher concentrations di-CI-DHAA suppressed VDCC 
currents (Sakamoto et al 2006).
A new scaffold based on modifications of the dehydroabetic acid (DHAA) 
molecule has been proposed that involves linking two pharmacophore centres 
together forming a dimer. It was hypothesised that this would enhance the 
binding probability of a compound to the tetrameric structure of the a-subunit. 
Through the introduction of a hetero atom and ketone into ring ‘B’ of DHAA, 
hexabenzazepinone derivatives were synthesised, from which di-chloro-
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substituted N-methy-hexahydrodibenzazepinone (Figure 1.20) formed the basis 
of a novel BKca channel pharmacophore.
Dimers were tethered to each other via a rigid diacetylenebenzene unit that 
linked each hexabenzaxepinone via n-propyl chains bonded to the N atom of 
hexabenzazepinone (Figure 1.20.) These propyl chains introduced molecular 
flexibility within the dimer. Furthermore, meta, para and ortho substitution of the 
benzene ring of the rigid diacetylenebenzene unit allowed to change the 
distance between the pharmacophore centres (Tashima et al 2006). This was a 
novel approach and was performed to try to probe particular binding sites and 
gain an understanding in terms of structure-fit relationships. There was no 
preference for a particular meta, para or ortho substitution pattern and Tashmia 
et al (2006) showed that some monomeric compounds particularly those 
possessing a terminal benzene were more potent than the dimers. The authors 
have recently obtained patent protection for the therapeutic use of PiMA 
derivatives as BKCaCO (Ohwada and Imaizumi, Tanabe Seiyaku, 2006).
1.12.2 Carbonic anhydrase inhibitors
Recently Tricarico et al (2004) examined the pharmacophore of a series of 
carbonic anhydrase (CA) inhibitors identified as BKCa channel openers (Figure 
1.21). This is typified by acetazolamide (ACTZ) used in the treatment of 
hyperkalemic periodic paralysis (hypoPP). ACTZ effects were dependent upon 
the level of intracellular Ca2+. CA compounds that activated BKCa channels all 
showed an intramolecular hydrogen bond with inter-atomic distances between 
1.82-3.01A and contained a ring poor of electrons. The lack of one of these two 
properties led to inactive compounds with methazolamide lacking aromacity and 
hydrochlorthiazide demonstrating a large inter atomic hydrogen bond (>3.01A). 
Further, analysis of spatial geometry and electrostatic potential profiles for 
ACTZ revealed three negative charges and one positive similar to that of NS004 
and could represent a complementary binding site on the channel (Figure 1.21). 
Due to the Ca2+ dependent effect of ACTZ action Triacarico et al (2004) 
proposed that ACTZ could act to stabilize binding of Ca2+ ions to the Asp rich 
Ca2+ binding sites of the channel and at physiological intracellular pH Asp 
sequences are negatively charged. Further potency didn’t correlate to logP or 
logD suggesting a cytosolic hydophillic site of action.
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Figure 1.21: Carbonic anhydrase inhibitors and Ketoconazole derivatives 
1.12.3 Ketoconazole
Ketoconazole is a synthetic biaryl compound that is used as an antifungal agent 
in the treatment of fungal skin infection. Power et al (2006) determined that 
ketoconazole was an opener of BKca channels in bovine pulmonary artery cells. 
The analysis of derivatives or partial structures of ketoconazole determined that 
the 2,4-dichlorophenyl group was essential for activity as its removal led to 
inactive compounds. In addition, the imidazole group of ketoconzaole was not 
important for activation. Removal of the acetyl moiety to leave piperizine as the 
moiety at position 4 of the phenoxy gave a compound that was similar in 
potency to ketoconazole. However, removal of the acetylpiperazine to leave a 
p-aminophenoxy group (Figure 1.21) gave a compound that was significantly 
more active than the ketoconazole. Interestingly, removal of the amino to leave 
a phenoxy group or substitution with bromine led to compounds that blocked 
BKCa channels, further replacement of the acetylpiperazine with piperidino 
(Figure 1.21) led to compounds that blocked BKCa channel currents (Power et al
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2006). Therefore the aniline nitrogen atom is thought to confer BKcaCO 
properties to these derivatives, such that it might act as a hydrogen bond 
acceptor or donor or increase the electron density in the phenoxy ring. 
Interestingly piperidino derivatives containing an anilino moiety was a BKca 
channel blocker, the anilino compounds that activated the channel had 
hydrophilic subsituents whereas the piperidino compound was lipophillic. 
Therefore, phenyl groups seem to be important for binding and that the type of 
phenoxy moiety is crucial for ability of compounds to activate the channel.
1.12.4 Structural derivatives of tamox ifen
Sha et al (2005) investigated tamoxifen and other structurally related 
compounds using a DiBAC4 fluorescent assay. It was determined that the N,N- 
dimethylaminoethyloxy group was not necessary for activity, and removal of this 
functionality to leave an acidic phenol was also not required for tamoxifen 
activity (Figure 1.22). Stilbene derivatives of tamoxifen were synthesised and it 
was shown that substitution of the ring (R1 group) with hydrophobic groups 
such as methoxy and trifluomethyl was crucial for activity where as halogens 
were not. Analysis of a structurally related synthetic non-steroidal derivative, 
diethylstilbestol (DES), was more potent than tamoxifen but a methoxybenzene 
derivative was the most potent compound examined (Figure 1.22). Structural 
differences resolved that the hydroxyl function of DES was not important and 
that the substitution with hydrophobic groups (methoxy) at the para position of 
the benzenes increased potency. In addition, substitutions of the 
dimethyloxystilbenes were more potent than the stilbene derivatives implicating 
the arrangement of benzene rings around the central double bond in 
determining the potency.
Tamoxifen Stilbene
derivatives OH Methoxy stilbene 
derivative
Figure 1.22: Xenoestrogens and their derivatives
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1.13 Indole and acrylamide derived BKCaCO's
1.13.1 NS-8 and 2-am ino-4-aza indoles
The pyrrole compound NS- 8  (2-amino-3-cyano-5-(2-fluorophenyl)-4- 
methylpyrrole) was identified by Tsuda at Nippon Shinyaku as a BKcaCO that 
showed significant efficacy in the rat systometry and hyper-reflexia in-vivo 
models of overactive bladder (Tsuda et al, Nippon Shinyaku, 1999) however a 
phase-l clinical trial of NS- 8  was recently discontinued (Japan Corporate News 
(2007), (Table 1.2).
Turner and colleagues at Abbott laboratories, using NS - 8  as a starting template, 
have developed several derivatives of 2-amino-4-azaindoles (Figure 1.23). SAR 
studies were informed by analysing different 2 -substituents of the azaindole 
nucleus. Compounds were assessed using a radioactive Rb+ efflux assay with 
smaller acyclic aliphatics groups (R’N(CH3) 2 and R’N(CH2CH3)2  preferred to 
longer chains (R’NHCH2 Ph) and for cyclic aliphatics 6  and 7 member 
substituted rings were preferred to 5-membered rings. Compounds with either 
piperidine or morpholine ring subsituent were the most potent producing 7-fold 
higher increase in whole cell BKca currents than NS8 . In addition the position of 
the OH group of the morpholine and its steric conformation had great effect 
upon potency (Turner et al 2003; Turner et al. Abbott Lab, 2004). Further to this 
work a series of pyrrolopyridine compounds, in particular 2 -amino-pyrrolpyridine 
(Figure 1.23), have been patented as novel BKca channel openers although 
detailed information on SAR studies has yet to be published (Turner et al. 
Abbott Lab, 2004).
Further researchers as GSK are working on the basis of a similar template 
(Figure 1.23) to 2-amino-4-azaindole that has been disclosed in patents (Dennis 
et al. GSK. 2005).
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Figure 1.23: NS-8 and related compounds 
1.13.2 Tetracyclic benzofuranindoles
Butera and colleagues at Wyeth have investigated tetracycle compounds as 
potential novel K a t p  channel openers based on structural modifications to 
Celikalim. Furanindole was the most potent of this series but examination of the 
vasorelaxant effect of these commpounds on pre-contracted bladder and aorta 
was not reversed by K a t p  channel blocker glibenclamide but could be reversed 
by application of IbTX (Figure 1.24). Interestingly these compounds showed 
selectivity in activation of BKca channels to bladder than in aorta with an aorta to 
bladder potency ratio of 8  to 46-fold. From a SAR point of view removal of 
bromine from furanindole led to a 2 -fold loss in potency but replacement with 
iodine, chlorine or nitro group led to a 2 -fold increase in potency and that the 
indole NH and carboxylic acid (acting as a proton donor) was critical for activity. 
Although, replacement of the oxygen atom of benzofuran with carbon was also 
tolerated (Butera et al 2001).
At the same time the research group of Park and Kim in South Korea identified 
benzofuranindoles as BKcaCO’s. Based on the superimposition, using a 
MOPAC2002 protocol, of a benzofuroindole skeleton with that of BMS-204352 a 
novel pharmacophore was suggested that led to the generation of compounds 
with substitution at positions 1, 2, 7 and 8  with EWGs (Cl, Br and CF3) or with a 
carboxylic acid. The most potent compounds, as tested in outside-out 
electrophysiology on cloned rat BKca channels expressed in Xenopus laevis, 
had chloro and trifluoromethyl group substitution at position 4 and 7 and
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carboxylic acid moiety at position 1 (Gorememis et al 2005). This fitted in with 
the pharmacophore of a benzofuroindole skeleton proposed by Butera and 
colleagues with negative charges at position 1 and electron withdrawing groups 
at position 4 and 7 (Butera et al 2001; Gorememis et al 2005).
COOHCOOH
Abbott Benzofuroindole
\ ___ /
Katp Channel opener: derivative of 
Cyclobut-3-ene-1,2-dione
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3
TBIC
NH
BKCa Channel opener: derivative of 
Cyclobut-3-ene-1,2-dione
Figure 1.24: Benzofuroindoles and substituted cyclobut-3-enes
Further investigation of compound 8  of this series by Ha et al (2006) termed 
TBIC (Figure 1.24), activated BKca channels in pyramidal neurons from the 
hippocampus with greater efficacy than those of cloned cell lines expressing rat 
BKCa channel a- and p1 subunits. Its action did not require the presence of p1 
subunit and shifted conductance-voltage curve without affecting voltage 
sensitivity. Furthermore, it increased P0 and demonstrated fast onset of 
activation when applied and fast inactivation of BKCa channel currents when 
removed and a more pronounced effect was observed when it was applied to 
the extracellular side. Further investigation of the allosteric sites of interaction 
on the a-subunit in addition to investigating differential effects in different 
tissues needs to be investigated to identify tissue specificity (Ha et al 2006).
Cyclobut-3-ene-1,2 -diones were developed as KAtp channel openers by 
researchers at Wyeth (Figure 1.24). However slight modification to this structure 
revealed new BKCaCO’s that did not demonstrate specificity to KAtp channels
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(could not be blocked by glibenclamide). This is typified by the removal of a N- 
atom of the cyclobut-3-ene-1,2-diones and replacing with aralkyl groups with the 
most potent derivatives achieving a bladder to aorta specificity ratio of >30 
(Butera et al 2005).
1.13.3 Acrylam ides
Another chemotype investigated by Wyeth were molecules composed of a 
cinnamic amyl group linked to an anthranilic acid group by an acrylamide linker 
(Figure 1.25) whose structures have been disclosed in patents (Lennox et al, 
Wyeth 1999; Lennox et al, Wyeth, 2000). These acrylamides share structural 
relationship to fenamates due to the presence of an anthranilic ring. These 
acrylamide compounds, as was demonstrated for cyclobut-3-ene-1,2-diones 
and benzofuroindoles, showed selectivity to bladder versus vascular tissue. 
Further SAR work revealed that EWG in both rings are important and that 
introduction of electron donor group such as methoxy was detrimental (Figure
1.25) to activity. Removal of Cl from right hand anthranilic acid ring led to a 
decrease of potency in smooth muscle relaxation but increased tissue 
specificity to bladder however on the left hand ring replacement of EWGs with 
other halogens was tolerated. The addition of a N atom into anthranilic acid ring 
or esterification of the carboxylic acid derivative was deleterious (Lennox et al, 
Wyeth, 1999, Lennox et al, Wyeth, 2000; Nardi and Olesen 2007). This work 
suggested that one of the aromatic groups should be substituted with an acidic 
H-bond donor such as that provided by carboxylic function and that this group is 
prefered in the ortho position to the linker region. Therefore these compounds 
have properties that have been ascribed for other BKcaCO’s (Coughlan et al 
2001; Calderone et al 2005a,b; Nardi et al 2006). The acrylamide in Figure 
1.25 and associated compounds were tested in the Malgrem's rat hypertrophied 
bladder model and led to a 70% reduction in spontaneous contraction 
(Argentieri et al 2006).
Nardi and Olesen at Neurosearch A/S investigated the structural similarity 
between benzofuroindole and acrylamides. Overlapping of the two molecules 
revealed that the right hand side of the rings demonstrated good alignment with 
a common polar feature formed from the O and NH within the linker regions and 
this is placed in close proximity to a carboxylic acid and phenyl groups.
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However the left hand side of the rings demonstrated poor overlap showing that 
these structures had tolerance to the different type of subsituents in this side of 
the molecule.
Wyeth: Acrylamide
H
Addic
Neurosearch: Template
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Tetrazole-acrylamide
Figure 1.25: Acrylamides
These compounds from Wyeth were limited in the patent protection to 
substituents in R4 or R5 as being either carboxylic acid or COOR, therefore due 
to the requirement of an acidic group in this position Neurosearch A/S 
investigated the optimal acidic moiety in this position (Nardi et al Neurosearch 
A/S, 2006; Nardi and Olesen 2007). They found that the optimal arrangement 
had an chlorine in position 5 and an acidic function in position 2, a similar 
optimal arrangement of a Cl in the para position to OH for a number of BKcaCO 
(including NS1619, NS004 and benzyl-benzylated benzimidazolones etc) has 
been reported. The bioisoteric replacement of the carboxylic acid function of the 
anthranilic ring with tetrazole ring (Figure 1.25) increased BKca channel current 
10-fold at 1|uM and substitution with a similar acidic sulphoxide moiety was also 
tolerated (Nardi et al Neurosearch A/S, 2006; Nardi and Olesen 2007). Nardi 
and Olesen (2007) propose a new template for the design of BKcaCO’s (Figure
1.25) as flexibility in the cinnamic amide/acrylamide linker retains BKcaCO 
properties. In addition, the acrylamide linker is a known Michael acceptor 
(common in a number of different drugs) and prone to exhibit metabolic or 
toxicological side effects. Therefore, modification of this linker may provide 
more suitable therapeutics. It should be mentioned that similar cinnamic amides
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based on modifications of the template (Figure 1.25) have been developed as 
potential KCNQ agonists (Nardi and Olesen 2007).
1.14 A generalised pharmacophore for BKCa channel openers
The current unavailability of a three dimensional crystal structure of BKca 
channels has prevented the generation of 3D pharmacophores that would 
enable the evaluation of potential drug-channel interaction/binding sites for 
BKcaCO's. The diverse range of structures shown to be BKca channel openers 
limits the generation of a unified pharmacophore model that encompasses all 
compounds. This is highlighted by the structural differences of compounds 
isolated from natural sources such as DHS-1 and synthetic molecules such as 
NS1619.
However, as reviewed here BKcaCO’s have shown to share similar structural 
features or requirements. This has led to a hypothesis of a generalised 
pharmacophore pattern that could form the basis to guide the design of new 
molecules demonstrating BKcaCO properties (Figure 1.26), (Coughlan et al 
2001; Calderone et al 2005a,b; Nardi et al 2007).
This pattern is represented by two phenyl rings, that can be symmetrical and 
structurally attached by a linker region. One of the phenyl rings (A ring) is often 
represented by a 2 -hydroxyphenol as with benzimidazolones, benzyl- 
benzimidazol-2-ones/BMS-189269 (Meanwell et al 1996; Hewawasam et al 
1997; Li et al 1997), quinolin-2-ones/BMS-223131 (Vrudhula et al 2007), 
oxadiazoles/BMS-191011 (Romine et al 2007). The replacement of the hydroxyl 
group or the presence of other acidic moieties is tolerated such as a carboxylic 
acid in benzofuroindole compounds (Butera et al 2001; Ha et al 2006), 
acrylamides (Lennox et al, Wyeth 1999; Lennox et al, Wyeth, 2000) fenamates 
(Ottolia and Toro 1994), PiMA (Imaizumi et al 2002) and di-C-DHAA (Ohwada 
et al 2003; Sakamoto et al 2006). Whether it is the carboxylic acid or the 
hydroxyl group of this moiety that is important remains unknown, Although, 
Meanwell et al (1996) and Hewawawsam et al (1997) suggested that the 
phenolic OH and carbonyl oxygen of benzimidaolones (NS1619 and NS004) 
and benzyl-benzimidazol-2-ones could mimic a carboxylic acid. Other classes of
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BKcaCO demonstrate the presence of hydroxyl group as an essential 
requirement and include phenolic compounds (Wu et al 2001; Nardi et al 2003), 
symmetrical bisphenols (Li et al 2003) and flavanoids such as phloretin (Koh et 
al 1994; Li et al 1997).
Variable length and flexibility tolerated 
Consisting o f  cyclic or fused rings or acyclic chains 
Sometimes presence o f aH-bond donor/acceptor
Usually acidic/proton donor 
functional group
EWG groups pref erred 
Additon of hydrophobic/l ipophillic 
groups tolerated
HO
Essential: Substitution at position 2
EW GLINKER
Subsitution with halogens in 
p-position preferred
Two phenyl rings can be symmetrical
Figure 1.26: A generalised pharmacophore pattern for the development of 
novel synthetic BKcaCO
Further bioisoteric replacement of the acidic/proton donor group with a tetrazole 
or sulphoxide is tolerated as demonstrated by certain cinnamic- 
amide/acrylamide compounds (Nardi et al., Neurosearch A/S, 2006; Nardi and 
Olesen 2007). Furthermore, the 2 ’ subsituent has been shown to be required in 
the ortho position to the linker region for certain benzimidazolone derived 
compounds and it has been shown that swapping of the 2 ’ acidic group in 
particular a hydroxyl group into other positions such as 5’ of the ring has shown 
detrimental effects. This data suggested that the proximity of the 2’ subsituent 
with the linker region maybe important for activity as demonstrated for 
acrylamides, NS1608, triazol-3/5-ones (Romine et al 2002) and 
benzimidazolone compounds (Meanwell et al 1996; Hewawasam et al 1997).
The 2’ acidic function is thought to impart an H-bond donor site with the channel. 
In addition, the ionic form of this group such as with the hydroxyl subsituent (O') 
could promote a dipole interaction with the channel. Replacement of an acidic
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moiety with a methoxy group is also tolerated but in certain compounds resulted 
in less active openers. Whether these discrepancies are due to either the steric 
‘bulk’ effect on the compound or the type of interaction with the linker region or 
the affinity of the compound to the channel remain un-resolved. Another 
structural requirement in this ring is the presence of a halogen in the para 
position to the 2 ’ subsituent and this has been best represented by a Cl atom. 
Further replacement of EWG groups in this para position with electron donating 
groups was detrimental to BKcaCO activity in NS1619 and NS004. However 
appendage of bulkier heterocyles is tolerated as demonstrated with 
oxadiazolones/BMS-191011 (Romine et al 2007) and quinolin-2-ones/BMS- 
223131 (Vrudhula et al 2005; Vrudhula et al 2007). Whether the EWG has 
electronic or steric effects on the molecule and its ability to be a BKcaCO 
remains unknown.
Interestingly the addition of EWG to the rings of bisphenols increased the acidity 
(pKa) of the phenolic OH and was critical for activity. Further, the positioning 
and type of halogenation greatly enhances the potency of pimaric acid 
derivatives (Imaizumi et al 2002; Ohwada et a /2003; Sakamoto et al 2006).
The constituents of the left sided 'B' phenyl ring of the molecule are less 
stringent. Although a number of BKcaCO usually have the presence of an EWG 
typified by a CF3 group whose positioning on the ring can affect potency. 
Interestingly the addition of hydrophobic groups such as alkyl chains or 
benzene rings can increase potency of compounds presumably through its 
effects on lipopholicity or steric hindrance of the compound. Further, the 
addition of a methyl group on the B ring has showed to increase potency for a 
number of compounds including triazoles and triazolones. Therefore, a 
combination of steric, lipophilic and electronic properties of the B ring can 
contribute to activating properties.
A linker region, when present, can be a five or six member cyclic ring typified by 
the triazole or triazolone compounds or a ring fused to one of the phenyl rings 
such as with the benzimidazolones. In addition, heterogeneous acyclic linkers 
are tolerated with separation of the phenyl rings by one bond as with magnolol 
and NS- 8  and by two bond linkers such as with symmetrical bisphenols and
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fenamates, four bond linkers provided in NS1608, phloretin and CGS-7181 and 
more recently acrylamides separated by 5-bond linkers have been reported. 
Therefore, flexibility in this linker region can be tolerated by the presence of 
different linker moiety.
Furthermore, as shown for cyclic or fused-cyclic linkers the insertion of a 
methylene spacer between the phenyl ring and the linker can be tolerated for a 
number of BKcaCO such as 1,2,3 and 1,2,4 triazoles and benzyl- 
benzimidazolones also bioisoteric replacement of linker regions can be 
tolerated. In addition, introduction of stereo-centres into the linker region can 
open up the structure and induce chirality. Further, chirality and apoisoterism 
where it exits can have an effect on potency with one isomer being more 
effective, for example, the (-) isomer for BMS-223131 and (+) isomer for 
BMS204352/MaxiPost has shown to be preferable.
It has been proposed that at least two H-bonding sites on a molecule are 
required for BKcaCO properties provided by an OH group (as part of the A ring) 
and an NH group. Interestingly an amino group has provided at least one 
potential site of H-bonding for a number of BKcaCO and typically occurs within 
either an acyclic or cyclic ring within the linker region. This is exemplified by an 
amide moiety found in the linker region of benzimidazolones, BMS-189269, 
NS1608 (Strobaek et al 1996), fenamates (Ottolia and Toro 1994), CGS-7181 
(Hu et al 1997), benzofuranindole (Butera et al 2001), TBIC (Gorememis et al 
2005), cyclobut-3-ene-1,2-diones (Butera et al 2005), triazolones (Romine et al 
2002) and acrylamides (Lennox et al., Wyeth, 2000; Nardi and Olesen 2007).
However the addition of a hydroxyl function into the ‘B’ ring for a number of 
compounds does not increase potency of BKcaCO’s particularly if there are 
additional sites of H-bonding in the ‘A’ ring or linker region.
Therefore, a simple model consisting of two phenyl rings separated by a linker 
region can form the basis of a template structure for the generation of BKca 
channel openers. Substitutions of these rings with various halogens, 
hydrophobic and hydroxyl groups in addition to chirality can have dramatic 
effects on potency and efficacy of BKca channel openers.
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1.15 Future perspectives in the identification of BKCaCO’s
At present compounds identified lack selectivity to a specific ion channel and 
display different degrees of ancillary pharmacology (Lawson 2000; Coghlan and 
Carroll 2001). As discussed, NS1619 and NS004 have shown interactions with 
a number other ion channels (Holland et al 1996; Patel et al 1998; Al Nakkash 
et al 2001). A lack of selectivity can induce unwanted side effects however the 
complexity of many pathological conditions including channelopathies where 
compounds displaying properties of multiple channel activation may be ideal 
(Lawson and Dunne 2001).
Interestingly subtle differences in template structures for K a tp  channel openers 
can have drastic effects switching specificity to BKca channels. In addition 
cinammic acrylamide compounds also share common pharmacophore pattern 
to that being optimised for KCNQ/KV7 channel modulators, this might reveal 
subtle differences in protein structures of KCNQ vs BKca channels that could 
account for the differential effects of these compounds. In addition, derivatives 
of ketoconazole deficient of an aniline group were BKca channel blockers, 
however, the presence of this function led to BKcaCO properties with these 
derivatives. In addition, other compounds such as abetic acid and menthol do 
not activate BKca channels but their respective structural isomers, PiMA and 
thymol, have demonstrated potent BKca channel activation profiles.
Further investigation of these compounds could help in the elucidation of 
binding sites and guide the better synthesis of more selective compounds. 
Consequently, a goal for KCO is the identification of ligand binding sites, 
recently the development of mutated cell lines has been used in combination 
with ligand binding assays to identify binding sites of particular protein 
structures using peptides and structures (Van regenmortel 2001; Lawson 
2001a,b).
Another issue with the identification of BKcaCO is the termination of lead 
compounds or investigation of particular pharmacophores, this in part due to the 
industry led nature of BKcaCO compound development. Furthermore, that the 
information obtained from in-depth SAR studies of these structures is hidden in
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patents or not disclosed for competition reasons. Further, the level of detail and 
types of investigation vary with different cell line expression systems, tissue 
types, organ bath setups, electrophysiology configurations and different 
parameters being tested which hinders comparison between levels of potency 
and mechanisms of action. Furthermore, many investigations do not include 
reference BKcaCO’s such as NS1619 to compare the properties of novel 
compounds against. Therefore detailed comparative studies of newer BKcaCO 
have not been reported. Gribkoff et al (1996) report the only multiple 
comparison of BKcaCO with NS1619, niflumic acid and phloretin. These studies 
have been limited by a lack of commercially available BKcaCO as 
pharmaceutical tools.
The assessment of BKCaCO compounds is usually achieved by determining the 
ability of a single concentration of the compound to increase currents of cloned 
channels expressed irrcell lines or oocytes, this limits comparisons of potencies 
and efficacies. Furthermore, other investigators assessment of compounds 
involves their functional ability to induce vasorelaxation of tissue following 
initiation of contraction with a partial depolarisation buffer. The controversy here 
is whether the compound itself results in relaxation through activation of BKca 
channels or that activation is a result of the depolarisation stimulus (V. 
Calderone 2007 personal communication). Interestingly in some studies where 
NS1619 was used as a control it has been unable to induce a vasorelaxant 
response (Baragatti et al 2000). In addition, the effects of potassium channel 
modulators on vasodilatation of tissue strips can be affected by the presence of 
the endothelium and its associated vascular mediators (Calderone et a /2007).
Discrepancies in rank order of potency have been reported when determining 
the effect of a single compound concentration to potentiate BKca current using 
whole cell electrophysiology Vs the vasorelaxant properties, as determined by 
the IC5o for relaxation of pre-contracted tissues. These differences could be 
attributed to the ancillary effect of these compounds on other channels and 
receptors in the tissue (Hewawasam et al 2003a; Hewawasam et al 2002d; Boy 
et al 2004). Whether this is due to the molecular composition of the channel, 
experimental set-up or ancillary pharmacology effects remain un-described
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Whether compounds associate with the a or p subunit has been determined for 
certain compounds, for example, some differentially activate BKCa channels with 
specificity to p-subunits such as DiBAC4, DHS-1 and tamoxifen and others 
activate through association with the a-subunit including benzimidazolones, 
PiMA and BMS-204352. However specific binding sites on the channel have 
not been fully elucidated for known BKca channel openers. Although sulphatides 
have shown decreased potency in cell lines expressing STREX splice variant 
(Chi and Qi 2006). Tissue selectivity has been reported for bladder over aorta 
for certain compounds (Lennox et al., Wyeth, 2000; Butera et al 2001; Butera et 
al 2005; Nardi and Olesen 2007) and again whether this is due to the molecular 
composition of the channel, experimental set-up or ancillary pharmacology 
effects remain un-reported.
Although the in-vivo effect of certain BKcaCO has been reported in disease 
models of stroke, erectile dysfunction, urinary incontinence and hypertension 
the specificity of action of BKcaCO is limited by the in-vivo toxicological effect of 
blockers. In addition good potentiation of BKca channel currents observed in 
electrophysiology does not always translate to in-vivo efficacy.
Detailed analysis of mechanism of action of compounds using electrophysiology 
has mainly been described for BKcaCO isolated from natural sources or 
ancillary agents such as enzyme activators and inhibitors. From these limited 
mechanistic studies most compounds activate BKca channels by 
hyperpolarising cells moving the membrane potential closer to the equilibrium 
potential for K+ (Ek) by increasing the open time kinetics of the channel with 
differential effects upon activation when applied to either aspect of the channel 
observed. Although NS1619 and NS004 have been extensively characterised 
and used as a pharmacological tool for a number of different studies there still 
remains a lack of consensus on the mechanism of action in the literature for 
many newer structural classes of BKcaCO's. In addition older synthetic BKCaCO 
compounds have shown different degrees of potency and have been relatively 
weak agonists (Kaczorowski and Garcia 1999; Coghlan and Carroll 2001) 
compared to those identified from natural sources.
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Other disadvantages to BKcaCO’s are that some (including DHS-1 and 
maxiKdiol) only activate BKCa channels when applied to the intracellular aspect 
of the channel and display poor cell membrane permeability, this consequently 
limits their potential as therapeutic tools. The expansion in the development of 
novel synthetic BKCa channel openers has been hindered by solubility issues of 
compounds in aqueous buffers. This has led to a trade off between potency and 
solubility in the selection of BKcaCO for further investigation, and to further SAR 
analysis to improve solubility or exploring the use of pro-drugs as with BMS- 
191011 (Hewawasam et al 2003b; Romine et al 2007).
There also remains little published molecular modelling data examining the 
molecular properties and energy minimised conformations of BKcaCO’s. 
However, over the past decade the field of identification of BKcaCO’s has made 
many advances in the identification of numerous heterogenous groups of 
compounds and elucidation of the properties of these compounds that impart 
BKca channel opener properties.
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1.16 Aims of the thesis
The work presented in this thesis aims to explore a series of compounds based 
on a benzanilide template for BKCaCO properties and to further probe the 
pharmacophore of BKcaCO’s. The initial phase involved the development, 
validation, and optimisation of a medium through-put, non-radioactive, Rb+ 
efflux assay as a technique to investigate the pharmacological properties of 
BKCa channel modulators (Chapter 2). The Rb+ efflux assay was used to test 
compounds on HEK293 cell lines expressing BKca channel a  subunit alone or 
co-expressed with the pi subunit for their efficacy, potency, and selectivity by 
testing against standard pharmacological tools as positive controls (Chapter 3).
The pharmacological profile established with Rb+ efflux was then assessed 
using whole cell patch clamp electrophysiology (Chapter 4). The candidate 
molecule, BKOEtl, identified from the Rb+ efflux and electrophysiological 
screen was further characterised in respect to its BKca channel activation 
properties using single channel patch-clamp electrophysiology recording. In 
addition, the specificity of BKOEtl to BKca channels was assessed by 
determining the Rb+ efflux from rat bladder myocytes in the presence of 
different potassium channel blockers (Chapter 5). The data obtained from these 
studies at a cellular level using rubidium (Rb+) efflux assay and patch clamp 
electrophysiology provides fundamental information regarding the nature of 
compounds with BKca channel opener properties. The use of molecular 
modelling techniques has enabled the development of a putative 
pharmacophore model of these compounds (Chapter 6).
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Chapter 2
Optimisation of a non-radioactive 
Rubidium (Rb+) efflux assay for 
the assessment of BKCa channel 
opener activity
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2.1 Introduction
2.1.1 Ion channel screening assays
In the past decade advances in understanding the physiology and the 
pathophysiology of ion channel function has highlighted them as attractive 
therapeutic targets for numerous diseases (Bennet and Guthrie 2003; Ebreth 
2002). However, until recently there was a lack of progress in ion channel drug 
discovery and this was in part due to the lack of high throughput screening 
technologies (HTS), (Bennett and Gutherie 2003; Gill et al 2003; Stankovich et 
al 2004).
The shift in direction was in part due to the phenomenon of drug induced long 
QT (LQT) syndrome and led to the introduction of new drug safety guidelines 
(Gill et al 2003; Stankovich et al 2004). LQT syndrome is a side effect of the 
action of many classes of drugs including, anti-arrythmics, antibiotics, anti­
histamine and anti-psychotics. The LQT effect has shown to be mediated by 
inhibition of the hERG (human ether a go-go) channel in cardiac myocytes that 
can lead to fatal ventricular fibrillation (Sanguinetti et al 1995). In light of this the 
US Food and Drug Administration requires the activity of all new drugs to be 
assessed against the hERG channel. This has lead to the development of new 
HTS assay technologies (Zheng et al 2004).
In the analysis of ion channels electrophysiology remains the gold standard 
technique for measuring biophysical characteristics of ion channel function (Gill 
et al 2003; Birch et al 2004; Zheng et al 2004), but despite advances in 
automation it remains labour intensive and highly specialised. However, HTS 
provides a more robust, cost effective, reproducible and informative method of 
assessing ion channel activity (Zheng et al 2004). An ideal HTS assay is 
ameanable to scale-up, automation and miniaturisation (Bennett and Gutherie 
2003; Gill et al 2003; Kiss et al 2003) and is a trade off between information 
content of the assay and throughput (Xu et al 2001; Bennett and Gutherie 2003).
Screening technologies that have been developed can be grouped into 
functional or non-functional assays that either provide a direct measure of ion 
channel activity such as with automated electrophysiology and ion flux assays;
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or an in-direct measure such as in membrane potential, calcium fluorescent and 
radioligand binding assays (Xu et al 2001; Bennett and Gutherie 2003).
Fluorescent based assays involve measuring membrane potential changes 
using voltage-sensitive membrane dyes (oxonal dyes, DiBAC4 series) or with 
calcium fluorescent dyes (Fura-2, Flo-3, -4) to detect changes in intracellular 
calcium. The development of instrumentation such as the fluorometric image 
plate reader (FLIPR) has enabled high-through screening for these fluorescent 
techniques and consequently the cost per data point is relatively low (Wheng et 
al 2004; Worley and Main 2002). However, there are many disadvantages to 
fluorescent techniques in that they only offer an indirect measure of channel 
function and suffer from high background noise, low sensitivity, selectivity, and 
expensive consumables (Xu et al 2001; Gill et al 2003; Wheng et a /2004).
The lack of ion specific intracellular dyes has limited this technique to the 
analysis of Ca2+ channels and Ca2+ activated K+ channels. Therefore, 
membrane potential assays have been the focus of further development 
particularly the use of fluorescent resonance energy transfer (FRET) based 
systems. However, limitations to this include a higher level of assay complexity, 
dye-compound interaction and slow response times (Birch et al 2004). 
Furthermore, recent studies of the membrane potential dye DiBAC4(3), 
commonly used for the assessment of BKca channel modulators (Yamamura et 
al 2002; Yamada et al 2001), have demonstrated potent BKca channel opener 
activity with selectively for channels composed the p1-subunit (Morimoto et al 
2007).
Another indirect method includes radioligand binding assays, for example, the 
use of radiolabelled charybdotoxin (125l-ChTX) as a ligand in binding assays for 
BKCa channel openers. These methods are limited and dependent upon the 
availability and affinity of different ligands. In addition, binding assays do not 
show those channel openers that work via an allosteric mechanism or via 
associated subunits (Kaczorowoski and Garcia 1999). However, this technique 
has allowed the identification of a number of BKCa channel openers including 
terpenes (McManus et al 1993; Singh et al 1994; Lee et al 1995).
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2.1.2 Ion flux assays
Ion flux assays are preferred to the techniques described above as they offer a 
more direct assessment of channel activity. In addition, studies have shown 
better correlation of compound potency determined between patch clamp 
electrophysiology and flux studies than with fluorescent based techniques. Ion 
flux involves the use of a tracer ion for detection of flow through ion channels. 
Traditional techniques used radioactive tracers including 22Na and 14C 
guanidium for Na+ channel, 86Rb or 42K for K+ channels, 45Ca for Ca2+ channels 
and 36CI or 125l for Cl" channels. These techniques used scintillation detection to 
asses the level of flux that occurs through the channels. For a number of 
different ion channels radio-active efflux experiments has shown to be 
comparable to electrophysiology in the determination of compound potency 
(Becq et al 2003; Gill et al 2003).
. There are a number of disadvantages in the radioactive approach that centre 
around the safety hazards associated with the use and disposal of radio­
labelled ions. In addition, ions such as 86Rb have high emission energy (pmax 
1.77MeV; ymax 1.08MeV) and a short-half life (18.65 days), these properties do 
not confer radioactive tracer ions meanable to automation and therefore in HTS 
applications (Terstappen et al 1999; Terstappen et al 2004).
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2.1.3 Non-rad ioactive Rb+ efflux assay
To address the issues associated with the use of radioactive Rb+ Terstappen 
(1999) introduced a non-radioactive method incorporating atomic absorption 
spectrometry (AAS) for qualitative and quantitative determination of ion fluxes.
AAS has long been used for the assessment of trace metals in environmental 
and biological samples due to its relative simplicity, precision and specificity in 
the analysis of a selected analyte (absence of matrix interference), (Apostoli et 
al 2002). In flame-AAS, a sample is atomised and sprayed into a flame, the 
thermal energy generates free ground state atoms that absorb light of a 
particular wavelength (Rb+, ^=780.1 nm). Applying the principles of Beer- 
Lamberts law, the amount of absorption by the sample is proportional to the 
concentration of the analyte, which is determined from standard curves of 
known amounts of analyte before each analysis (Morton and Roberts 2003).
Non-radioactive AAS flux assays have shown to offer a versatile technique that 
has been applied to a variety of ion channels (Table 2.1), including the use of 
Li+ ions for the detection of Na+ channels, and the use of Ag+ ions to detect Cl' 
ions measured as efflux through channels (Gill et al 2003; Stankovich et al 2004; 
Birch e ta l 2004).
Rb+ efflux assays have shown to be cost effective and be a better tool than 
membrane potential assays and calcium fluorescence assays (Tang et al 2001) 
amenable to automation and comparable in terms of potency to patch clamp 
electrophysiology (Gill et al 2003).
The development of ion flux HTS assays has been led by the pharmaceutical 
industry for a number of different ion channels (Table 2.1). Although any AAS 
instrument could be used for detection, recent developments in novel high 
throughput instrumentation technologies such as the ICR8000 and ICR12000 
developed by Aurora Biomed enable the analysis of up to 60,000 wells/day 
(Aurora Biomed 2007).
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The rubidium (Rb+) efflux assay has provided a useful method for the screening 
of compounds that have modulating effects on efflux through potassium (K+) 
channels (Terstappen 1999). Here, Rb+ is used as a tracer ion for detecting ion 
flow through K+ channels due to it having a similar atomic radius to K+ and its 
absence in cellular systems (Terstappen 2004). The method is relatively easy 
to perform but requires a number of assay validation experiments. A number of 
channels (usually in recombinant cell lines) have been optimised with respect to 
the assay (Table 2.1) and continues to be proven as a reliable technique for the 
assessment of K+ channel function (Scott et al 2003; Terstappen et al 2004; 
Chaudry et a /2006; Jow et al 2006; Wang et al 2006; Gill et al 2007).
Kv1.1
| Kv1.3 
Kv1.4 
Kv1.5 
Kv7.1 (KCNQ1) 
Kv7.2 (KCNQ2) 
Kv7.2/3 (KCNQ2/3) 
Kv11 (hERG)
BK
SK
nAChR
P2X
Na+ K+ 
ATPase
K+ c r
Co-transporter
1---------------------------------------------  1
Table 2.1: Current examples of channels that non-radioactive Rb+ efflux 
has been developed and optimised
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2.2 Chapter Aims
The aim was to optimise and validate a medium through-put, Rb+ efflux assay to 
quantify BKca channel activity for the assessment of candidate molecules as 
potential BKca channel openers.
• Validity of HEK293 cells expressing BKca channels as a cell model to use 
in Rb+ efflux assay.
• Optimise the individual assay parameters: Instrument validation: Rb+ 
loading, extracellular washes, basal efflux and stimulating efflux. ,
• Determine the ability of the assay to discriminate known BKca channel 
modulators on the basis of efficacy and potency.
• Test the specificity of these openers to BKca channels in the cell line 
used.
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2.3 Methods
2.3.1 Materials
Cell culture reagents and equipment
BD Biosciences, Oxford, U.K: T75 cell culture flasks, serological pipettes (10ml), 
96-well microplates and Falcon tubes (15 and 50ml).
Invitrogen (GIBCO), Paisley, U.K: Dulbecco's modified eagles medium (DMEM), 
Dulbecco's phosphate buffered saline (D-PBS), fetal calf serum (FCS) and 
trypsin-EDTA (0.05%).
Merck Biosciences (Calbiochem), Nottingham, UK: G418 sulphate solution 
Sigma Aldrich, Gillingham, UK: Brightline Flaemocytometer
General Purpose Reagents
Sigma Aldrich, Gillingham, U.K: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (FIEPES), phosphate buffered saline (PBS) tablets, rubidium chloride (RbCI) 
and, triton X-100.
VWR International Ltd: BDH, Lutterworth, U.K: Calcium chloride (CaCb), colour 
Key pH buffer solutions, dimethylsulfoxide (DMSO), glucose, magnesium 
chloride (MgCb), potassium chloride (KCI), sodium chloride (NaCI), sodium 
dihydrogen phosphate (NaH2P 0 4).
Ion channel modulators
Sigma Aldrich, Gillingham, U.K: 1-(2'-hydroxy-5'-trifluoromethyl phenyl)-5 
trifluoromethyl-2(3H)benzimidazolone (NS1619), 4-aminbpyridine (4-AP), 
calcium ionophore A23187, glibenclamide, niflumic acid, ouabain, phloretin and 
tetraethylammonium (TEA).
Axxora Ltd, Nottingham, U.K: paxilline (pax)
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2.3.2 HEK293 cells
The parental Human Embryonic Kidney (HEK293) cell line was generated by 
Graham et al in 1977 through the transformation of HEK cells with adenovirus 5 
DNA. HEK293 cells have epithelial cell morphology and grow as an adherent 
monolayer (Graham et al 1977). This cell line has previously been generated 
(Ahring et al 1997) and characterised as stably expressing the zero variant of 
the human BKca a-subunit (hS/o, KCMNA), (Hartness et al 2003).
2.3.3 Cell culture and preparation of cells for Rb+ efflux assay
Cell culture was performed under sterile conditions using high efficiency 
particulate air filters (HEPA) in a class II lamina flow-hood (Heraeus, Germany). 
All plastics used were sterile and appropriate aseptic techniques were used. 
Culture media was warmed in a 37°C water bath prior to its use. All cells were 
grown by incubation at 37°C in a 5% C 0 2 humidified incubator (Heraeus, 
Germany).
HEK293 cells were grown in T75 vented cell culture flasks with Dulbecco's 
modified eagles media (DMEM with 1.0 g I'1 glucose and sodium pyruvate) 
supplemented with fetal calf serum (10%) and G418 sulphate (0.5pg/pl).
Cells were initially grown from frozen stocks (DMSO, 10%) and then routinely 
passaged throughout the experimentation period (passage number 10 to 35).
Prior to cell passage the flasks were checked for the degree of confluence and 
morphological state, in addition the flasks were checked for the absence of 
microbial contamination.
Confluent cells were passaged by decanting the media, washing adherent cells 
once with calcium free Dulbecco's phosphate buffered saline (D-PBS, 10mls) 
and incubating with trypsin-EDTA (3mls, 0.05%) for 3-5 minutes in the incubator. 
Cells were then detached from the surface of flasks by gentle agitation and re­
suspended by dilution with DMEM (10mls). The cell suspension was then split 
into various densities (1:5 - 1:40) in DMEM (total volume 20mls) in a new T75 
flask to acquire confluent cells when needed.
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Detached and re-suspended cells were counted using a Brightline 
hemocytometer and seeded in 96-well tissue culture plates at a density of 
20,000 cells per well in a total volume of 200pl of media. Plates were incubated 
for 48-hours as above until cell growth in the wells reached confluence.
2.3.4 General m ethod for Rubidium (Rb+) efflux assay
To prepare the cells, media was removed and the cell monolayer was washed 
once with PBS (200pl). Following this cells were incubated (200pl/well) with 
rubidium chloride (RbCI) buffer (mM: RbCI 5.4, NaCI 150, MgCI2 1.0, NaH2P 0 4 
0.8, CaCb 2.0, HEPES 25.0 and Glucose 5.0) for 0.5-5.0 hours and then 
washed rapidly 4 times (PBS, 200pl/well), in certain experiments these washes 
were collected for analysis of Rb+ content.
Following the washes cells were then exposed to drug treatment or vehicle 
(DMSO) in KCI buffer (mM: KCI 5.4, NaCI 150, MgCI2 1.0, NaH2P 0 4 0.8, CaCI2 
2.0, HEPES 25.0 and Glucose 5.0). At specified time intervals the supernatant 
(Extracellular effluxed Rb+) was removed from individual wells and collected for 
analysis, by transferring to a 96-well plate. The cells were immediately lysed to 
obtain intracellular Rb+ by the addition of Triton X-100 (0.1% , 200pl/well) in KCI 
buffer for at least 30-minutes before analysis.
For depolarisation experiments, a high extracellular, isosmotically adjusted, KCI 
(50mM) buffer was prepared (mM: KCI 50, NaCI 105.4, MgCI2 1.0, NaH2P 0 4 0.8, 
CaCI2 2.0, HEPES 25.0 and Glucose 5.0).
In competition experiments, ion channel blockers were added to the RbCI buffer 
for the final 20 minutes of the loading stage and to the KCI buffer containing the 
test compounds or vehicle. Variations to this general method are described 
where appropriate.
If sample analysis was not performed immediately following an experiment then 
96-well plates would be stored in a damp environment (at 4°C) without 
detriment to the result.
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2.3.5 Atom ic Absorption Spectrom etry (AAS) analys is
The supernatant, lysate and wash samples were analysed, for Rb+ content, 
using an S-series Atomic Absorption Spectrometer (Thermo Scientific, Hemel 
Hempsted, U.K) coupled to a Gilson 222XL auto-sampler (Thermo Scientific, 
Hemel Hempsted, U.K). The absorbance of Rb+ was determined at a 
wavelength of 780.1nm from the samples following atomisation in a 
stoichometric air-acetylene flame.
Prior to analysis the instrument was cleaned and allowed to warm up for 20- 
minutes with the Rb+ hollow cathode lamp and flame on. The instrument was 
validated, to ensure optimal and consistent performance, by the addition (300pl) 
of RbCI standards (0-100pM prepared in KCI buffer) into a microtitre plate and 
comparing the absorption values obtained to ensure values did not exceed 5% 
error of each other. These values were recorded as a quality control measure to 
ensure consistent instrument performance.
The samples were diluted with KCI buffer (1 OOpil) prior to analysis. This provided 
the minimum volume required to ensure confidence and consistency in 
obtaining a steady state Rb+ absorbance reading. In addition, dilution ensured 
that absorption readings did not exceed the maximum limit of detection for the 
instrument.
The sample in each well was nebulised for one second by the instrument and 
then following this the absorption was measured continually for one second, 
from which the average absorbance value from this period was recorded. An 
inter-well wash time (10 seconds in distilled water) of the needle of the auto­
sampler was sufficient to clean the instrument.
Standard curves were generated from the measurement of 1-100pM RbCI 
standard solutions prepared in KCI buffer prior to each 96-well plate analysis. 
Standard curves were constructed before and after each analysis to ensure 
reliability in analysis.
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2.3.6 Data Analysis
Rb+ efflux (%) was calculated as follows:
%  efflUX = ------ ; [R b * W ellular)   x 1 qq
[Rb ] (Extracellular) ] (Intracellular)
Efflux values were exported to Microsoft Excel for data analysis in preparation 
for graph and statistical analysis in GraphPad PRISM software (version 4). BKca 
channel opener data was normalised as the percentage (%) increase in Rb+ 
efflux above control (KCI buffer with appropriate vehicle).
Sigmoidal-concentration response curves were constructed using the four 
parameter logistic equation as follows:
Y=Bottom + (Top-Bottom)/(1+10A((LogEC50-X)*HillSlope))
X is the logarithm of concentration. Y is the % activated Rb+ efflux.
Emax (maximal % increase in Rb+ efflux) and EC4o% (the concentration of 
compound that results in a 40% increase in Rb+ efflux above control) were 
calculated.
Results are presented as means±SEM for n determinations. Data was analysed 
using either Student’s un-paired t-test or for multiple comparisons one-way 
ANOVA followed by Dunnett’s or Bonferroni’s multiple comparison test 
(Wallenstein et al 1980). The accepted level of significance was p<0.05.
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2.4 Results
2.4.1 Instrument validation and performance
The optimised AAS instrument was able to detect to a sensitivity of 1 .OpM RbCI 
in KCI buffer (0.005 Absorbance units), (Figure 2.1). The precision of the 
instrument was tested by application of standard (300pl of 60pM Rb+) to each 
well of a 96-well. The average absorbance (0.483±0.001, n=96) and concurrent 
concentration value (60.5±0.1|iM , n=96) showed good reproducibility in analysis. 
This is further supported by the precision in measuring RbCI standards for 40 
separate determinations (Figure 2.1).
Rb+ measurements were not affected by the presence of other ionic 
components of the buffer, cell lysates or Triton X-100.
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Figure 2.1: Standard curves of RbCI
Absorbance values determined by the AAS from RbCI standards (0-100pM) 
prepared in KCI buffer. Data represents the average absorbance value taken 
from 40 determinations (mean±SEM). Data points were fitted by linear 
regression (y= mx + C) analysis, 1^=0.998.
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2.4.2 M easurem ent of Rb+ uptake by HEK293 cells
HEK293 cells were exposed to RbCI buffer (0.5-5.0 hours) and immediately 
lysed following removal of extracellular buffer by washing. The Rb+ content of 
the lysate of the HEK293 cells progressively increased with time of incubation in 
Rb+ buffer (Figure 2.2). The Rb+ content appeared to become saturated from 
two hours incubation and a four hour incubation period was sufficient to reach 
maximal loading (92.4±4.1pM, n=24; Figure 2.2).
86
on
a:
T T T T T T0.0 1.0 2.0 3.0 4.0
Incubation time (Hrs)
5.0
Figure 2.2: Time course of Rb+ loading in HEK293 cells expressing BKca 
channels
Cells were incubated with RbCI buffer. At timed intervals up-to 5-hours the 
extracellular buffer was removed and cells were washed 4 times with PBS 
before lysis with Triton-X100. The Rb+ content of lysate (A ) and fourth wash (v )  
samples are represented as means ± SEM (n=24).
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2.4.3 Extracellular wash ing optim isation
The optimum number of washes was determined to have the confidence that all 
intracellular Rb+ measured following the loading time period reflected that which 
was inside the cell and not a consequence of extracellular Rb+ associated with 
the cell surface. Following incubation in RbCI buffer (4-hours during the loading 
stage) the cells were washed (D-PBS, 200pl/well) a number of times and 
samples were collected and analysed to determine Rb+ content (Figure 2.3). 
Following three sequential washes a low extracellular Rb+ concentration was 
obtained (Rb+=10.2±2.0pM) that did not significantly (Student’s un-paired t- 
test,>0.05) vary with further washes (4 washes= 4.2±0.81 pM; 5 washes 
3.5±0.98 pM, p>0.05, n=24). These findings support the Rb+ content of the 
lysate reflects the intracellular concentration of the ion and not that as a 
consequence of insufficient washing.
The effect of insufficient washing on Rb+ efflux was determined by measuring 
the Rb+ efflux from cells (10-minutes exposure to KCI buffer) after different 
numbers of PBS washes (1-4). Insufficient washing leads to artificially high 
efflux values (Figure 2.4), these values significantly decreased (p<0.05) with 
subsequent washes (1 to 4 washes). The fifth wash did not significantly affect 
the measured Rb+ efflux (Four washes= 25.2±2.9%; Five washes= 21.6±2.6% , 
P=0.41, n=24). Therefore this value after four washes represents the Rb+ efflux 
in response to exposure to the KCI buffer and not that which is associated from 
insufficient washing.
Although three washes removed extracellular Rb+ from the cells, four washes 
was chosen to ensure confidence in removal of all cell surface Rb+.
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Figure 2.3: Rb+ content of extracellular wash buffer
The effect of the number of sequential washes (PBS, 200pl) on the removal of 
Rb+from the extracellular compartment of HEK293 cells (■), Data presented as 
means±SEM (n=24). Student’s un-paired t-test, *=p<0.05, ***p<0.01 indicates 
significance level relative to previous wash number
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Figure 2.4: The effect of incomplete removal of Rb+ on efflux values
Cells were exposed to KCI buffer for 10-minutes following sequential washes.
Rb+ content determined in KCI buffer and lysate were used to calculate % efflux. 
Data expressed as means±SEM (n=24) per group. Student’s un-paired t-test, 
*=p<0.05, indicates significance level relative to previous wash number.
90
2.4.4 Determ ination of Basal Efflux
2.4.4.1 Effect of time on Rb+ efflux following exposure to KCI buffer
The Rb+ efflux response from Rb+ loaded HEK293 cells following 2-30 minutes
exposure to non-depolarising KCI (5.4 mM) buffer was assessed (Figure 2.5). A 
Rb+ efflux of 27.5±1.6% (n =32) was observed after 2 minutes, this value did not 
differ with increased exposure time (Bonferroni’s multiple comparison test 
p>0.05), (Figure 2.5). In the presence of the K+ channel blockers, 4-AP (1mM) 
and TEA (10mM), the Rb+ efflux following 2-30 minute exposure to KCI (5.4 mM) 
buffer did not differ from values obtained in the absence of treatment (Figure 
2.5).
2.4.4.2 Effect of selective K+ channel blockers and ouabain on basal 
Rb+ efflux
The Rb+ efflux during 10-minute exposure to KCI (5.4 mM) buffer was also not 
modified by the presence of the selective blockers iberiotoxin (0.1 pM), (BKca 
channels, test values = 29.7±2.6% and control = 30.1 ±3.7% (n=8)) and paxilline 
(10pM), (BKCa channels, test =30.8±2.2% , control =33.3±3.1%) or glibenclamide 
( K a t p  channels, test = 27.7±0.7% , control = 28.3±0.9% (n=16), (Figure 2.6). In 
addition, ouabain (100pM), a Na+/K+ATPase inhibitor, failed to modify the Rb+ 
efflux (10-minutes) from cells in KCI (5.4 mM) buffer (ouabain: 24.1 ±2.9% , 
control: 27.0±4.6% , n=8), (Figure 2.6).
These finding are consistent with the Rb+ efflux from un-stimulated cells (basal 
efflux) not involving K+ channel and is not dependent on the activity of Na+/K+ 
ATPase.
2.4.4.3 DMSO effects on Rb+ efflux
Dimethylsulphoxide (DMSO) was used as the solvent for the preparation of 
stock concentrations for the majority of pharmacological tools used including 
novel BKCa channel agents. The effect of DMSO on basal efflux in response to 
KCI buffer was examined. DMSO (0.3-20% v/v in KCI buffer) had no significant 
effect on Rb+ efflux values compared to KCI buffer alone (Figure 2.7).
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Figure 2.5: Effect of time on Rb+ efflux following exposure to KCI buffer
Cells were exposed for varying times to KCI buffer in the absence (□) or in the 
presence of 4-AP (1.0mM) and TEA (10mM), (a ) .  Data presented as 
means±SEM (n=32/group).
92
80 n
70
60
50
40
30 i  n
*  20 
10 
0-*
x3
t£0)
IbTX Pax Glib O uab
Figure 2.6: The effect of selective K+ channel blockers and ouabain on 
basal Rb+ efflux
Rb+ efflux during 10 min exposure to KCI buffer in the absence (clear bars), and 
presence (filled bars) of the following treatments, glibenclamide (Glib, 10pM), 
iberiotoxin (IbTX, 0.1 jliM ), paxilline (pax, 10pM) and ouabain (Ouab, 100pM). 
Each treatment group was paired to corresponding KCI buffer (clear bars) 
control. Data presented as means±SEM (n=8-16).
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Figure 2.7: DMSO effects on Rb+ efflux
Rb+ efflux from cells exposed to KCI buffer (10-min) alone (Clear bar) or 
containing DMSO (0-20%) (Blue bars). Data presented as means+SEM (n=16- 
20).
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2.4.5 Stimulation of cells by depolarisation and calcium ionophore
Exposure of HEK293 cells to a depolarising KCI (50 mM) buffer for 2-minutes 
produced an efflux (43.8±5.1% , n=16) that did not significantly (Bonferroni’s, 
p>0.05) change with further incubation time. In addition at all time points high K+ 
KCI buffer produced significantly greater efflux than that observed with 
exposure to low (5.4mM) KCI buffer (Figure 2.8).
Exposure of cells to calcium ionophore A23187 (1-1 OOpiM) produced significant 
(Dunnett's test p<0.05) increases in efflux relative to vehicle control (Figure 2.9).
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Figure 2.8: The effect of high extracellular K+ (depolarisation) on 
Rb+ efflux
Cells were exposed, for varying time points (2-30min), to high K+ (50mM) KCI 
buffer (♦, n=16) or 5.4mM KCI buffer (□, n=32). Data presented as means ± 
SEM.
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Figure 2.9: The effect of calcium ionophore A23187 on Rb+ efflux
Cells were exposed to calcium ionophore (1-100pM) for 10 minutes in KCI 
buffer. One-way ANOVA with Dunnett’s test *=p<0.05, **=p<0.01, indicates 
significance compared to control (KCI buffer including vehicle). Data presented 
as means±SEM, (■ , n=16).
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2.4.6 Tim e dependent effects of NS1619 on stim ulating Rb+ efflux
The Rb+ efflux response to the BKca channel opener NS1619 (30pM) was 
assessed following differing tinned exposure (2-30mins). NS1619 produced a 
Rb+ efflux response that was significantly different from control (un-stimulated 
efflux with KCI buffer for 10-minutes) that was not time dependent and the full 
response to NS1619 was observed within 2 minutes (57.1±3.9% n=16), (Figure 
2 .10).
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Figure 2.10: Time-dependent effect of NS1619 on stimulating Rb+ efflux
Cells were exposed to NS1619 (30pM) in KCI buffer for varying timed intervals 
(2-30 minutes). C= un-stimulated efflux (KCI buffer with DMSO (0.3%) for 10- 
minutes exposure only). Data presented as means±SEM (n=16).
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2.4.7 Characterisation of BKCa channel openers
The effects of BKca channel openers NS1619, niflumic acid and phloretin 
(0.001 -100pM) on Rb+ efflux were assessed (Figure 2.11).
NS1619 and niflumic acid evoked significant concentration related increases in 
Rb+ efflux above baseline producing significant differing Emax and EC4o% values, 
phloretin produced only significant increases in Rb+ efflux above control at 
higher concentrations (100pM), (Figure 2.11; Table 2.2).
Niflumic acid (105.7±11.4% n=24) produced a significantly greater (Bonferroni’s 
p<0.05) Emax compared to NS1619 (79.0±9.8% n=32) and phloretin (40.3±7.4%  
n=24). In addition the maximum response to NS1619 was significantly greater 
(p<0.001) than that achieved by phloretin (Figure 2.11, Table 2.2).
The potency of the BKca channel openers was measured as the EC4o% 
(concentration of compound required to stimulate an increase in efflux above 
background by 40%). Niflumic acid (0.13±0.10pM , n=24) and NS1619 
(0.32+0.19pM, n=32) had achieved similar levels of potency where as phloretin 
was unable to stimulate Rb+ above 40% over the concentration range tested 
(Table 2.2).
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BKCa Opener ^max (° /° ) ^ ^ 4 0 %  (P ^ l )
NS1619 ,OH 79.0±9.8 0.32±0.19
Niflumic Acid
Phloretin
105.7±11.4 0.13±0.10
co2h
HO
ho ^  c .ch2.ch2 ^ oh
OH
40.3±7.4 n.d
Table 2.2: Pharmacological Properties of BKCa channel openers
Potency (EC4o%) defined as the concentration of compound required to increase 
Rb+ efflux above baseline by 40% and efficacy (Emax), defined as the maximum 
increase in activated efflux was determined for each BKCa channel opener 
tested. Data presented as means±SEM. Student’s un-paired t-test, *p<0.05, 
**p<0.01 indicate differences in efficacy achieved between NS1619 and the 
other compounds tested, n.d = not determined.
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2.4.8 The effect of Iberiotoxin (IbTX) on NS1619 activated Rb+ efflux
In the presence of IbTX (0.1 |liM), NS1619 (3, 10 and 30jliM) failed to 
significantly (Dunnet's p>0.05) modify the Rb+ efflux response above control 
levels (5.4 mM KCI buffer alone) in contrast to NS1619 alone (Figure 2.12). 
These findings are consistent with the activation of the BKca channel expressed 
in the HEK 293 cells.
Preliminary experiments were performed to determine whether iberiotoxin (IbTX) 
was needed to be included in the washes in addition to its inclusion in RbCI 
buffer (Figure 2.13). NS1619 (10|uM in KCI buffer) significantly (Bonferroni's 
p<0.001) increased Rb+ efflux (47.6±2.2% , n=8) relative to vehicle control 
(23.8±3.3% , n=8). NS1619 failed to significantly (Bonferroni's P>0.05) increase 
Rb+ efflux above background (vehicle controls: DMSO 0.3% and BSA 0.1% in 
PBS) upon co-incubation with IbTX (0.1 jaM in KCI buffer). The degree of 
inhibition in efflux by IbTX was unaffected by the inclusion of IbTX in the PBS 
washes (absence = 23.2±3.4%; presence = 28.7±2.1% n=8, Bonferroni's 
p>0.05), (Figure 2.13).
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Figure 2.12: Effect of Iberiotoxin on NS1619 induced Rb+ efflux
Cells were exposed to NS1619 (3, 10, 30pM) or to vehicle control in the 
absence (clear bars) or presence (black bars) of iberiotoxin (0.1 pM). Data 
presented as means±SEM (n=16). Student’s un-paired t-test *p<0.05, **p<0.01 
indicate significant differences in Rb+ efflux relative to the absence of IbTX. 
One-way ANOVA with Dunnett’s post t-test, #=p<0.05, ##=p<0.01 indicates 
significant difference in efflux compared to control.
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Figure 2.13: Optimising Iberiotoxin blocking experiment
Cells were exposed to KCI buffer with vehicle control (Green bar, DMSO 0.3%, 
0.1% BSA in PBS) treated or with NS1619 alone (Black bar) or with co­
incubation of IbTX (0.1pM) following either the inclusion absence (light purple) 
or presence (dark purple) IbTX during PBS washes, x = excluded in treatment, 
s  included in treatment. p<0.01 indicates significance relative to control 
(Bonferroni's) and P>0.05 indicated no difference between groups, (n=8).
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2.4.9 Ouabain
To determine whether the response to NS1619 (30pM) was affected by Rb+ re­
uptake by the Na+/K+ ATPase, ouabain (100pM) a blocker of this pump was 
tested in the absence and presence of NS1619 (Figure 2.14). NS1619 (30pM) 
alone significantly raised efflux relative to vehicle control (KCI buffer=17.4±6.0%; 
NS1619=43.5±1.0% , n=16) and was not modified by the presence of ouabain 
(KCI buffer=23.1+2.9%; NS1619=43.1±2.9% , (n=16). Therefore, the effect of 
NS1619 on Rb+ efflux represented the maximum effect and was not limited by 
Rb+ recycling back into the cells (Figure 2.14).
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Figure 2.14: The effect of the Na+/K+ ATPase blocker ouabain on Rb+ efflux
The effect of ouabain (lOOjaM), (red bars) on the Rb+ efflux response to KCI 
buffer alone or with the addition of NS1619 (30piM). Student's un-paired t-test 
(*p<0.05, **p<0.01) indicate significance to relevant control (NS1619, OpM ± 
ouabain), (n=16).
107
2.5 Discussion
An optimised Rb+ efflux assay can provide the basis for the assessment of 
novel compounds as K+ channel modulators. A successful assay protocol 
depends upon the expression system used and the evaluation of each of the 
steps critical for assay performance (Bennett and Gutherie 2003; Terstappen 
2004). These steps were important to optimise to gain understanding of the 
properties and the reliability of the assay. In addition to providing a framework to 
compare the results obtained by pharmacological stimulation of BKca channels 
with novel openers.
2.5.1 HEK293 cells as su itable cell model for Rb+ efflux assays
The most common cell types used for HTS screening are Chinese Hamster 
Ovary (CHO), COS and HEK293 cells. The choice of cell type is important 
because of the presence of endogenous ion channel expression. HEK293 cells 
have been shown, with electrophysiology to express various types of currents 
including five types of chloride, two types of potassium and an unknown cation 
current. Furthermore mRNA and protein has been detected for a number of 
different members of the Kv and VDCC families (Zhu et al 1998; Thomas and 
Smart 2005). Zhu et al (1998), suggest that HEK293 cells would make good 
vectors for the expression of K+ and Na+ channels but not Cl' channels. HEK293 
cells are preferred to Ooccytes as only transient expression can be achieved in 
Oocytes and HEK293 offer a human cell phenotype.
The HEK293 cells used in this study have been previously been modified and 
characterised as stably expressing BKca channel subunits for use in 
electrophysiology (Hartness et al 2003). HEK293 cells contained a homogenous 
population of BKca channels that was further confirmed by Rb+ efflux studies.
Problems in the development of ion flux assays can be associated with the 
creation and choice of cell line to use. Ion channels are encoded by large 
cDNA’s and are composed of multiple accessory subunits. Therefore, problems 
associated with cDNA stability and localisation can occur, in addition proteins 
can be toxic when over expressed. The use of inducible systems and the
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inclusion of ion channel blockers to cell culture media can prevent toxicity 
(Worley and Main 2002).
Another factor to consider is the adherent' strength of cells to the plastic of 96- 
well plates as the cells must be able to withstand multiple solution changes and 
washes. For example Wang et al (2004) used poly-l-lysine coated multi-well 
plates for the growth of CHO cells. Furthermore, HEK293 cells have been 
shown to be weaker adherent than other cell lines (Worley and Main 2002). 
However, during experimentation careful washing was used to ensure cells 
were not unnecessarily washed away.
Cell behaviour can be affected by seeding at high or low density formats, cell­
cell interactions, cell cycle stage and length of exposure to trypsin can affect 
channel activity in cells. In addition, cells exhibit differential toxicity towards 
solvents (Worley and Main 2002). Therefore, the cell culture phase was kept as 
precise as possible in terms of seeding density and length of growth on plates. 
Cells were also checked for changes in morphology or sudden changes in cell 
growth rates. The cell passage number did not have an effect on the Rb+ efflux 
response from HEK293 cells as demonstrated in the reliability of efflux values 
recorded under basal conditions (KCI buffer alone) and for the response to 
NS1619 over a number of different experiments and cell passages.
2.5.2 Rb+ as a tracer ion
Rb+ is found intracellular in various tissues with values ranging from 1300 - 
1700 ng g'1 of tissue. The physiological role of Rb+ is not well characterised, 
however, Rb+ has shown to regulate synaptic neurotransmitter levels, K+ 
homeostasis and leukocyte function (Canavese et a /2001). However, the use of 
cloned cell lines negates the presence of intracellular Rb+. However studies 
have detected Rb+ (7-1 OnM) in deionised water (Canavese et al 2001). 
Although Rb+ could be present in water used in preparation of buffers the level 
is well below that of the sensitivity of the instrument, furthermore Rb+ could not 
be detected in the PBS wash or KCI buffer.
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The sensitivity in the detection of Rb+ effluxes depends upon a number of 
factors including the requirement of a cell with a high level of channel 
expression (Worley and Main 2002; Parihar et al 2003) and secondly an 
optimised and sensitive detection system. Therefore, it was initially important to 
elucidate the instruments parameters for optimal analysis of Rb+, including, 
determining nebulisation, measurement, and inter-well wash times In addition, 
to implement quality control measures to obtain reliability in function and 
maintain sensitivity of the instrument. The instrument was sensitive to 1pM and 
reproducibility was achieved in the determination of standard curves measured 
over a number of experiments. Rb+ determination was performed using a 
Thermo Russell AAS which allowed medium-throughput analysis of samples.
2.5.3 Optim ising the parameters
2.5.3.1 Rubidium Loading
The maximum amount of Rb+ loaded is dependent upon the basal activity of the 
cell (Terstappen 1999; Terstappen 2004), studies have shown that Rb+ uptake 
by cells is associated with Na+/K+ ATPase activity and that the application of the 
inhibitor ouabain depress Rb+ uptake (Gill et al 2004).
Four hours was required to saturate cells with Rb+, a loading phase time of 2 to 
4 hours is a common, time for recombinant cell lines. Wang et al (2004) for 
KCNQ/M channels expressed in CHO cells loaded cells for 3-hours, Scott et al
(2003) determined 3 hours for KCNQ2/3 in HEK293 cells and Terstappen et al 
(1999) a 4-hour incubation time for pheochromocytoma PC-12 cells. In addition, 
analysis of the collected fourth wash revealed that the Rb+ measured in the cells 
reflected that which had been loaded and not associated with the extracellular 
compartment this is in accordance with that observed previously.
2.5.3.2 Extracellular Washing
It is essential to determine the optimum washing conditions necessary to 
remove excess Rb+ from the extracellular compartment of cells, following Rb+ 
loading stage, as inefficient washing leads to artificially high efflux values and 
could account to false positive results.
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A Rb+ loading time was chosen (4-hours) and washes collected following four 
sequential washes. Four washes were required to gain confidence in the 
clearance of excess extracellular Rb+. In addition, less than 3 washes produced 
artificially high efflux values. Therefore, four washes was chosen to ensure 
confidence in removal of cell surface Rb+ and to save an 'economy in time' of 
performing excess washing. Variations to PBS used as a wash buffer include 
washing with KCI buffer without glucose (Wang et al 2004).
The frequency of washing is dependant upon a number of conditions including 
cell type, density and the system of washing used (Terstappen 2004) although 
in HTS flux assays three washes are typically used but whether three washes 
was the optimal number to use had not properly been defined in the literature 
(Scott et al 2003; Wang et al 2004; Gill et al 2004; Parihar et al 2003).
2.5.3.3 Determining basal Rb+ efflux
Basal efflux values were examined to gauge the efflux generated in response to 
differing timed exposure to KCI buffer. This was because K+ channel modulators 
were added to this and to establish whether basal efflux was affected by the 
duration of incubation with KCI buffer.
The average basal efflux observed in HEK293 cells was approximately 25-30%. 
Terstappen (1999) observed a similar level of efflux in response to KCI buffer 
(20-30%) in HEK293 cells expressing Kv channels and a lower 10-20% in CHO 
cells and PC-12 cells expressing BKca and SKCa channels respectively, 
furthermore, this value was not different to wild-type HEK293 cells.
The basal level of Rb+ efflux from the cells resulting from exposure to the KCI 
buffer is dependent upon a number of factors including the concentration of 
extracellular K+ in the buffer and the native cell phenotype including the level of 
expression of endogenous pores, ATPases and ion channels.
This basal efflux response to KCI buffer was time independent and not modified 
by the presence of K+ channel blockers (4-AP/TEA, Glib, IbTX and pax). The 
IC50 of ouabain for inhibiting Rb+ uptake has been determined as 87pM for 
Na+/K+ ATPase’s expressed in CHO cells and that its inhibition was unaffected
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by K+ concentration (Gill et al 2003). Application of ouabain could not inhibit the 
Rb+ efflux response to KCI buffer, indicating that this efflux level observed was 
not maintained by Rb+ re-uptake into cells via the Na+/K+ ATPase.
Therefore, K+ channel blockade did not lower the average efflux value below 
that achieved in KCI buffer; this indicates that potassium channels are not being 
activated. Consequently this observed efflux value represents a basal level that 
may have resulted from leakage through other channels and pores including 
non-specific cation channels (Terstappen 2004).
In addition, DMSO (0-20% in KCI buffer) demonstrated no significant effect on 
basal efflux following 10-minutes exposure. No other studies have reported the 
effects of low concentrations of DMSO on Rb+ efflux results. DMSO was used in 
the preparation of the majority of pharmaceutical tools used. For future 
experiments DMSO concentration did not exceed 0.3%.
Having established loading times, wash numbers and the basal level of efflux 
the next phase was to determine the maximum amount of efflux generated by 
stimulating the channel.
2.5.3.4 Stimulating Rb+ efflux
Activating BKca channel by mimicking endogenous conditions including partial 
depolarisation (by increasing extracellular K+) or by increasing intracellular 
calcium through the application of calcium ionophore. Rb+ efflux through BKca 
channels was sensitive to changes in intracellular calcium and membrane 
voltage with both conditions stimulating a similar maximal increase in Rb+ efflux. 
Previous studies by Terstappen (1999) examined the effect of calcium 
ionophore (25pM) on efflux from CHO cells expressing BKca channel a and p1 
subunits. An efflux of 70% was observed in CHO cells compared to 40% (at 
30pM) observed here in HEK293 cells. An increased efflux value observed by 
Terstappen could be due to the presence of the p1 subunit and its effect upon 
calcium sensitivity of the BKca channel. Other studies have used calcium 
ionophore to yield a maximum Rb+ efflux response to use as a positive control 
to normalise data against (Parihar et al 2003). However, the concentration
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response relationship to ionophore has not been fully characterised in these 
assay systems. High potassium buffers are used in certain efflux assays in the 
assessment of compounds as channel blockers. For example in hERG channel 
screening, cells are depolarised with high K+ buffers (20-40mM) are used to 
activate the channel to test the effect of channel blockers (Rezazadeh et al 
2004; Chaudry et al 2006; Wang et al 2007).
2.5.4 Pharmacological characterisation with BKCa channel openers
Pharmacological stimulation of BKca channels with NS1619, niflumic acid and 
phloretin was used to characterise the maximum response that could be 
obtained from this system with known BKca channel openers. In addition to 
determine whether the assay could discriminate accurately between differences 
in potency and efficacy values.
NS1619 (30jaM) increased Rb+ efflux above control and that this response was 
not modified by time over a 30-minute period. Therefore, the length of time to 
expose cells to KCI buffer containing ion channel modulators was chosen as 10- 
minutes. In addition, 10-minutes gave sufficient time to perform the liquid 
handling requirements of the assay and to physically do the experiment. Most 
HTS flux assays incorporate a 10-minute exposure time (Scott et al 2003).
Although not modified by time the effect of NS1619 on Rb+ efflux was 
concentration dependent. Further, it was important to establish that the efflux 
observed in the presence of NS1619 was due to the activation of BKca channels 
and not through its ancillary effects (activation of other channels and affecting 
membrane permeability). Blockers were incorporated into the final 20 minutes of 
Rb+ loading stage, a similar pattern has been observed by other research 
groups (Parihar et a /2003; Scott et al 2003). IbTX prevented NS1619 meditated 
increases in efflux. Therefore, the maximum efflux determined is representative 
of efflux through BKca channels.
Niflumic acid demonstrated concentration related increases in Rb+ efflux 
producing a similar level of potency to NS1619. However phloretin was less 
potent only evoking significant increases in Rb+ efflux at the highest
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concentration tested. NS1619 bears closer structural similarity to niflumic acid 
than phloretin and this may explain the comparable potency observed between 
NS1619 and niflumic acid.
Different ‘windows’ of activation in Rb+ efflux have been observed, Terstappen
(2004) defined a 2-fold or greater increase in Rb+ efflux upon activation above 
basal level for a good quality HTS assay. A 2-4 fold window was observed with 
NS1619, niflumic acid and phloretin. Parihar et al (2003) showed a 3-4 fold 
window for BKca channels expressed in HEK293 cells.
The addition of ouabain to KCI buffer containing NS1619 failed to increase the 
maximum efflux obtained with NS1619 alone showing that the maximum efflux 
achieved was not affected by Rb+ being recycled into the cell by the Na+/K+ 
ATPase, and represented the maximum level of Rb+ efflux achieved with 
NS1619.
2.5.5 Considerations
AAS offers a sensitive technique that was able to measure Rb+ concentrations 
in low micro-molar ranges. Furthermore, the recombinant HEK293 cells used 
demonstrated a high expression level of channels and a high cell density. 
These two factors are important to obtain a high signal to noise ratio. Therefore, 
common problems with optimisation of efflux assays are associated with lack of 
weak positive signals from cells, however, the system used afforded a 2-4 fold 
window upon stimulation.
Furthermore, some ion channels are only activated transiently (sub-millisecond) 
and so the limited time resolution of the assay, means Rb+ efflux can not be 
measured for certain ion channels (Gill et al 2003), this was not a factor for 
BKCa channels with some channels requiring manipulating to stay open (Gill et 
al 2003; Wang et al 2004). Furthermore, the assay, in comparison to 
electrophysiology, does not provide any kinetic measurements and does not 
allow for the real-time assessment of Rb+ effluxes.
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Another important variable in flux assays is the control of membrane potential, 
in that flux experiments are not performed under voltage clamp. Therefore, the 
membrane potential will be affected by buffer composition, cell size and the 
number of channels expressed, consequently changes in membrane potential 
can therefore alter ion channel conductance (Willumsen et al 2003). In addition, 
compounds with a voltage dependent mechanism of action could be lost in Rb+ 
efflux screening.
It may have been favourable to compare more BKCa channel openers using the 
assay. This could be used to generate a compendium of knowledge comparing 
the potencies of a wide range of known BKca channel openers that could 
provide clues into the pharmacophoric nature of BKCa channel openers. 
However, the lack of commercial availability limited an in-depth analysis.
2.6 Conclusions
Presented here is a fully optimised Rb+ efflux assay for the assessment of 
potential compounds as BKca channel openers. The assay comprised many 
components including the cell biology (growth of cells expressing BKca oi- 
subunit), the assay (optimal assay development) and validating the analysis of 
sample (atomic absorption spectrometry).
Xu et al (2001) define the requirements of an ideal HTS assay that include, 
sensitivity, specificity, through-put, robustness, information content, flexibility, 
cost and physiological relevance. Therefore to meet these requirements it was 
vital to optimise each step of the assay to gain an understanding of the assay 
limits and performance. The optimised assay presented here has good reliability 
and reproducibility over a number of different experimental conditions. In 
addition, the assay was able to discriminate between different levels of efficacy 
and potency for BKca channel openers providing a significant amount of 
pharmacological data. Furthermore, it is important to characterise these 
reference opener responses, because in the testing of novel compounds as 
BKca openers it is essential to have a point of reference to compare against
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potency and efficacy and in addition to providing a positive control for assay 
performance.
Therefore, an optimised non-radioactive Rb+ efflux assay can provide a 
relatively quick and sensitive tool that can differentiate novel compounds based 
on potency and efficacy in their ability to activate BKCa channels.
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Chapter 3
Identification of novel benzanilides 
as BKca channel openers using a 
non-radioactive Rb+ efflux assay
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3.1 Introduction
Novel BKcaCO structures have been proposed based on the general 
pharmacophore template of two substituted phenyl rings linked by a spacer unit. 
Initial studies have shown that compounds composed of two multi-substituted 
rings separated by an amido function introducing a three bond linker (Figure 3.1) 
could offer a new template for BKcaCO’s (Biagi et al 2004). Using in-vitro tissue 
bath studies these benzanilides have showed, IbTX sensitive, vasorelaxant 
activity to pre-contracted (with 20mM K+ Krebs buffer) rat aortic rings with 
comparable potency to NS1619 (Biagi et a /2004).
R
Figure 3.1: The template structure of benzanilides
Preliminary SAR work has revealed that the presence of a 2-OFI function on N- 
phenyl ring is an important feature (Calderone et al 2006a,b). In addition 
replacement of the benzene ring with heterocycles such as thiopene, pyrrole, 
furan and indole is deleterious except if the ring is a pyridine then BKcaCO 
properties are retained (Calderone et al 2006a,b). Insertion of a methylene 
bridge between the amido function and the benzene is not tolerated as all 
phenyl acetamides tested were deleterious. Further that inclusion of a second 
hydroxyl group to the other ring introducing a third site of hydrogen bonding 
resulted in a lowering of potency (Calderone et al 2006a,b). However, previous 
work has identified that compounds pertaining to the benzanilide structure have 
shown potency and efficacy similar to NS1619 in organ bath experiments 
(Calderone et al 2006a,b).
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From this work seven novel benzanilides were selected to study the 
pharmacophore of this template structure. The benzanilides* investigated have 
substitutions within the ring systems that have an N-phenyl ring that is either a 
pyridine with a N atom at the ortho, meta or para position or with an phenyl ring 
with alkyl chains. The other phenyl ring is either a hydroxyphenyl or 
methoxyphenyl ring with a Cl atom in the para position (Figure 3.2).
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NS1619 BKPr2 BKPr3 BKPr4
3.2 Chapter Aims
To investigate a series of novel benzanilides for BKca channel opener properties 
using an optimised non-radioactive Rb+ efflux assay.
• Characterise pharmacological properties of benzanilides.
• Examine the effect of the BKca channel p1 subunit on BKca channel 
opener properties of benzanilides.
• Determine the specificity of benzanilides to BKca channels in the cell 
lines used.
121
3.3 Methods
3.3.1 Materials
3.3.1.1 Compound preparations
Novel compounds to be assessed were provided by Dr Vincenzo Calderone 
from the chemical library of the Departmento di Scienze Farmaceutiche, 
Universita di Pisa, Italy.
The synthetic route for the preparation of the compounds is described by 
Calderone et al (2006a) and Biagi et al (2004). Compounds were supplied as 
powder (~20mg) and prepared as required by dissolving in DMSO (100%) to a 
stock concentration of 10 or 100mM and aliquots (10-1 OOpil) stored at -20°C.
3.3.2 Cell Culture
HEK293 cells previously characterised (Hartness et al 2003) and stably 
expressing either the human BKca channel a-subunit alone (referred to as BKca 
a) or with co-expression of the human BKca channel pi subunit (referred to as 
BKCa a + p1 ) were used. Cells were prepared for experimentation as described 
previously in Chapter 2, section 3.3.
3.3.3 Rb+ efflux assay
The methodology is as that described in Chapter 2 section 3.4.
NS1619 was used as a positive control and appropriate vehicle controls were 
used. Each compound was tested in replicates of 6-8 wells per plate and was 
tested at least 3 times.
3.3.4 Data Analys is
Rb+ efflux (%) was calculated and values normalised as described previously 
(Chapter 2.3.6) from which sigmoidal-concentration response curves were 
constructed using the four parameter logistic equation as follows:
Activatedefflux= Bottom+ (Top-bottom )/1  + 1 0 A[(logEQ 0 -  X )*  H illSlope]
X is the logarithm of concentration. Y is the response. From which Hill slope, 
Emax and EC4o% were calculated.
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Results are presented as mean (±SEM) for n determinations. Data was 
analysed using either Student’s un-paired t-test or for multiple comparisons 
one-way ANOVA followed by Dunnett’s or Bonferroni’s multiple comparison test 
(Wallenstein et al 1980). The accepted level of significance was p<0.05.
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3.4 Results
3.4.1 BKCa channel opener properties of benzanilides and NS1619
The Rb+ efflux response to varying concentrations of benzanilides or NS1619 
was examined on cells expressing BKca oc alone or co-expressing BKca a + p1 
subunits (Figures 3.3, 3.4 and 3.5).
The concentration response curves (CRC) determined for the benzanilides 
demonstrated that certain compounds showed activation profiles above and 
below that achieved for NS1619, with the benzanilides producing varying 
degrees in efficacy and potency.
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3.4.1.1 Efficacy profile
Efficacy (Emax) defined as the maximum increase in activated Rb+ efflux was 
determined for each compound and NS1619 tested. A range in efficacy (Emax = 
49 - 99%, n=24-32) in BKca a cells for the benzanilides was determined with 
BKH1 (62.5±7.2%), BKMel (59.7±5.2%), and BKOEtl (69.9±3.9%) displaying 
Emax values comparable to that observed for NS1619 (61.7±3.1%), (Table 3.1). 
The benzanilides; BKPr3 (72.5±3.3%), BKPr4 (99.2±8.8%) and B K W  
(86.4±11.1%) produced a significantly (p<0.05, One-way ANOVA with 
Bonferroni’s) greater level of Emax than NS1619. Conversely BKPr2 (49.1±2.5%) 
had significantly less Emaxthan NS1619 (Table 3.1).
A range in efficacy (Emax = 32 - 99%, n=24-32) was determined for benzanilides 
tested on BKca a + p1 cells. The majority of compounds including BKPr2 
(42.0±3.8%), BKH1 (32.9±4.2%), BKMel (56.8±7.6%) and B K W  (54.4±6.9%) 
demonstrated a significant (p<0.05, One-way ANOVA with Bonferroni’s) 
reduction in efficacy compared to NS1619 (76.6±5.8%). However, BKPr3 
(68.8±9.3%) and BKPr4 (65.1 ±10.2%) demonstrated comparable efficacy to 
NS1619. The only compound to increase Emax above that achieved for NS1619 
was BKOEtl (99.5±12.6%), (Table 3.1).
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3.4.1.2 Potency profile
The compounds demonstrated a 40-fold range in potency (EC40% = 0.12- 
4.47pM) in BKca oc cells (Table 3.2). Compounds BKPr3 (0.31±0.3pM), BKPr4 
(1.12±0.5pM), BKOEtl (0.21±0.3pM) and B K W  (0.12±0.3pM) demonstrated 
potency comparable to that obtained with NS1619 (0.35±0.1pM). However, 
others including BKH1 (1.41±0.18pM), BKMel (2.95±0.24|uM) and BKPr2 
(4.47±0.18pM) were significantly (p<0.05, One-way ANOVA with Bonferroni’s) 
less potent than NS1619 (Table 3.2).
Conversely, the benzanilides demonstrated an 80-fold range in potency (EC4o% 
= 0.56-46.8pM) in BKCa a + (31 cells with BKOEtl (0.12±0.3pM) achieving
potency levels comparable to NS1619 (0.79±0.4pM), (Table 3.2). However,
BKPr2 (46.8±1,4juM), BKPr3 (3.47±0.2pM), BKPr4 (4.16±0.1pM) and BKMel 
(3.63±0.2pM) were significantly (p<0.05, One-way ANOVA with Bonferroni’s) 
less potent than NS1619. BKH1 was unable to stimulate Rb+ efflux above 40% 
in BKCa oc + (31 cells (Table 3.2).
T h e o rd e r o f p o ten cy (E C 40o/o) o f th e  co m p o u n d s  w as: 
BKCa a  cells
NS1619 I BK O Etl I B K W  / BKPr3 > B K P r4 1 BKH1 > B K M el > BKPr2  
BKCa a  + p i cells
NS1619 I BK O Etl > B K W  > BKPr3 I B K M el I BKPr4 > BKPr2 > BKH1
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3.4.1.3 Hill slopes
The Hill slopes were determined from the Rb+ efflux CRC obtained for the 
benzanilides and NS1619 tested in both the BKca a  and BKca a  + p i cells 
(Table 3.3). The benzanilides (except BKPr4) produced a range of slope values 
(benzanilides = 0.62 - 1.50, NS1619 = 0.97±0.05) and (benzanilides = 0.22 - 
0.95, NS1619 = 1.99±0.22) around unity when tested on BKCa ot cells and in 
BKCa a  + p i cells respectively. BKPr4 demonstrated a significant steeper Hill 
slope from unity in both cell lines (BKca oc = 3.79±0.86; BKca a  + p i = 9.65±3.4), 
(Table 3.3).
For the benzanilides BKPr2, BKPr3 and BKPr4; the presence of the BKca 
channel p i subunit had no significant effect on the shape of the concentration 
response curve. In contrast, compounds BKH1, BKOEtl and B K W  had 
different shapes in CRC in the presence of the p i subunit.
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Hill Slope BKca a BKca a + pi
NS1619 0 .97±0 .05 1 .99±0 .22**
BKPr2 1.19±0.03 0 .7 4± 0 .0 3 *** :
BKPr3 1 .02±0 .05 0 .9 5±0 .0 3
BKPr4 3 .79±0 .86** 9 .6 5±3 .4 *
BKH1 1 .50±0 .08*** 0 .48±0 .06*
BKMel 1 .47±0 .06*** 0 .9 2±0 .0 4
BKOEtl 1 .08±0 .14*** 1 .09±0 .17
BKVV 0 .6 2±0 .0 8*** 0 .2 2 ±0 .2 3 ***
Table 3.3: Hill slopes determination
Hill slopes determined from Rb+ efflux CRC for each benzanilide and NS1619 
tested on BKCa a and a +  (31 cells. Data presented as means±SEM. Student’s 
un-paired t-test *p<0.05, **p<0.01, ***p<0.001, indicates significant difference in 
Hill slope from unity (n=24-32).
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3.4.2 The effect of the BKCa channel p1 subunit on potency and 
efficacy
The effect of BKca channel composition on the potency of compounds was 
determined by comparing EC4o% values determined in the two cell lines (Figure 
3.6). NS1619 and BKOEtl were the only compounds to demonstrate similar 
potency. All other benzanilides showed a significant (p<0.05, Student’s un­
paired t-test) 2-10 fold reduction in potency in the BKca a + pi cell line 
compared to BKca ot cells.
Differences in efficacy were demonstrated by comparing Emax values 
determined in BKca a  and BKca a + p1 cells (Figure 3.7). Compounds BKPr2, 
BKPr3, BKMel and NS1619 demonstrated apparent similar Emax whereas a 
1.5-2.0 fold reduction in efficacy was demonstrated for BKPr4, BKH1 and B K W  
in the BKca a  + p1 cells compared to BKca a  cells. However, BKOEtl 
demonstrated an increase in Emaxin BKca a  + p1 cells.
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3.4.3 Sensitivity of BKCaCO induced Rb+ efflux to selective BKCa 
channel blockers
To determine whether the increase in Rb+ efflux stimulated by the benzanilide 
compounds was due to the specific activation of BKca channels experiments 
using selective BKca channel blockers were performed. The ability of 
benzanilides and NS1619 (100pM) to increase Rb+ efflux was assessed in the 
presence and absence of IbTX (0.1 pM).
For BKCa a  cells all benzanilides (100pM for 10-minutes) evoked significant 
increases in Rb+ efflux above control (KCI buffer alone) achieving levels of 
activated Rb+ efflux (51 - 88%) in the range of that determined previously (51 - 
88%, Table 3.1). The addition of IbTX significantly (p<0.05) inhibited the Rb+ 
efflux to all benzanilides and NS1619 to a level that was not significantly 
different to vehicle control (KCI buffer, DMSO 0.3%, IbTX 0.1 pM), (Figure 3.8).
The ability of IbTX to prevent benzanilide and NS1619 induced Rb+ efflux on 
BKCa a  + p i cells was assessed (Figure 3.9). Initially the effect of IbTX on 
NS1619, BKH1, BKMel and BKOEtl (1 OOjuM) mediated efflux was assessed. 
In the absence of IbTX these compounds were able to significantly increase Rb+ 
efflux above basal control (KCI buffer alone) to a level (32 - 88%) similar to that 
achieved previously for these selected compounds (33-100% , Table 3.1). 
However, IbTX (0.1 pM) failed to modify the increase in Rb+ efflux evoked by 
these compounds (Figure 3.9).
In contrast, in BKca a  + p i cells paxilline (10pM) significantly reduced (p<0.05) 
benzanilide (except BKH1) and NS1619 mediated increases in Rb+ efflux to a 
level that was not significantly different to vehicle control (KCI buffer, DMSO 
0.3%, Pax 10pM), (Figure 3.10).
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Figure 3.9: Effect of IbTX on the Rb+ efflux response to benzanilides or 
NS1619 in BKca a + pi cells
BKca a + p i cells were exposed, for 10-minutes, to benzanilides (100pM) or 
NS1619 (100pM) in the presence (coloured bars) or absence (clear bars) of 
IbTX (0.1 pM). V = Vehicle (DMSO 0.3% and IbTX 0.1 pM) Data was normalised 
as the percentage increase in Rb+ efflux above control (KCI buffer alone) for 
each concentration and is represented as 0% activated efflux (not shown. Data 
presented as means±SEM (n=24-32).
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3.5 Discussion
A series of novel benzanilides were examined for BKca channel opener activity 
using an optimised Rb+ efflux assay. All compounds evoked significant 
concentration related increases in Rb+ efflux achieving activation profiles in the 
range of that determined for NS1619. The assay was able to discriminate the 
compounds ability to activate BKca channels on the basis of potency and 
efficacy. In addition it was able to determine any differences in these 
parameters between cells expressing BKca a alone or BKca channel a + p 
subunits.
3.5.1 Determ ination of pharm acolog ical properties of benzanilides
NS1619 showed equal potency and efficacy in the two cell lines. This is in 
agreement with other studies of this compound using electrophysiology, in that 
NS1619 activity is independent of p1 subunit expression (Olesen et al 1994b; 
Dworetsky et al 1996). BKOEtl demonstrated high levels of potency (in the sub 
pM range) and was equi-potent in both cell lines. Compounds in the BKPr 
series were all significantly less potent in cells expressing the p1 subunit with 
apparent parallel shifts in the concentration response curve. In addition, the Hill 
slope determined for these compounds were similar to each other in the two cell 
lines examined. The other benzanilides (BKH1, BKMel, BKOEtl and B K W ) 
showed different shapes in the concentration response curves producing 
significant differences in Hill slope compared to unity.
A Hill slope of around unity for NS1619 (0.97-1.99) was determined, this is in 
agreement with previous published data that has shown a similar Hill slope 
(1.14-1.83) for the effects of NS1619 on the relaxation of uterine muscle strips 
and on activation of BKca channel currents from uterine myocytes (Khan et al 
1998).
Although there was a smaller range in efficacy values than potency significant 
differences in Emax were observed between the two cell lines for benzanilides 
with BKPr4, BKH1 and B K W  having significantly higher Emax values in BKCa a  
cells.
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3.5.2 BKCa channel openers and subunit dependence
For DHS-1 (Giangiacomo et al 1998), DiBAC4 derivatives (Morimoto et al 2007), 
tamoxifen (Dick 2001) and 17p estradiol (Valverde et al 1999) it has been 
shown that activation of BKca channels specifically requires the presence of a 
(31 -subunit whereas KB130015 has demonstrated increased activation in the 
presence of BKca channel pi subunit (Gessner et al 2007). The action of other 
BKCa activators such as NS1619 (Olesen et al 1994b), pimaric acid (Imaizumi et 
al 2002), NS1608 (Siemer et al 2000) and MaxiKdiol (Singh et al 1994) do not 
require the presence of a p1-subunit and its presence does not affect the 
strength of the activating effect.
A subunit dependence, with specificity towards the a-subunit, has been 
demonstrated for the action of compounds BKPr2, BKPr3, BKPr4 and BKH1. 
These compounds had decreased potency in stimulating Rb+ efflux when tested 
on cells co-expressing the BKca channel p-subunit. Synthetic molecules 
showing decreased potency in the presence of the pi subunit have not been 
reported previously. However, ethanol has shown to cause potentiation of BKca 
channels in skeletal muscle cell t-tubules and HEK293 cells expressing mSlo 
(Chu et al 1998). Whereas cells expressing the p1 subunit and to a lesser 
extent the p4 subunit reduced the effect of ethanol on activating BKCa channels 
(Feinberg-Zadek and Treistman 2007). Furthermore, it has been determined 
that ethanol can inhibit BKCa channel currents in channels composed of a and 
p-subunit (Dick 2007). Therefore, evidence suggests that the stimulatory effect 
of ethanol on BKca channels is dependent upon expression of BKca channel a- 
subunit only.
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3.5.3 Potential explanations for differences in potency and efficacy
Addressing the issues of why certain compounds displayed differing abilities to 
activate BKca channels in the presence of the p1 subunit could be explained by 
a number of theories.
3.5.3.1 Physical hindrance
The ability of the compounds to access the binding site on the channel may be 
hindered by the presence of the p-subunit. This physical hindrance may be in 
part down to the affinity of the molecules for a binding site near the point of pi 
subunit coupling to the a-subunit. BKca channel a-subunits couple to p1 
subunits via the S0 transmembrane domain (Wallner et al 1996; Meera et al 
1997). Recent evidence has shown, using chimeric pi and p2 subunits, that 
functional coupling primarily occurs through intracellular association of N’ 
termini of the a-subunit and the C’ terminus of the p-subunits, and to a lesser 
extent coupling occurs between residues in the transmembrane regions having 
some effect with the extracellular loop playing a minor role (Orio et al 2006). 
Therefore, the chemistry of these compounds could confer a binding site on the 
N’ terminus of the a-subunit that potentially occurs on the intracellular side or 
within the transmembrane region of the channel.
However, the binding site could be occluded by the extracellular loop of the pi 
subunit. The loop plays an important role in determining K+ ion penetration and 
affects toxin binding (e.g p i subunit is a requirement for ChTX binding), 
(Hanner et al 1998). In addition, the extracellular loop is glycosylated (Knaus et 
al 1994a). Therefore, the presence of secondary protein structures could 
occlude access to the channel pore for the compounds or provide other sites of 
interaction.
Compounds BKPr2, BKPr3 and BKPr4 are structurally similar and all showed a 
decrease in potency in the presence of the pi subunit indicating that physical 
hindrance of a binding site by the pi subunit. Further investigation of this could 
be achieved by expressing mutant BKca channel a-subunits without a S0 
domain or by selected mutagenesis of particular S0 domain residues.
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Hill slopes determined from the Rb+ efflux activation profiles were not different 
in the presence of the pi subunit for BKPr2, BKPr3 and BKPr4 indicating that 
there is not a change in the co-operativity in molecules binding and activating 
the channel. Therefore a change in potency but not in Hill slope could indicate a 
change in the affinity for the binding site that is hindered by the presence of a 
p1 subunit.
The compound BKH1, over the concentration range tested, could not activate 
efflux above the 40% level in BKca a  + p1 cells where as BKMel showed 
slightly less potency in a + p1 cells and BKOEtl was equi-potentent. Hill slope 
values for these compounds were different indicating that the p1 subunit may 
have affected the co-operativitiy in the association of molecules with the 
channel but had varying different effects on potency. This may suggest that this 
series of compounds could act at different sites to the BKPr series.
Another point to consider is that the compounds could mimic the effect of the 
interaction of the pi subunit with the a-subunit. Seimer et al (2000) propose that 
NS1608 interacts with the So segment at a site for p-subunit association on the 
extracellular surface of the channel. This was because experimental data and 
the lipophilicity of NS1608 rule out the possibility of an association with 
intracellular C’ termini of the channel. In addition, Hu and Kim (1996) proposed 
that the lipophilic trifluoromethyl carbocyclic part of the molecule lies within the 
site of action.
3.5.3.2 Physiological effect of the p-subunit on BKca channels
The p1 subunit has been shown to enhance the Ca2+ sensitivity of the channel,
in that 5-10 fold less Ca2+ is required with the p1 subunit for 50% activation of 
the channel at a particular membrane potential compared to a-subunits alone 
(McManus et al 1995; Meera et al 1996; Nimigean and Magleby 1999). The p1 
subunit causes a decrease in the voltage dependence of the channel (Orio and 
Latorre 2005) and activation kinetics (Dworetzky et al 1996; Meera et al 1996; 
Tseng-Crank et al 1996). Therefore, the ability of compounds to activate the 
channel may be affected by the intrinsic voltage and calcium sensitivity or the
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altered macroscopic kinetics in BKca a + p1 cells. This could be investigated 
further using electrophysiology.
3.5.3.3 Two binding sites?
An alternative hypothesis to physical hindrance is the presence of two binding 
sites on the channel one that activates the channel at higher compound 
concentrations and the other site is activated at lower concentrations. The lower 
concentration binding site could be occluded by the presence of the p1 subunit 
and hence more compound would be required to produce the same effect. This 
in theory could be supported from the data if a biphasic relationship was 
observed. However, the compounds did not show a biphasic pattern.
Other openers such as phloretin, when examined on cloned mSlo and hSlo, in 
Xenopus oocytes demonstrated a biphasic relationship with an EC50 of 30pM 
and >200pM (Gribkoff et al 1996). Therefore, the concentration range used 
(0.1-100pM) may not have been sufficient to observe bi-phasic activity, in that a 
second low affinity binding site would probably require sub-mM concentrations 
of benzanilides.
Therefore, it would be of interest in terms of future work to determine whether 
the pi subunit affects the potency of these compounds through physical 
hindrance or by the phenotypic effect of the p1 subunit on the functional state of 
the channel. Using specific blockers such as tetradrine (Dworetsky et al 1994) a 
BKCa channel p-subunit specific blocker and other BKca channel blockers such 
as IbTX and ChTX could be used in binding assays (125l-ChTX) to elucidate 
potential binding sites, however this may be limited to activators and blockers 
that act on the same site of the channel (Knaus et al 1994b; Kaczorowski et al 
1999; Imaizumi et al 2002). In addition blockers could be used in determining 
the affinity of the compounds by using the principles of Cheng-Prussof for cells 
expressing different BKca channel p-subunits with different a-subunit splice 
variants (Calderone 1998).
Furthermore, the assay could be used to determine the additive effects of 
different combinations of different openers. This may provide an insight into the
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mechanism of action of these compounds. Gressner et al (2007) studied the 
additive effects, using electrophysiology, of NS1619 and KB130015 (a potential 
new BKCa channel opener) and determined no discernable difference when 
added together versus their effects when tested independently indicating that 
they could act in a similar mechanism.
In addition, the effect of different p-subunits (pi - p4) with their different structure 
and functional effect may provide further understanding of the compounds 
mechanism of action and elucidate further specificity of these compounds.
3.5.4 Therapeutic potential of benzanilide com pounds
BKH1, BKPr3 and BKPr4 showed a decrease in potency and to some degree 
efficacy when tested on BKca a  + p i cells. Such agents showing differential 
activity profiles in the absence and presence of the pi subunit could be used as 
therapeutic agents in a number of clinical conditions. In particular these agents 
could be beneficial therapeutically for diseases associated with changes in a- 
subunit or in tissues with the expression of BKca channel a-subunit only. 
Further, BKcaCO compounds that are dependent upon p-subunit for binding are 
not necessarily advantageous as therapeutics because changes (decreases) in 
expression of the p-subunit with age and disease have been reported so BKca 
channel a-subunit specific activators would be more advantageous (Zakharov et 
al 2005).
BKCa channels are ubiquitously distributed in nearly all tissues (except in 
cardiomyocytes), however tissues display differential expression levels of a or p 
subunits. The predominant BKca channel in brain regions and spinal chord are 
composed of BKca channel a-subunits only (Knaus et al 1996; Chang et al 1997; 
Jiang et al 1999) except in the cerebellum and corpus callosum (Tseng-Crank 
et al 1996). Furthermore, BKca channels have recently been discovered to be 
expressed in inner mitochondrial membrane of rat brain (Douglas et al 2006). 
Therefore, BKca channel openers could be potentially used to treat neuronal ion 
channel disorders (Lawson 2000a).
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3.5.4.1 Skeletal muscle
Tissues displaying a-subunit expression alone include skeletal muscle 
(Nimigean and Magleby 1999) which has demonstrated low or no p-subunit 
mRNA expression in human, canine, or rat skeletal muscle (Jiang et al 1999; 
Chang et al 1997; Tseng-Crank et al 1994). In addition, the p-subunit selective 
activating properties of 17p estradiol were unable to elicit BKca channel current 
in rat skeletal muscle (Valverde et al 1999).
In contrast to smooth muscle BKCa channels, which have been shown to be 
critical regulators of vascular tone, the physiological role of skeletal muscle 
BKCa channels is much less defined (Marijic et al 2001). The majority of 
research into skeletal muscle BKca channels has come from the work of 
Tricarico and colleagues. They have shown that in skeletal muscle BKca 
channels are opened by changes in membrane potential and intracellular 
calcium as well as by protein kinase A (PKA) phosphorylation. Skeletal BKca 
channels increase the duration between after-hyperpolarisations between action 
potential burst and buffer the accumulation of intracellular Ca2+ ions (Tricarico et 
al 1997; Tricarico et al 2000). In addition, BKca channel activity in skeletal 
muscle is increased in aged rats (Tricarico e ta l 1997).
Enhanced BKca channel activity has been implicated in the pathogenesis of 
hyperkalemia in particular following ischaemia-reperfusion in a rat model of 
skeletal ischaemia. Furthmore it is an unwanted side effect that can cause 
sudden death in patients affected by reperfusion disorders. Therefore 
modulation of Kca currents in skeletal muscle could prove therapeutically 
beneficial (Tricarico e ta l2002).
The carbonic anhydrase inhibitor acetazolamide (ACTZ) has been used 
clinically to treat hypokalemic periodic paralysis (hypoPP) disorder with patients 
suffering episodes of flaccid paralysis with muscle weakness lasting from hours 
to days. Treatment restores muscle strength and reduced frequency of attacks 
(Links et al 1988; Tricarico et al 2000). The disorder is characterized by low 
plasma K+ levels and muscle depolarisation in response to insulin (Tricarico et 
al 2000; Tricarico et al 2004).
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Tricarico et al (2000) identified that ACTZ mode of action was not through 
blocking carbonic anhydrase enzymes but via the activation of Kca channels. 
The application of ACTZ to a hypokalemic rat model prevented paralysis that 
was reversed by K c a channel blockade (using ChTX) but not by K a t p  channel 
blockade (using glibenclamide). Furthermore, that excised patches of 
.dissociated rat fibers from K+ deficient mice showed that ACTZ activated BKca 
currents (Tricarico et al 2000). Further to this structure-activity relationships for 
a series of carbonic anhydrase (including ACTZ) inhibitors have been reported 
(Tricarico et al 2004). However, ACTZ treatment has shown in some patients to 
be ineffective and can exacerbate the condition (Tricarico et al 2005).
Recently, the differential effects of ACTZ have been shown to result from the 
expression of two types of BKca channel in rat skeletal muscles. BKca channels 
from slow twitching soleus muscles are Ca2+ and ACTZ insensitive while the 
BKCa channel phenotype from fast twitching flexor digitorum brevis muscles are 
ACTZ sensitive and display normal Ca2+ sensitivities. A change in phenotype 
can occur following ACTZ treatment and prolonged muscle disuse (Tricarico et 
al 2005). Furthermore, BKca and Katp channels have been implicated in muscle 
fatigue caused by potassium imbalances in skeletal muscle (Kristensen et al 
2006).
BKcaCO’s with selectivity to skeletal muscle (expressing BKca channel a- 
subunits only) could provide a therapeutic advantage to current treatments for 
hypoPP and other disorders associated with muscle weakness and fatigue.
3.5.4.2 Endothelial cells
In porcine cultured endothelial cells BKca channels expressing only the a- 
subunit has been reported (Papassotiriou et al 2000). In addition, 17p estradiol 
had no effect on BKCa channel currents in cultured human vascular endothelial 
cell line derived from umbilical cord (HUV-EC-C) where as other BKca openers 
including niflumic acid and Evans blue elicited paxilline sensitive BKca currents 
(Chiang and Wu 2001). It has been reported that endothelial BKca channels are 
important elements in coupling of shear stress and the release of endothelial
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vasoactive compounds such as NO and prostaglandins that elicit dilation of 
arterioles of skeletal muscle (Sun et al 2001). Furthermore, it has been 
demonstrated that the BKca channel openers NS1619 and resveratol induce NO 
release from endothelium of rat aorta but fail to induce it in denuded aorta 
(Calderone et al 2007). Furthermore, increases in endothelial NO synthesis 
have been reported in cultured Human endothelial cells upon exposure to 
NS1619 and that this increase involves p42/p44 MAP kinase and calcium 
induced activation of eNOS system (Kuhlmann e t a l2004).
In addition, it has been demonstrated that BKCaCO do not effect the proliferation 
of endothelial cells and that they could be advantageous in the treatment of 
hypertension and other cardiovascular diseases (Calderone et al 2007) without 
producing hypertension induced vascular remodeling. Therefore, BKca channel 
subtype specific openers identified here could potentially be useful as 
therapeutic tools in the treatment of hypertension and other cardiovascular 
problems.
3.5.5 Blocking experim ents
To determine the specificity of benzanilides in activating Rb+ efflux from BKca 
channels in the two cell lines the effects of benzanilides were tested in presence 
of the specific blockers channel blockers. IbTX (Garcia et al 1991) and Pax 
(Knaus et al 1994b) were able to block benzanilide induced increases in Rb+ 
efflux in BKca a and BKca a + p1 respectively. IbTX was unable to block 
benzanilide induced increases in Rb+ efflux in BKca a + p1. The insensitivity of 
BKCa channels expressing the p1 subunit to block by IbTX has been 
documented previously in HEK293 cells (Lippiat et al 2003; Ahring et al 1997) 
and oocytes (Dworetsky et al 1996) expressing either a alone or a + pi 
subunits, with an approximate 30-fold shift in IC50 for IbTX from ~30nM to 
~300nM.
Therefore, blocking with the IbTX (100nM) concentration used may not have 
been sufficient to block BKca channels in the BKca a + p1 cell line. However, 
pax which was able to block BKca a + p i cells has shown to block a and a + pi 
subunits with similar affinity (Ahring et al 1997). In addition, the IC5o for pax (1- 
200nM), (Sanchez and McManus 1996; Ahring et al 1997; Li and Cheung 1999)
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was well below that used in the blocking experiments (10pM). For future work it 
may have been useful to have looked at different concentrations of blocker in 
the presence of fixed amounts of benzanilide. This could be used to build up a 
picture of affinity of the compounds and the use of different blockers with 
different binding sites could lead to an understanding of sites of interaction on 
the channel.
3.5.6 Considerations
Potency (EC4o%) has been used to assess those benzanilides with the greatest 
BKCa channel opener ability. In the pharmaceutical industry potency in HTS is 
the predominant criterion used in the selection of potential lead candidate drugs 
(Abad-Zapatero and Metz 2005). However, current thought is that potent 
compounds do not always result in good drugs (Hopkins et al 2004; Abad- 
Zapatero and Metz 2005). In that other parameters should be taken into 
consideration, in particular molecular weight. In addition, physiochemical 
properties such as polar surface area, affinity (Kd) and IC5o have been used in 
the development of indexes to asses new compounds potential to become 
drugs (Hopkins et al 2004). For example, ligand efficiency which uses the 
number of non-hydrogen atoms as a normalising factor against differences in 
affinity measured for different compounds. Percentage efficiency index (PEI) 
and binding efficiencies index (BEI) based on molecular weight and surface- 
binding efficiency index (SEI) based on the polar surface area and or polarity of 
a compound (Abad-Zapatero and Metz 2005). Molecular modelling of these 
compounds could aid in assessing the physio-chemcial properties of the 
benzanilides. Any potential differences in the properties of these compounds 
could be related to variations in their structures and their differential potency 
profiles. This could provide information that could guide the synthesis of more 
potency and specific BKcaCO from this series.
Therefore, defining compounds on their ability to activate BKCa on the basis of 
potency is still a good measure but should consider the physiochemical effects 
of these compounds (Chapter 6) to determine their potential for lead selection.
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3.6 Conclusions
This assay has identified 7 novel compounds as potential BKCa channel openers 
that display varying degrees of potency and efficacy and that some compounds 
show specificity to the BKca channel a-subunit.
151
Chapter 4
Assessment of benzanilides as 
B K c a C O ’s using whole cell 
electrophysiology
4.1 Introduction
Patch clamp electrophysiology was developed in the mid-70's by E. Neher and 
B. Sakmann and allowed the characterisation of single channels within a 
membrane; this has become the definitive method for ion channel studies 
(Neher and Sakmann 1976, Hamill et al 1981).
The use of the patch clamp technique coupled with developments in molecular 
genetics has been fundamental in the characterisation of the cellular functions 
of potassium channels (Calderone 2002; Korovkina et al 2002). Furthermore, 
the whole cell electrophysiology recording configuration (WCR) has provided a 
powerful technique for the assessment of K+ channel modulators (Olesen et al 
1994b; Gribkoff et al 1996; Holland et al 1996; Hu and Kim 1996; Hu et al 1997; 
Gribkoff et al 2001b; Imaziumi et al 2002; Wu et al 2002; Nardi et al 2003; 
Sakamoto et al 2005; Huang et al 2007). Currently, it remains the preferred 
technique for the verification of compounds identified using Rb+ efflux assay 
(Tang et al 2001; Parihar et al 2003; Scott et al 2003; Willumsen et al 2003; 
Rezazadeh et al 2004) as K+ channel modulators.
The Rb+ efflux assay reported in chapter 2 provided a robust and informative 
assay to assess novel BKcaCO compounds. The Rb+ efflux studies reported in 
chapter 3 revealed a series of benzanilides that demonstrated differential 
potency and efficacy profiles. However, electrophysiology allows for detailed 
examination of the activation properties of the benzanilides on BKca channels 
and is the preferred method for the analysis of ion channel function.
153
4.2 Chapter Aims
To further characterise the activation of BKca channels by benzanilides using 
whole cell electrophysiology.
• Asses the effect of benzanilides on activity of BKCa channels by 
determining their effects on voltage-dependent activation, V5o’s, 
activation and deactivation times.
• Validation of Rb+ efflux assay in determining the potency of benzanilides 
vs. that obtained with whole cell electrophysiology.
. •  Determine the specificity of activation of benzanilides to BKCa channels in 
this cell line.
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4.3 Methods
4.3.1 Materials  
Cell culture equipment
Scientific Laboratory Supplies, Nottingham U.K: Nunc Dishes (35mm)
General purpose reagents
VWR International Ltd, Lutterworth, U.K: Potassium hydroxide (KOH), methanol
Sigma Aldrich, Gillingham, U.K: (p-aminoethylether)-N, N, N’, N’-tetraacetic acid 
(EGTA)
Electrophysiology
VWR International Ltd, Lutterworth, U.K: Acrodisc syringe filter (0.2pl).
Thermo Electron Corporation, Auchtermuchty, U.K: lonplus Ca2+ module and 
electrode.
World Precision Instruments (WPI), Stevenage, U.K: CALBUF-1: Calcium 
standard buffers, 24AWG 34-Guage 70mm long microfilm syringe
Harvard Apparatus, Edenbridge, U.K: Borosilicate glass capillaries (1.2mm O.D 
X 0.69mm I.D).
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4.3.2 Cell culture
BKCa ot cells were maintained in continuous culture as described in chapter 2 
section 3.3. Cells were prepared for electrophysiology by seeding 35mm nunc 
dishes with 10,000 cells/ml in DMEM (2mls). Cells were used 1-4 days post 
plating. Isolated cells were selected for WCR.
4.3.3 Electrophysiology
4.3.3.1 M icroelectrode Fabrication
Patch pipettes were fabricated from borosilicate glass capillaries (1.2mm O.D. X 
0.69mm I.D.) using a Sutter Instrument Company P-97 Flaming/Brown 
micropipette puller (Intracell, Shepreth, U.K.) yielding two symmetrical pipettes 
(with an optimised shape) from each pull. These were then fire polished using a 
Narishige Microforge MF-830 (Intracell, Shepreth, U.K) to obtain electrodes with 
a resistance of 2-5MQ.
4.3.3.2 Drugs and solutions
Extracellular bath solutions contained; (mM) KCI 120, KOH 20, MgCI2 1.0, 
CaCI2 0.01, HEPES 10 and intracellular pipette solution contained; (mM) KCI 90, 
KOH 50, MgCI2 1.0, CaCI2 0.01, HEPES 10. The pH of both solutions was 
adjusted to 7.4 (KOH 1M) and calcium Ca2+ concentration was adjusted to 
0.3pM with EGTA (10mM) using a Ca2+ selective electrode calibrated using 
Ca2+ buffer standards (0.1, 1.0 and 10pM). Solutions were warmed to room 
temperature (18-24°C) prior to experimentation and intracellular pipette solution 
was filtered using an acrodisc syringe filter (0.2pM) before filling pipettes.
Drugs were prepared from frozen stocks as described previously (chapter 2) 
and diluted to the required concentration in extracellular solution. Solutions 
were applied to the bath using a gravity fed perfusion system (at a rate of 10.0 
ml/min) which allowed for complete exchange of bath solution within 2-minutes. 
Perfusion system tubing was cleaned by washing through with methanol (100%) 
and then with double-distilled water (resistivity >18 MQ cm'1), this procedure 
was carried out following experimentation after the addition of BKca channel 
modulators.
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Control recordings were made in the presence of extracellular solution and 
during the perfusion of compounds, the perfusion system was turned off before 
recordings were acquired.
4.3.3.3 Data Recording
Whole cell currents were recorded using conventional patch clamping 
techniques (Hamill et al 1981). Currents were recorded in voltage clamp mode 
using an EPC-10 patch-clamp amplifier via an IPTC16 digital interface (HEKA, 
Lambrecht, Germany). Current signals, after compensation for whole-cell 
capacitance, series resistance and liquid junction potential, were low-pass 
filtered at 2.9 KHz using a 4-pole Bessel filter and sampled at 10 KHz and 1 
KHz before being stored on the hard disk drive of the computer. BKca channel 
current, under these conditions, did not run down during the following 30-40  
min of the experimentation period.
4.3.3.4 Whole cell patch formation and Data acquisition
Single isolated cells were chosen to patch; following seal formation whole cell
access was acquired by applying gentle suction to the pipette to disrupt the cell 
membrane, seals >2GQ were accepted. Breakthrough was performed by 
applying gentle suction following seal formation and detecting a change of 
current and the appearance of small capacitance transients when voltage 
pulses were applied.
In whole cell the time for solution exchange between the pipette and the 
intracellular contents of the cell was ~10s based upon the parameters defined 
by Thomas and Smart (2005) for HEK293 cells. Therefore within 1-2 mins of 
membrane breakthrough complete solution exchange would have occurred.
Currents were elicited using a voltage step protocol (Figure 4.1); from a holding 
potential of OmV for 50ms the voltage was ramped to -100mV for 100ms to 
deactivate BKCa channels, following this the voltage was stepped to the first 
voltage to be analysed for 500ms. Subsequently the voltage was then stepped 
to -100mV and held at this potential for 100ms to close all of the channels 
(instantaneous tail current), this was followed by a period of rest when the 
potential was returned to OmV for 50ms. This cycle was repeated 21 times from
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-100 to + 100mV with each cycle increasing the voltage applied to the 
membrane by 10mV.
+ 1 0 0 m V  .____________________________________
OmV — i
-100mV ^ -------- ’Y
100ms
Figure 4.1: Voltage-step protocol for recording of BKCa channel currents
4.3.3.5 Data analysis
Data was analysed offline for peak current at each stepwise increase in 
membrane voltage using HEKA Pulsefit software and values exported to 
Microsoft Excel.
Conductance-voltage curves
Peak current values were converted to conductance using the formula G= IA/m 
where G is conductance, V  is the membrane potential and I the current elicited. 
Conductance was normalised to the highest conductance within the patch 
(Gmax). Normalised data was pooled and used to generate normalised 
conductance (G/Gmax) -  voltage (V) curves (G-V) to which Boltzmann 
sigmoidal function was fitted;
G/Gmax = (1 + exp[(V50 -  Vm )/S])‘1
From which V 5o, S and Vm representing voltage required for half-maximal 
activation, slope and membrane potential were determined respectively 
(Gribkoff et al 1996; Ahring et al 1997; Zakharov et al 2005). Current traces 
were exported from HEKA PulseFit to use as visual representations of the data.
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Tail currents and deactivation time
For current-deactivation studies; tail currents were evoked following a +100mV 
activating pulse by a step to a deactivating -100mV potential and then 
repolarising to OmV for 100ms. Tail currents were best fit using a one- 
component exponential model (Dworetsky et al 1996; Zhang et al 2001; 
Horrigan and Aldrich 2002) of the form;
l(t) = a0 +a, exp(-f/r ,)
From which deactivation time constant (x, ms) was determined. Time to peak 
currents were measured directly with both values obtained using PulseFit 
software.
Inhibition profile
The inhibitory profile of the blockers TEA, IbTX and pax was determined by 
calculating the relative inhibition of current (l/lo) compared to control current 
recorded at +60mV membrane potential. The data was fitted by the following 
modified Hill equation (Sanchez and McManus 1996);
l / l 0 = Bottom + (Top-Bottom )/1 + 10A((log/C50 -  X ) *  Hillslope))^
From which the IC50 (the concentration of blocker giving 50%  inhibition) of a 
blocker was determined.
All data was fitted using GraphPad Prism 4 software and are presented as 
mean (±SEM) for n determinations. Data was analysed using either Student’s 
un-paired or paired t-test or for multiple comparisons one-way ANOVA followed 
by Dunnett’s post test analysis or Bonferroni’s multiple comparison test 
(Wallenstein et al 1980). The accepted level of significance was p<0.05.
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4.4 Results
4.4.1 The effect of K+ channel blockers on /K from BKCa a cells
To determine that the control currents observed were due to the activation of K+ 
channels (/k) the non-specific K+ channel blocker TEA (applied to extracellular 
bath solution) was used. The assessment of blocker action was determined as 
the % decrease in current at +60mV membrane potential. TEA was able to 
completely block /k currents in the cell with an IC50 value determined as 
5.24±1.00mM (n=4), (Figure 4.2).
To assess whether the K+ current was carried by BKca channels the specific 
blocker IbTX was applied to the extracellular solution. In symmetrical K+ 
(140mM) IbTX at supra-maximal concentrations (0.5pM) was unable to 
completely block /«, with an IC5o value determined as 0.22±0.15pM (n=4). 
However, in asymmetrical K+ (5.4:140mM) the IC50 value was lower 
0.08±0.07pM (n=4), with greater block observed at each concentration tested 
(Figure 4.3). Although at high concentrations (0.5pM) IbTX was unable to 
completely block /k. In contrast, the BKCa channel blocker pax (0.001-10|nM) 
blocked /k currents in a concentration dependent manner from which an IC5o of 
0.09±0.2pM (n=6) was determined. Complete inhibition of channel currents was 
observed at 10pM pax (Figure 4.4).
The blocker action for TEA, IbTX and pax was reversible upon washout with 
extracellular buffer and complete washout accomplished within 5-10 minutes of 
continual perfusion (50-100mls), (Data not shown).
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Figure 4.2: Effect of TEA on control whole cell currents from BKCa a  cells
Whole cell currents were elicited under control conditions (O.OmM TEA, 0.3pM 
Ca2+ and symmetrical 140mM K+) and following application of TEA (1-100mM).
(a) Inhibition CRC determined where reduction of current relative to control (at 
+60mV membrane potential) for each concentration tested, (b) Representative 
current traces for the effect of different concentrations of TEA as indicated. Data 
presented as means±SEM, (n=3-4).
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(140:140mM) (■) or asymmetrical (5mM extracellular) potassium (□), from which the IC5o (Inhibitory concentration 50%) was determined. 
Data presented as means±SEM, (n=6-9). (b) Representative current traces for data determined in symmetrical (i) and asymmetrical ii) in 
the absence (control) and presence of differing IbTX concentrations.
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Figure 4.4: Effect of Paxilline on control whole cell currents from BKca a  
cells
Whole cell currents were elicited under control conditions (O.OpM Pax, 0.3pM 
Ca2+ symmetrical ((140mM)) potassium) and following application of pax (0.001- 
10pM). (a) Inhibition CRC determined as the reduction of current relative to 
control (at +60mV membrane potential) for each concentration tested. Data 
presented as means±SEM (n=4-6). (b) Representative current traces for 
different concentrations of pax as indicated.
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4.4.2 Benzanilide activation of whole cell BKCa channel currents
Benzanilides and NS1619 (30pM) were tested for their ability to elicit whole cell 
BKCa channel current activity from BKca a cells. Each cell was exposed to one 
compound at a single concentration and compounds were tested in randomised 
order on cells from different passages.
Application of NS1619 (30pM) resulted in an increase in whole-cell BKca 
channel currents (above control) that was more pronounced with further 
depolarisation (Figure 4.5b) producing significant displacement of G-V curve 
towards more hyperpolarised voltages (Figure 4.5a), indicative of BKCa channel 
activation. The effect was evaluated by comparing the voltage required to 
produce 50% activation (V5o). Under control conditions (0.3pM Ca2+) a V50 of 
85.3±1.5mV (n=9) was determined and was not modified by application of 
extracellular bath solution containing DMSO (0.3%) (V50 = 85.1±9.4mV, n=3). 
The addition of NS1619 (30pM) produced a significantly (Student’s paired t-test, 
p<0.001) decreased V5o (13.4±3.3mV, n=9) value (Figure 4.5c).
All benzanilide compounds (30pM) independently tested produced significant 
increases in whole-cell BKca channel currents above control that was more 
pronounced with further depolarisation (Figure 4.5b-4.12b). Each benzanilide, 
like NS1619, produced significant leftward displacement of the G-V curve from 
control in the hyperpolarising direction, indicative of BKca channel activation 
(Figure 4.5a-4.11b). For the benzanilides, a range (29.9-63.OmV, n=6-9) in V5o 
values was produced. These were all significantly decreased compared to their 
respective V50 values determined under control conditions (Figure 4.5c-4.12c).
The effect of the benzanilides and NS1619 was reversible upon wash-out with 
extracellular solution. However, an extensive washing time was required of 15- 
20 minutes (~150mls of extracellular solution) continual perfusion to return the 
level of activation to control levels (Data not shown).
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4.4.3 Time to peak current and deactivation kinetics
The time to peak current was measured as the time required to achieve 
maximum current following induction of voltage step following a holding 
potential of -100mV. NS1619 significantly (p<0.01, Student’s paired t-test) 
increased the time (25.0±2.4ms, n=6) for current to reach a peak value relative 
to control (12.3±1.7ms, n=6), (Figure 4.5c). Under control conditions a range of 
activation times (11.1 ±2.5 to 15.1±3.4ms, n=6-9) was determined that was not 
significantly (Student’s paired t-test, p>0.05) affected by application of each 
benzanilide (10.0±1.1 to 14.4±3.6ms, n=6-9), (Figure 4.6c-4.12c). Therefore, no 
individual benzanilide affected the time to reach peak current relative to the 
control measurement made prior to the application of compound.
The deactivation kinetics for benzanilides and NS1619 was assessed by 
determining the deactivation time constant from instantaneous tail current 
generated from the voltage step protocol by application of -100mV following a 
+100mV activating test pulse. NS1619 significantly (p<0.01, Student’s un-paired 
t-test) increased the time (12.5±2.9ms, n=6) for the channel to deactivate 
relative to control measurements made prior to application of NS1619 
(2.6±0.6ms, n=6).
Under control conditions a range of values (2.4±0.3 to 6.2±2.3ms, n=6-9) 
determined that were not significantly (Student’s paired t-test, p>0.05) affected 
by application of each benzanilide (4.2±2.0 to 7.5±2.8ms, n=6-9). Therefore, no 
individual benzanilide tested affected the time for the channel to deactivate in 
response to an inactivating potential relative to the control measurement made 
prior to the application of compound.
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Control 85.3+1.5 12.3+1.7 2.6+0.6
DMSO (0.3%) 85.1+9.4 n.d n.d
NS1619 13.4+3.3*** 25.0+2.4*** 12.5+2.9*** |
Figure 4.5: The effect of DMSO and NS1619 on BKCa channels
In whole cell configuration BKCa channel currents were elicited from BKca a cells 
by applying test pulses in 10mV increments from -100mV to +100mV from a 
holding potential of -100mV. (a) Averaged normalised G -V  relationships were 
determined under control conditions ( ) and following exposure to DMSO 
(0.3% ■ ) then NS1619 (30jaM T ) from which V50 and slope factor were 
determined (C). (b) Representative current traces obtained in the absence 
(control, Top) and presence of DMSO (middle) and then followed by NS1619 
(30|aM) (Bottom) from which time to peak current was measured and 
deactivation time constant determined from tail currents (at -100mV) (c). Data 
presented as means±SEM (n=6-9). Student’s paired t-test, ***p<0.001 indicate 
significant differences from control, n.d = not determined.
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Figure 4.6: Stimulatory effect of BKPr2 on BKCa channels
In whole cell configuration BKca channel currents were elicited from BKca a cells 
by applying test pulses in 10mV increments from -100mV to +100mV from a 
holding potential of -100mV. (a) Averaged normalised G -V  relationships were 
determined under control conditions ( ) and during exposure of BKPr2 (30jaM, 
Z ) from which V50 and slope factor were determined (c). (b) Representative 
current traces obtained in the absence (control; top) and presence (bottom) of 
BKPr2 (30pM) from which time to peak current was measured and deactivation 
time constant determined from tail currents (at -100mV) (c). Data presented as 
means±SEM, (n=6-9). Student’s paired t-test, **p<0.01 indicate significant 
differences from control.
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Figure 4.7: Stimulatory effect of BKPr3 on BKCa channels
In whole cell configuration BKCa channel currents were elicited from BKca a cells 
by applying test pulses in 10mV increments from -100mV to +100mV from a 
holding potential of -100mV. (a) Averaged normalised G -V  relationships were 
determined under control conditions ( ) and during exposure of BKPr3 
(30|aM,A) from which V50 and slope factor were determined (c). (b) 
Representative current traces obtained in the absence (control; top) and 
presence (bottom) of BKPr3 (30pM) from which time to peak current was 
measured and deactivation time constant determined from tail currents (at - 
100mV), (c). Data presented as means±SEM, (n=6-9). Student’s paired t-test, 
***p<0.001 indicate significant differences from control.
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Figure 4.8: Stimulatory effect of BKPr4 on BKCa channels
In whole cell configuration BKCa channel currents were elicited from BKca a cells 
by applying test pulses in 10mV increments from -100mV to +100mV from a 
holding potential of -100mV. (a) Averaged normalised G -V  relationships were 
determined under control conditions ( ) and during exposure of BKPr4 (30pM, 
(V) from which V50 and slope factor were determined (c). (b) Representative 
current traces obtained in the absence (control; top) and presence (bottom) of 
BKPr4 (30pM) from which time to peak current was measured and deactivation 
time constant determined from tail currents (at -100mV), (c). Data presented as 
means±SEM, (n=6-9). Student’s paired t-test, ***p<0.001 indicate significant 
differences from control.
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BKH1 51.6±1.8*** 13.3±1.7 3.5±0.4
Figure 4.9: Stimulatory effect of BKH1 on BKCa channels
In whole cell configuration BKca channel currents were elicited from BKca oc cells 
by applying test pulses in 10mV increments from -100mV to +100mV from a 
holding potential of -100mV. (a) Averaged normalised G -V  relationships were 
determined under control conditions ( ) and during exposure to BKH1 (30|aM, 
O) from which V 50 and slope factor were determined (c). (b) Representative 
current traces obtained in the absence (control; top) and presence (bottom) of 
BKH1 (30|aM) from which time to peak current was measured and deactivation 
time constant determined from tail currents (at -100mV), (c). Data presented as 
means±SEM, (n=6-9). Student’s paired t-test, ***p<0.001 indicate significant 
differences from control.
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Figure 4.10: Stimulatory effect of BKMel on BKCa channels
In whole cell configuration BKCa channel currents were elicited from BKCa a cells 
by applying test pulses in 10mV increments from -100mV to +100mV from a 
holding potential of -100mV. (a) Averaged normalised G -V  relationships were 
determined under control conditions ( ) and during exposure of BKMel (30pM, 
( • )  from which V50 and slope factor were determined (c). (b) Representative 
current traces obtained in the absence (control; top) and presence (bottom) of 
BKMel (30pM) from which time to peak current was measured and deactivation 
time constant determined from tail currents (at -100mV), (c). Data presented 
as means±SEM, (n=6-9). Student’s paired t-test, **p<0.01 indicate significant 
differences from control.
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Figure 4.11: Stimulatory effect of BKOEtl on BKCa channels
In whole cell configuration BKCa channel currents were elicited from BKca a cells 
by applying test pulses in 10mV increments from -100mV to +100mV from a 
holding potential of -100mV. (a) Averaged normalised G -V  relationships were 
determined under control conditions ( ) and during exposure of BKOEtl (30pM, 
( ) from which V50 and slope factor were determined (c). (b) Representative 
current traces obtained in the absence (control; top) and presence (bottom) of 
BKOEtl (30pM) from which time to peak current was measured and 
deactivation time constant determined from tail currents (at -100mV), (c). Data 
presented as means±SEM, (n=6-9). Student’s paired t-test, ***p<0.001 indicate 
significant differences from control.
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BKVV 49.7±1.6*** 12.9±2.9 7.5±2.8
Figure 4.12: Stimulatory effect of BKVV on BKCa channels
In whole cell configuration BKCa channel currents were elicited from BKca a cells 
by applying test pulses in 10mV increments from -100mV to +100mV from a 
holding potential of -100mV. (a) Averaged normalised G -V  relationships were 
determined under control conditions ( ) and during exposure of B K W  (30pM, 
(O) from which V50 and slope factor were determined (c). (b) Representative 
current traces obtained in the absence (control; top) and presence (bottom) of 
B K W  (30pM) from which time to peak current was measured and deactivation 
time constant determined from tail currents (at -100mV), (c). Data presented as 
means±SEM, (n=6-9). Student’s paired t-test, ***p<0.001 indicate significant 
differences from control.
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4.4.4 Order of effectiveness of benzanilides
The rank order of efficacy for the benzanilides and NS1619 was assessed by 
the degree of displacement in the G-V curve represented by the change in V50 
values from control for each compound examined (Figure 4.13).
The order of activation based on the degree in shift of V50 was:
NS1619 > BKOEtl > BKPr3 I B K P r41 BKVV > BKH1 > BKM el I BKPr2
The benzanilides (30|iM), in non-saturating Ca2+ concentrations and in 
symmetrical K+ produced a range of shifts (10-60mV) of V50from control; that 
for NS1619 was 68mV. BKPr3 showed similar efficacy to BKPr4 but both of 
these compounds were significantly more effective than the structurally related 
BKPr2. However, of all the benzanilide compounds tested under these 
conditions BKOEtl was the most effective and demonstrated a 2-fold greater 
shift in V50 relative to the next most effective benzanilide.
4.4.5 Selective antagonists
To examine whether current increases evoked by BKOEtl were due to the 
activation of BKca channels, experiments in the presence of selective channel 
blockers (IbTX or pax) were performed. Co-application of IbTX (0.1 pM) failed to 
significantly (p>0.05, Student’s paired t-test) block BKOEtl stimulated increases 
in current (V50 control = 100.9±3.5mV; BKOEtl = 34.5±5.6mV; + lbTX= 
43.5±7.4mV) from BKCa oc cells. However, co-incubation with pax (10pM) 
completely abolished all BKCa channel currents (Figure 4.14). Paxilline (10pM) 
also completely abolished the increases in current evoked by each of the other 
benzanilides tested (Data not shown).
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Figure 4.13: Effect of test compounds on V50 values relative to control
The changes in V50 values from control conditions as a consequence of 
compound (30piM) activation of BKca channels. Negative values indicate a shift 
in G-V curve to more hyperpolarising voltages. Data was presented as 
MeansiSEM (n=6-9).
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Voltage (mV) 
(b)
V50 (mV) 100.9±3.5 34.5±5.6 43.5±7.4 n.d
Figure 4.14: The effect of IbTX or pax on blocking BKOEtl mediated 
activation of BKca channels
Whole cell BKCa channel currents were elicited from BKCa a cells by applying 
voltage steps in 10mV increments from -100 to +100mV from a holding potential 
of -100mV. (a) Normalised G-V relationships were determined under control 
conditions ( ) and following the perfusion of BKOEtl (30jiM, ) and then
either co-application of BKOEtl with either IbTX (0.1 jaM, ■ ) or Pax (1 OjaM, ■ ).
(b) The V50 values determined under different incubations as indicated. Data 
presented as means±SEM, (n=3). n.d not-determined.
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4.5 Discussion
A series of novel benzanildies were examined for BKCa channel opener activity 
using whole cell patch clamp electrophysiology.
4.5.1 Benzanilides as BKCaCO’s
All benzanilides evoked significant, paxilline sensitive, increases above control 
in BKCa channel current and increased with further depolarisation. This 
produced leftward shifts in the hyperpolarising direction of the G-V curve 
indicative of BKca channel activation and similar to NS1619 the reference 
BKCaCO tested.
The benzanilides (30pM) were able to shift V50 from control in a range of 10 to 
60mV. This shift was in the range of or greater than those achieved by other 
BKCa channel openers such as tamoxifen -3 0  mV (Dick et al 2001), pimaric acid 
-21 mV shift (Imaizumi et al 2002), naringenin ~20mV shift (Saponara et al 2006) 
and KB130015 shift of ~40mV (Gessner et al 2007). Furthermore, a series of 
novel openers based on derivatives of hexa-hydro-dibenzazepinones have 
displayed shifts of between 5 and 25mV in V50 values (Tashmina et al 2006).
NS1619 produced a 68mV shift in V50 from control, similar to that observed 
previously (-70m V) in bovine myocytes (Olesen et al 1994b) and for hSIo 
channels (~42mV) expressed in HEK293 cells (Gessner et al 2007). However, 
the benzanilide series of compounds were not as potent as DHS-1 which still 
remains one of the most potent BKca channel opener with a -120m V  shift 
(Giangiacomo et al 1998), although this was examined in isolated bovine aortic 
smooth muscle cells which express the BKCa channel pi-subunit. Therefore, the 
benzanildies demonstrate effectiveness in a similar range to those observed for 
a diverse range of synthetic compounds.
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4.5.2 Activation and deactivation properties
Benzanilide compounds did not effect the time for BKca channels to reach peak 
current, conversely, NS1619 increased the time to reach peak current.
The benzanilides did not affect the deactivation time of the channel determined 
from instantaneous tail current following an inactivating pulse (at -100mV). From 
analysis of tail current traces it can be observed that for NS1619 there is an 
expansion of width of the tail current. However, this difference is not observed 
with benzanilides.
This is an interesting finding as a number of other BKca channel openers have 
shown to increase the deactivation time constant. For example 
mallotoxin/rottlerin (0.5jiM) increased the deactivation time constant to ~2.0ms 
from a control value of ~0.5ms (in 0.02pM Ca2+) determined by applying a 
-80mV inactivating pulse following either a +50mV or +200mV activating voltage 
pulse from whole cell instantaneous tail currents recorded in HEK293 cells 
expressing mSlo (Zakharov et al 2005).
In addition, NS1608 in has been shown to increase deactivation time from ~2ms 
under control conditions (0.5pM Ca2+) to ~5.0ms (5.0pM) as determined from 
instantaneous tail currents generated from a -100mV inactivating pulse 
(Strobaek et al 1996). In addition, KB130015 (IOOjliM) has shown to increase 
deactivation time constant from ~0.5ms to 1.5ms in HEK293 cells expressing 
hSIo in response to a -150mV deactivating potential (Gessner et al 2007).
From analysis of current-traces it can be determined that benzanildies did not 
significantly increase the maximal level of instantaneous current relative to 
control suggesting that the compounds had no affect on conductance or the 
number of channels that were open and that no more channels could be 
opened.
Therefore, benzanilides did not effect the activation time or deactivation 
consequently further electrophysiological investigation would be of interest to 
further elucidate the BKCaCO properties of benzanilides.
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4.5.3 Com parison of order of effectiveness of benzanilides  
obta ined in whole cell vs Rb+ efflux
The following rank order of potency was determined for the compounds and 
NS1619 from the degree of shift in V50 from control:
NS1619 > BKOEtl > BKPr3 I B K P r41 BKVV > BKH1 > BKMel I BKPr2
That determined by Rb+ efflux screening was (EC40%):
NS1619 I BKOEtl / BKPr3 I BKPr4 / BKVV > BKH1 I BKMel I BKPr2
A good agreement was observed between the order of potency determined for 
benzanilides in BKCa a-cells using EC4o% values obtained from Rb+ efflux 
studies and that based on the V50 values determined using whole cell 
electrophysiology. Compounds BKH1, BKMel and BKPr2 with both methods 
were the least potent compounds. However, electrophysiology seemed to be 
able to discriminate between compounds with higher potency with more 
resolving power than in Rb+ efflux.
Comparing the rank order of benzanilide activation of BKCa channels based on 
calculated V5o and EC40% for the two methods tested may not be reliable; this is 
because EC40% represents potency calculated by testing a range of 
concentrations where as V50 represents the effect on voltage at a single 
concentration of compound tested. However, there is good agreement between 
the two methods.
Discrepancies between potency profiles based on calculated values of IC50 or 
EC50 from electrophysiology and those determined from Rb+ efflux studies (both 
non-radioactive and radioactive efflux) have been previously reported (Tang et 
al 2001; Wang et al 2003; Rezazadeh et al 2004). For example, Tang et al 
(2001) have shown that in the assessment of hERG channel blockers a 5-20 
fold higher potency was observed with Rb+ efflux than when measured with 
electrophysiology, although a similar rank order in potency was achieved. This
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was further supported by the work of Rezazadeh et al (2004) who observed 
similar discrepancies in potency values for a series of hERG channel blockers 
and that the non-radioactive Rb+ efflux assay was less able to discriminate 
between compounds with highest potency as well as electrophysiology, 
although a similar rank order of agreement was determined.
Furthermore, Scott et al (2003) demonstrated a similar rank order in potency 
between electrophysiology and Rb+ efflux for inhibitors of Kv7.2 (KCNQ2) 
channels but differences in potency values. In addition, Wang et al (2003) 
showed that EC5o values determined by Rb+ efflux and electrophysiology for 
KCNQ/M channels showed positive correlation; although potency values were , 
approx 2-10 times higher in Rb+ efflux than in electrophysiology.
In an attempt to understand why these differences occur Rezazadeh et al (2004) 
examined the potency of hERG channel blockers determined in patch clamp 
using either Rb+ or K+ as the conducting ion. The substitution of K+ for Rb+ 
resulted in a ~10-fold reduction in blocker potency. They hypothesise that this 
discrepancy could be either due to Rb+ conduction through the pore occurring 
via a different mechanism to that of K+ and this interferes with the site of blocker 
binding or that conditioning of the drug binding site by Rb+ could occur; but the 
potential mechanisms of this are not fully understood (Rezazadeh et al 2004).
Whether this explanation can be applied to compounds that act as K+ channel 
openers has not been addressed. BKca channel openers discovered to date 
have not shown to affect conduction of K+ through the channel pore. K+ channel 
blockers main mechanism of action is to occlude ion passage through the 
channel pore, therefore whether BKCaCO’s could themselves affect Rb+ 
conduction through the pore via competition between the two remains unknown 
and therefore probably can not account for discrepancies in rank order of 
effectiveness of BKCaCO.
Another difference between the two assays that may contribute to potency 
differences is that in electrophysiology the voltage across the membrane can be 
controlled and that in Rb+ efflux the membrane potential across the cell is 
dependent upon the K+ ion concentration and basal activity of the cell
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(contribution of other background channels). Therefore, discrepancies observed 
may be due to incomplete control of the membrane voltage in the Rb+ efflux 
assay.
Potency differences observed could be due to the difference in conducting ion, 
sensitivity of the Rb+ efflux assay itself or via incomplete control of membrane 
potential. Further examination would be required to elucidate these differences, 
maybe through determining the resting membrane potential of the cell or by 
assessing the effect of BKcaCO's in the presence of different depolarising 
strength (20-50mM K+) KCI buffers. Further the effect of benzanilides on BKca 
channel activity as measured using whole cell electrophysiology could be 
assessed again but by substitution of K+ conducting ion for Rb+ and comparing 
the rank order of efficacy achieved with the two conducting ions.
4.5.4 Determ ination of /k currents in BKCa a  cells
In BKCa a  cells, currents elicited under control conditions were completely 
blocked by application of TEA to the external side of the channel therefore the 
current evoked is mediated through K+ channels. Application of IbTX failed to 
completely block all /K channel current at concentrations 10-50 times greater 
(0.1-0.5pM) than the reported IC50 of 1-1 OnM (Galvez et al 1990; Kaczorowski 
et al 1996; Gutman et al 2003) from BKCa a  cells. However, when the K+ 
concentration on the outside of the cell was reduced (5.4mM) IbTX blocked 
BKCa channel currents more effectively. However, complete block was not 
achieved at concentrations several times greater than the reported IC5o for IbTX. 
The effects of IbTX were reversible following extensive washout. A potential 
explanation for this discrepancy can be sought from the initial work by 
Giangiacomo et al (1992) and Candia et al (1992) on the mechanism of IbTX 
action.
IbTX blocks BKCa channels in a reversible bimolecular reaction and can only 
block from the external side of the channel through its association with the 
external mouth of BKCa channels. Channel block is characterised, at the single 
channel level, by long lived non-conducting states separating bursts of activity. 
From analysis of the kinetics of IbTX block it has been observed that the 
positively charged IbTX molecule associates with negatively charged residues
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of the mouth of the channel and that this electrostatic attraction increases the 
apparent toxin concentration near the channel pore. Furthermore, changes in 
external K+ ion concentration from 12.5 to 31 OmM resulted in a greater than 10- 
fold reduction in the association constant of IbTX. The increase in K+ ion 
concentration affected local charges on the external pore of the channel that 
consequently affects the binding of an IbTX molecule (Giangiacomo et al 1992; 
Candia et al 1992). Therefore, the decreased potency could be due to 
application of IbTX in a high extracellular K+ solution and therefore the 
increased potency observed in asymmetrical (low external K+) could be due to 
lowering of extracellular potassium concentration.
Nevertheless, in asymmetrical K+ even a high concentration of IbTX (0.5pM) 
was unable to fully block BKca channel activated currents; this could indicate 
that BKCa channel is not the sole channel conducting Ik currents from these cells. 
This is important as mRNA and protein has been detected in native HEK293 
cells for a number of other potassium channels such as members of the Kv 
channel family (Kv1.1-1.6, 3.1, 3.3, 3.5 and 4.1) and SK channels (Thomas and 
Smart 2005). Furthermore, unknown background potassium and chloride ionic 
currents have been detected in wild type HEK293 cells (Zhu et al 1998).
The IC50 for IbTX has generally been calculated from experiments on primary 
isolated cells from tissue that have a lower BKca channel expression, in that the 
cloned cell, lines used here BKca channel expression is regulated by a strong 
promoter producing constitutive expression. Consequently the concentration of 
IbTX used could have not have been enough to physically block all the 
channels activated under control conditions and following addition of 
benzanilides. However, this depends upon the stoichometry of IbTX binding to 
the channel and the total number of channels in the cell that need to be 
activated to evoke a full response.
To address whether the inability of IbTX to block BKca channels was due to its 
physiochemical properties or that under control conditions other K+ channels 
were being activated pax was used. Pax inhibited k currents in a concentration 
dependent manner with complete block of /k current at 10pM and prevented 
BKOEtl from activating the channel.
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4.5.5 BKOEtl as a BKCa channel opener
From the series of benzanilides examined BKOEtl was identified as the most 
potent BKCa channel opener. To determine that the effects of BKOEtl were 
specific to BKca channels the effect of the blockers IbTX and pax were studied. 
Co-application of IbTX failed to antagonise BKOEtl mediated increases in BKca 
current where as co-application of pax abolished BKCa channel activation. A 
previous study has shown that supramaximal concentrations of IbTX have not 
been able to completely antagonise the response of NS1619, phloretin and 
niflumic acid on BKca channels expressed in Oocytes (Gribkoff et al 1996). This 
observation is in line with the inability of IbTX to block control BKca channel 
currents from BKCa a cells. Pax was able to prevent BKca channel activation at 
10pM, this compares with previous observations in that where IbTX has failed to 
block NS1619 responses in cloned cell lines pax was more successful (Gribkoff 
et al 1996). Gribkoff et al (1996) suggested that pax should be the preferred 
blocker of choice for complete BKca channel antagonism (Gribkoff et al 1996).
4.6 Conclusions
All compounds tested activated BKca channels in BKca a cells producing 
different levels of channel activation. All benzanilides tested did not affect the 
kinetics of activation or deactivation. Furthermore, the whole cell activating 
profile of benzanilides showed good agreement with that obtained using the Rb+ 
efflux assay. Identification of the mechanism of action of these compounds as 
BKCa channel opener may lead to clues into the structure activity relationship 
between the benzanilide series structure and there differential activating profiles. 
Using both the electrophysiology and Rb+ efflux techniques BKOEtl was 
identified as a novel and potent BKca channel opener.
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Chapter 5
Characterisation of BKOEtl 
as a novel BKca channel 
opener
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5.1 Introduction
The most effective novel benzanilide identified as a BKca channel opener using 
Rb+ efflux assay and whole cell electrophysiological screen was BKOEtl.
Further characterisation of the BKCaCO properties of BKOEtl were performed 
using whole cell and single channel electrophysiological recording. In particular 
potency, open pore probability and effects on single channel conductance were 
determined. Furthermore, the Ca2+ dependence of activation and the effect of 
BKOEtl on intracellular Ca2+ was assessed with the latter determined using a 
Fura-2/AM fluorescent intracellular calcium assay.
The non-radioactive Rb+ efflux assay was used to examine the Rb+ efflux 
activation profile of BKOEtl in rat bladder myocytes and then to examine 
whether the Rb+ efflux observed was specific to BKCa channels by determining 
the ability of BKOEtl to activate Rb+ efflux in the presence of different K+ 
channel blockers
The properties of BKOEtl were compared to other known BKca channel 
openers. Analysis of this compound could offer new information about the 
action of this series of benzanilides on activating BKCa channels. Further this 
would contribute novel electrophysiological data pertaining to compounds based 
on the generalised pharmacophore pattern proposed for BKcaCO’s.
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5.2 Chapter Aims
Characterise the BKca channel opener properties of BKOEtl by:
•  Further characterising the whole cell activating properties of BKOEtl in 
BKCa a cells.
•  Examine the effect of BKOEtl on single channel electrophysiological 
properties of BKCa channels.
•  Assess the calcium dependence of activation and the effect of BKOEtl 
on intracellular Ca2+
•  Investigate the effect of BKOEtl on Rb+ efflux from K+ channels in rat 
bladder myocytes.
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5.3 Methods
5.3.1 Materials  
Cell culture and isolation
Sigma Aldrich, Gillingham, U.K: Collangenase, pluronic acid, probencid 
protease type XXIV, trypan blue and trypsin inhibitor
Invitrogen (GIBCO), Paisley, U.K: Penicillin G, Streptomyocin
Fisher Scientific UK, Loughborough, U.K: Nunc LabTek 8-well chamber slides
Ion channel modulators and pharmacological agents
Sigma Aldrich, Gillingham, U.K: Apamin, Fura-2AM 
Axxora Ltd, Nottingham, U.K: Margatoxin (marg)
Tocris Biosciences, Bristol, U.K: Forskolin, TRAM-34, ryanodine
Immunocytochemistry reagents
Sigma Aldrich, Gillingham, U.K: Mouse anti-smooth muscle a-actin mAb, 
bovine serum albumin (BSA)
Invitrogen (Molecular Probes), Paisley, U.K: Alexa Fluor 568 anti-mouse IgG 
and Alexa Fluor 568 donkey anti-mouse IgG
Santa Cruz, California, USA: Goat anti-vimentin C-20 polyclonal antibody and 
Mouse anti-cytokeratin 18 monoclonal antibody
Vecta laboratories, Peterborough, U.K: 4 ’-6-Diamidino-2-phenyiindole (DAPI)
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5.3.2 HEK293 cells
A different recombinant clone of BKca a  cells was used to that in chapter 2  and 
3. This had the human BKca channel a-subunit but with an additional 132bp 
segment between the S0 and Si intracellular loop. This splice variant behaves 
biophysically as the zero variant and the rest of the channel has the same 
sequence and major structural features of the zero variant (Korovkina et al 
2001). The variant was used because it displayed less BKca channel current 
density in patches and thus enabled more reliable recordings of single channel 
BKCa currents. Some studies have reported that BKca channels containing the 
132bp region can lead to a decrease in cell surface expression of the channel 
(Korovkina et al 2006). These cells termed BKca 01+132 cells were continuously 
cultured and plated as described previously for electrophysiology (Chapter 3, 
section 3.2).
5.3.3 Bladder myocytes
5.3.3.1 Myocyte dissociation
Myocytes were dissociated from whole rat bladders using partial enzymatic 
digestion followed by mechanical dissociation. Male Wistar rats (200-300g) 
were killed by cervical dislocation following stunning. The abdominal cavity was 
opened by a midline incision exposing the internal organs, the entire bladder 
was removed and transferred to a dissecting dish containing ice cold calcium 
free Hanks buffered saline (HBSS) (mM: KCI 5.3, KH2 P 0 4 0.44, N aH C 0 3 4.17, 
NaCI 137.9, Na2 H P 0 4 0.338, Glucose 5.56). The prostate and serosal 
connective tissue was removed and a longitudinal incision from the bladder 
dome to the base was made, the bladder was unfolded and the urothelium layer 
removed by scraping with a scalpel. The tissue was cut into approx 5mm2 
pieces and transferred to a Petri dish containing HBSS (10mls) and placed in a 
at4°C , for 20-30mins.
Tissue was transferred to a Nunc dish containing digestion cocktail mix. This 
was made by diluting a pre-prepared frozen stock in Ca2+ free HBSS (1ml) to 
yield a solution containing a final concentration of (mg ml'1) collagenase type IA
3.0, protease type XXIV 0.2, bovine serum albumin (BSA) 2.0, trypsin inhibitor
2.0, the solution was sterilised using an acrodisc (0.2pM) filter. Tissue was
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incubated with the digestion cocktail mix for 15 min at 37°C in a tissue culture 
incubator, then the tissue pieces were transferred to a Nunc dish containing 1ml 
of filtered Ca2+ free HBSS and a sterilised magnetic flea (10mm), cells were 
gently agitated for 10 min using a magnetic plate stirrer. Following this 
dissociated cells were collected and transferred to a sterile eppendorf tube in 
preparation for cell culture and HBSS (1ml) was added to the remaining cells 
and collected following agitation for another 10-minutes.
5.3.3.2 Myocyte cell culture
The cell culture technique and equipment used is that as described in chapter 2, 
section 3.3. Dissociated cell suspensions of myocytes were transferred to a T75 
cell culture flask containing DMEM (20mls) supplemented with FCS (10%), 
penicillin (100 U ml'1) and streptomycin (100 pg ml'1). Cells were grown and 
passaged for two generations (P2), (~2 weeks growth in total); cells were 
passaged as before, however, the trypsinisation was modified compared to that 
described for HEK293 cells to include a longer incubation (5-min) and in a 
greater volume of Trypsin-EDTA (5mls) due to the adherent strength of 
myocytes compared to HEK293 cells.
5.3.3.3 Cell preparation for Rb+ efflux assay
Cells were prepared as before (Chapter 2, section 3.3) but seeded at an 
approximate density of 5000 cells/well (200pl of media) of a 96-well plate from 
which two plates were prepared from one confluent flask of bladder myocytes.
5.3.4 Im m unocytochem istry
Immunocytochemistry (ICC) was used to characterise the cell types that were 
cultured following dissociation from the bladder, antibody (Ab) for markers used 
include smooth muscle a-actin (for myocytes), vimentin (mesenchymal cells 
such as fibroblasts and connective tissue) and cytokeratin (epithelial cell 
marker).
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Smooth muscle a-actin Mouse anti-smooth muscle a-actin mAb (Sigma- 
Aldrich, Cat No A5228)
Alexa Fluor 568 anti-mouse 
IgG (H + L, 2mg ml'1)
( Molecular Probes, 
Invitrogen Cat No A11061)
Vimentin (C-20)
Goat anti-Vimentin C-20 
polyclonal Ab, (Santa Cruz 
Biotechnology Cat No sc- 
7557)
Alexa Fluor 488 donkey 
anti-goat IgG (H + L, 2mg 
ml'1) (Molecular Probes, 
Invitrogen Cat No A11055)
Cytokeratin (C-18)
Mouse anti-cytokeratin 18 !
mAb (Santa Cruz 
Biotechnology Cat No sc- 
32329)
Alexa Fluor 568 donkey 
anti-mouse IgG (H + L, 2mg 
ml'1) (Molecular Probes, 
Invitrogen Cat No A11055)
1_______________________________________________________________________1
Table 5.1: Primary and secondary antibodies used in ICC
For ICC myocytes were seeded into 8 well chamber slides at a density of 5000 
cells/well in DMEM (200pl) and grown for 48-hours. Following this media was 
discarded and the cells washed once with ice cold PBS (200(il). Cells were fixed 
in ice cold methanol (100%, 400pl) that was added to each chamber and the 
slides were transferred to -20°C for 15 mins, the methanol was then decanted 
and cells washed once with PBS and cells left to air dry at room temperature. 
Cells were then blocked (0.1% BSA in PBS) for 30 min cells prior to incubation 
with 1° Ab (1:50 and 1:200 dilution) for 18 hours at4°C in a humidified chamber. 
Cells were then washed (3 times for 5 min in PBS) prior to incubation with 2° Ab; 
this was prepared by dilution (1:200) in a solution of 1% BSA in PBS of which 
200pil was added to each well. This was left to incubate at 37°C for 1 hour in the 
dark followed by washes (3 times, 5 mins) with PBS. Incubation with equal 
volume of PBS in place of 1° Ab was used as negative controls.
Cover slips were mounted with Vecta-shield mounting media containing 4 ’-6- 
diamidino-2-phenylindole (DAPI) that forms fluorescent complexes with dsDNA 
enabling visualisation of the cell nucleus. Images were obtained using an 
Olympus BX60 fluorescent microscope using a Cool Snap Pro colour digital 
camera (Media Cybernetics, Silver Spring, USA) with LabWorks image 
acquisition and analysis software.
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5.3.5 Rb+ efflux assay
Rat bladder myocytes grown to confluence in 96-well plates were prepared for 
Rb+ efflux experiments as described previously. The methodology was used as 
that described in Chapter 2, section 3.4.
5.3.6 W hole cell electrophysiology
The whole cell configuration and experimental protocol used was as described 
in Chapter 4, section 3.3.
5.3.7 Single channel recording
Single channel currents were recorded from excised inside-out patches of BKca 
a +132 cells using standard patch-clamp recording procedures (Hamill et al 1981). 
Pipettes were fabricated (Chapter 4, section 3.3.1) for inside-out excised 
patches pipettes and were fire polished to a final resistance of 8-12MQ. Pipette 
and extracellular solutions were prepared as previously (Chapter 4, section 
3.3.2) described (symmetrical 140mM potassium) with the pipette solution 
containing 0.3|aM Ca2+ and bath solutions containing a range of Ca2+ (0.1- 
10pM). Excised patches with seals within a range of 2-60GQ were used, not all 
patches obtained demonstrated channel opening and current activity. In these 
instances rapidly cycling the membrane voltage between positive and negative 
potentials on occasion stimulated channel opening. However, air exposure of 
the pipette was required in those instances when cycling between membrane 
potentials failed to stimulate activity.
5.3.7.1 Data recording and acquisition
Currents were recorded in voltage clamp mode using an EPC-10 patch-clamp 
amplifier via an IPTC16 digital interface (HEKA, Lambrecht, Germany). Current 
signals, after compensation for capacitance, series resistance and liquid 
junction potential, were low-pass filtered at 2.9 KHz using a 4-pole Bessel filter 
and sampled at 10 KHz and 1 KHz before being stored on the hard disk drive of 
the computer. Single channel data was acquired from patches with < 8  channels 
by measuring the current response during continuous recordings (for at least 60 
seconds) to varying membrane potentials (-30 to + 100mV) as specified in the 
figure legends before and after the application of differing drug treatments.
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5.3.7.2 Electrophysiology data analysis 
Open pore probability
Data was analysed offline using TACFit software (Bruxton, Seattle, USA). 
Current threshold for event detection was set to 0.5 times the amplitude. From 
which all-points current amplitude histograms were compiled. Current levels 
were identified by peaks in the histograms to which Normal (Gaussian) 
distribution curves were fitted. Open pore probability (P0) is determined as the 
area under the amplitude histogram for peaks representing ‘open’ channels 
divided by the total area. The relationship between membrane potential and P0 
was fitted using the Boltzmann equation (Lee et al 1995a):
NP0 = /> max/( 1 + exp[(V 50 -  V m )/S])
Where NP0) V50, Vm and S represent normalised open pore probability, voltage 
required for half maximal activation, membrane potential and slope factor 
respectively. Pmax is the maximum P0 determined for a particular concentration 
(Ca2+ or BKOEtl) tested across all voltages tested.
Voltage sensitivity
The effect of BKOEtl on voltage sensitivity of the channel was assessed by 
determining the slope of In [P0/1 -Po] vs membrane voltage. From which the e- 
fold shift in P0 per mV change in voltage was determined (Lee et al 1995a; 
Dichiara and Reinhart 1995; Khan et al 1998) in the absence (control; 0.3pM 
Ca2+) and presence of BKOEtl (3-100|aM).
The effect of BKOEtl on V 50 was assessed by determining the slope of V 50 vs In 
[BKOEtl pM]. The change in V 50 per e-fold increase in concentration was 
determined (Lee et al 1995a) for BKOEtl when applied to either the 
extracellular aspect of the channel in whole cell recording or to the intracellular 
aspect of excised inside-out patches.
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Single channel conductance
Single channel conductance was calculated from the slope of the function G = 
IA/m. where G is conductance, Vm is membrane potential and I is the current 
elicited from the opening of single ion channel at that particular membrane 
potential.
Potency and co-operativity
The EC50 (concentration equal to half maximal effect) was determined using the 
following modified Hill function (Gribkoff et al 1996; Gessner et al 2007):
AV50 = Bottom + (Top - Bottom)/1 + 1 0[(IO9EC5^ X)*Hi"slope)l 
Where X is the concentration of BKOEtl and AV50 is the shift in V 50 from control.
5.3.8 Intracellular Fura-2 calcium assay
Fura-2, based on the chemistry of the Ca2+ chelator EGTA, has been used in 
numerous applications as a fluorescent indicator of Ca2+ (Malgaroli et al 1987). 
The acetoxymethyl ester of Fura-2 (Fura-2/AM) is a cell permeable molecule 
that once cleaved by intracellular esterases will fluoresce following excitation, 
when chelated with free intracellular Ca2+ (Malgaroli et al 1987). Briefly BKca 
a +132 cells were loaded with Fura-2/AM in the presence of pluoronic acid to help 
disperse and solubilise the dye; cells are washed and left for a period of time to 
allow esterase cleavage of the dye. Probencid is included in the buffers to 
block dye leakage out of the cell through non-specific anion pumps. Cells were 
then exposed to drug treatment and subsequent fluorescence is measured over 
time.
Cell culture media was removed from wells and cells were then washed (1 x 
PBS, 200pl) before being loaded (200pl/well) with Fura2/AM (3pM) prepared in 
Krebs buffer (mM: NaCI 118.4, KCI 4.7, N aH C 0 3 24.9, D-Glucose 11.7, MgS0 4  
1.15, KH2 PO4 1.15, CaCl2 1.9, pH 7.2) containing pluoronic acid (0.01%) in a 
37°C incubator in the dark for 40 minutes. For depolarisation conditions a high
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K+ Krebs buffer was prepared containing 50mM KCI isosmotically adjusted by 
decreasing the NaCI concentration (68.4mM). Cells were then washed twice 
with Krebs buffer (200pl) containing probencid (2.5mM) and a 150pil volume of 
Krebs containing probencid was added to the wells. Fluorescence readings for 
each well were then recorded using a Wallac Victor2 1420 multi-label counter 
(PerkinElmer Ltd, Turku, Finland) fitted with the appropriate filters. Following 
addition of 150pl of Krebs buffer to each well the fluorescence was measured 
and the plate was placed in a 37°C incubator in the dark for 30 min to allow 
cleavage of the ester. Treatments were prepared during this time at a 
concentration 4x greater than the final concentration required in 50pil aliquots. 
These were added (using a multi-channel pipette) to the wells (final volume 
200pl) of the micro-titre plate to yield the correct concentration. A fluorescence 
reading was taken prior and at subsequent times (1, 5 ,1 0  and 20 min) after the 
addition of the drug treatments.
5.3.9 Data analys is
All data was fitted using GraphPad Prism 4 software and are presented as 
mean (±SEM) for n determinations. Current traces were exported from HEKA 
PulseFit or TacFit to use as visual representations of the data.
Data was analysed using either Student’s un-paired or paired t-test or for 
multiple comparisons one-way ANOVA followed by Dunnett’s post test analysis 
or Bonferroni’s multiple comparison test (Wallenstein et al 1980). The accepted 
level of significance was p<0.05.
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5.4 Results
5.4.1 Effect of BKOEtl on whole cell BKCa channel currents
The effect of BKOEtl on whole cell BKca channel currents tested over an 
extended concentration range was examined. Patches were obtained in 
symmetrical (140mM) K+ with 0.3pM Ca2+ in the pipette and bath solutions. Cell 
exposure to BKOEtl (3-100pM) led to increases in BKca channel current within 
1-minute of application (Figure 5.1b). BKca channel activation was assessed by 
comparing the voltage required to produce 50% activation (V50) as determined 
from normalised averaged conductance-voltage curves generated for each 
concentration that was tested (Figure 5.1a). Increasing concentrations of 
extracellular BKOEtl shifted V50 from a control value of 90.1±1.0mV to 
77.5±0.7mV, 43.9+6.3 mV, 27.7±1.4 mV and 6.8±3.7 mV for 3, 10, 30 and 
100pM respectively to more hyperpolarised potentials (Figure 5.1c). This 
resulted in a 16.99±4.50mV change in V50 per e-fold increase in extracellular 
BKOEtl concentration (Figure 5.5). From the degree of shift in V50 from control 
an EC5o of 9.79±0.78pM and a Hill slope of 1.26±0.38pM was determined 
(Figure 5.3). The effect of BKOEtl (30pM) was sensitive to block upon co­
application with paxilline (10jiM) which blocked all BKCa channel currents 
(Figure 5.1c).
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5.4.2 Effect of BKOEtl on single BKCa channel currents
The effect of BKOEtl on single BKca channel currents was examined in inside- 
out patch configuration. Patches were obtained with pipette and bath solutions 
containing low Ca2+ (0.3pM) and symmetrical (140mM) K+. The effect of voltage 
(-30 to +80mV for at least 60s for each voltage) on BKca channel currents under 
control bath conditions and following the perfusion of increasing concentrations 
of BKOEtl (3, 10, 30 and 10OpiM) was determined from which P0 was measured 
(Figure 5.2a). Cumulative application of BKOEtl increased BKCa channel 
opening in a concentration dependent manner with an increase in P0 from 
control (0.058±0.02) to 0.469±0.17, 0.836±0.09, 1.00±0.09 for 10, 30 and 
1 OOjliM  at +40mV holding potential (Figure 5.2c) the effect was reversible upon 
washout (Data not shown).
The relationship between P0 and voltage was fitted with Boltzmann relationship 
from which V50 values were determined (Figure 5.2b). BKOEtl increased P0 at 
the potentials examined relative to control. This produced shifts in V5o to more 
negative potentials (Figure 5.2b). This resulted in a 16.1±2.6mV change in V50 
per e-fold increase in intracellular BKOEtl concentration (Figure 5.4). 
Furthermore, the relationship between shift in V50 (from control) vs log [BKOEtl] 
concentration was fitted by a modified Hill equation from which an EC50 of 
9.14±0.65pM and a Hill slope of 1.05±0.36pM was determined (Figure 5.3). 
Linearisation of open pore probability data showed that the channel underwent 
an e-fold change in P0 per change in membrane potential of 13.48±3.2mV 
under control conditions and 5.46±1.37mV in 10pM, 5.06±1.36mV in 30juM and 
5.8±5.00mVin 100pM BKOEtl respectively (Figure 5.4a,b).
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Figure 5.3: Potency and co-operativity of BKOEtl at activating BKCa 
channels
(a) The effect of BKOEtl (0-100pM) on the shift in V50 from control was 
determined in WCR ( ) and from excised inside-out patch ( ) configuration 
from which the EC50 (half maximal concentration) and Hill slope was calculated
(b). Data presented as means±SEM, (n=4-6). BKOEtl at 1pM represents data 
obtained from 1-2 observations.
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Figure 5.4: The effect of BKOEtl on voltage sensitivity of BKCa channel 
activation
(a) To examine the effect of voltage on P0 under control ( ) and the presence 
of increasing BKOEtl (10 A , 30 • ,  and 100 O) concentrations applied to the 
intracellular aspect of excised inside-out patches (b) Corresponding slope 
values indicating the e-fold increase in P0 per mV change in membrane 
potential. Data presented as means±SEM (n=6 -8 ). Data fitted by linear 
regression analysis. One-way ANOVA with Dunnett’s, *p<0.05, ***p<0.001 
indicate levels of significance in V50 and P0 values relative to control.
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Figure 5.5: The effect of BKOEtl on V50 when applied to the outside or 
inside aspect of the channel
(a) The effect of increasing concentrations of BKOEtl on V50 was determined 
when applied in whole cell configuration to the extracellular aspect of the 
channel (dashed line) and when exposed to the intracellular aspect (solid line) 
of excised inside-out patches. V50 values are those determined previously 
(Figure 5.1c and 5.2c). (b) From the slope of the line V50 vs In [BKOEtl] (pM) 
the change in V50 per e-fold increase in BKOEtl was determined. Data 
presented as meanstSEM (n=6 -8 ). Data fitted by linear regression analysis. 
There was no significant difference (Student’s paired t-test, p>0.05) between 
change in V50 values determined for the effect of BKO Etl.
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5.4.3 Single channel current voltage relationships: determination  
of conductance
The effect of BKOEtl on single channel conductance was determined by 
measuring the current amplitude from a single ion channel at different 
membrane potentials (-30 to +80mV) before and after the application of BKOEtl 
(30pM), from which the slope of the relationship of current vs voltage yielded 
the conductance (Figure 5.6a). The conductance value obtained in the 
presence of BKOEtl (278.9±2.2pS) was not significantly (Student’s paired t-test, 
p>0.05) different to that determined under control conditions (277.1±3.2pS), 
(Figure 5.6b). Therefore, BKOEtl did not alter the single channel conductance 
of BKCa channels.
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Voltage (mV)
(b)
G (pS) 278.9±2.2 1
Figure 5.6: Determining the effect of BKOEtl on BKCa channel 
conductance
(a) Current from a single open channel recorded at different voltages (-3 0  to 
+80mV) before ( ) and after (O) application of BKOEtl to the intracellular 
aspect in excised inside-out patches (30jLtM) form which single channel 
conductance (G) was determined (b) from linear regression analysis of the 
slope of the relationship I vs. V. Data presented as means±SEM, (n=6 ). There 
was no significant difference determined (Student’s paired t-test, p>0.05) 
between conductance values measured before and after application of BKOEtl.
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5.4.4 The effect of Ca2+ on BKOEtl mediated activation of BKCa
channels
To determine whether the effect of BKOEtl was dependent upon the 
concentration of intracellular Ca2+ the open pore probability (at +30mV) was 
measured from excised inside-out patches in the presence of a range of Ca2+ 
concentrations (0.3-1 OpM) and then in the presence of BKOEtl (30pM). In the 
presence of 0.3, 1.0 and 3.0pM Ca2+ the corresponding P0 value increased in a 
concentration dependent manner with the corresponding P0 values determined 
as 0.0±0.0, 0.039+0.029, and 0.321±0.128 (Figure 5.7). Following application of 
BKO Etl, P0 was significantly increased (Student’s paired t-test, p>0.05) above 
that achieved for 0.3, 1.0 and 3.0 pM Ca2+ alone achieving similar P0 levels of 
0.885±0.009, 0.823±0.067, 0.875±0.078 respectively. BKOEtl (0.892±0.09) did 
not significantly (p<0.05, Student’s paired t-test) increase P0 above that 
achieved in the presence of 10pM Ca2+ (0.723±0.120), (Figure 5.7).
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5.4.5 Intracellular Ca2+ Fura-2 assay
Fura-2/AM was used to detect changes of intracellular calcium over time in the 
presence and absence of different treatments. The technique was used to 
elucidate whether BKOEtl affected the level of intracellular Ca2+ to identify 
whether BKOEtl mediated activation of BKca channels was secondary to 
VDCC activation or that it activated BKca channels via secondary cellular 
signalling mechanisms resulting in increases in Ca2+ from intracellular stores 
(Figure 5.8).
Calcium ionophore (10pM) was used as a positive control and resulted in a ~4- 
fold increase in fluorescence that was not significantly modified over time. In 
addition, FCS (10%) stimulated intracellular signalling pathways and peaked at 
5-mins following exposure. Background fluorescence was determined from cells 
that had not been loaded with Fura-2/AM and appropriate ‘negative’ controls 
included the addition of Krebs buffer in the presence of vehicle (DMSO), (Figure 
5.8).
Treatment of cells with depolarising Krebs buffer (high K+, 50mM) resulted in a 
significant (One-way ANOVA with Bonferroni’s, p<0.05) increase in 
fluorescence that peaked at 1 min following application and decreased over 
time, this indicated that the increase in intracellular Ca2+ could be attributed to 
VDCC channel activation and subsequent Ca2+ influx from the outside of the 
cell (extracellular concentration of Ca2+ = 1.9mM). Examination of the effect of 
forskolin (50pM), an activator of adenylate cyclase, leading to the formation of 
cAMP and subsequent increase in Ca2+ through VDCC, did not result in a 
significant increase in fluorescence above background. Ryanodine was used to 
stimulate intracellular Ca2+ release from stores via activating ryanodine 
receptors (RyR) in the endoplasmic reticulum, treatment with 0.1 pM led to a 
significant (One-way ANOVA with Bonferroni’s, p<0.05) increase in 
fluorescence that peaked at 5-mins following application (Figure 5.8). However, 
treatment of cells with BKOEtl (100pM) or NS1619 (100pM) did not elicit any 
significant increase in fluorescence above background (Krebs buffer + vehicle) 
for all time points examined (Figure 5.8).
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Figure 5.8: The effect of BKOEtl on intracellular calcium in HEK293 cells
BKca a+132 cells grown to confluence on 96-well plates were loaded with Fura- 
2/AM and the time dependent effect of differing treatments (in Krebs buffer) on 
increasing intracellular calcium was observed by measuring changes in 
fluorescence excited at 340nm and measured at 510nm. Controls included no 
dye treatment, those exposed to Krebs buffer alone or including vehicle. 
Calcium ionophore A23187 (1 OpiM), Fetal calf serum (FCS, 10%) were used as 
positive controls. The effect of ryanodine (0.1 pM), forskolin (50jiM), high K+ 
Krebs buffer (50mM), NS1619 (100pM) and BKOEtl (100pM) was assessed. 
Results expressed as means±SEM, (n=16-24). One-way ANOVA with 
Bonferroni’s, **p<0.01, ***p<0.001, was used to determine differences in 
fluorescence before and at each time point following the addition of treatments.
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5.4.6 Rat bladder myocytes
5.4.6.1 Myocyte dissociation
One rat bladder (50-60mg) yielded approximately 5000 cells that were greater 
than 90% viable as determined using trypan blue staining. Cells isolated from 
one bladder were cultured and reached confluence within 6 days, cells were 
then seeded into 8-well chamber slides for ICC.
5.4.6.2 Characterising cell types in culture
ICC demonstrated that all dissociated cells in the field of view, compared to 
DAPI staining, were positive for anti-smooth muscle actin indicative of a 
myocyte cell type (Figure 5.9). Furthermore, no staining was observed for 
markers of epithelial cells (cytokeratin) and mesenchyme cell types such as 
fibroblasts and connective tissue cells (vimentin); as expected corresponding 
negative controls displayed no positive staining (Figure 5.9 a-j).
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Figure 5.9: Rat bladder myocyte characterisation
ICC staining of rat bladder myocytes (P2) visualised using fluorescent 
microscopy (x2 0 0 ) for either smooth muscle a-actin (a), vimentin (c), cytokeratin 
(e) and corresponding nuclear staining with DAPI (b, d, f). Images (g) and (i) 
are the respective negative controls for Alexa-Fluor 468 and 568 2° Ab (PBS v/v 
replacing the 1° Ab) and concurrent counter stain with DAPI (h and j).
5.4.7 Rb+ efflux studies
5.4.7.1 Rb+ uptake by rat bladder myocytes
Rat bladder myocytes were exposed to RbCI buffer (0.5-5.0 hours) and 
immediately lysed following removal of extracellular buffer by washing. The Rb+ 
content of the lysate of the myocytes progressively increased with time of 
incubation in Rb+ buffer (Figure 5.10). The Rb+ content appeared to become 
saturated from 3.5 hours incubation and a four hour incubation period was 
sufficient to reach maximal loading (19.4±0.7pM, n=16; Figure 5.10). Four 
washes were sufficient to remove all Rb+ from the extracellular compartment of 
the cells.
Rat bladder myocytes were assessed for their viability after 4 hour exposure to 
RbCI buffer using the trypan blue dye exclusion procedure, from which it was 
calculated that =85% of cells were still viable.
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Figure 5.10: Time course of Rb+ loading in rat bladder myocytes
Cells were incubated with RbCI buffer. At timed intervals up-to 5-hours the 
extracellular buffer was removed and cells were washed 4 times with PBS 
before lysis with Triton-X100. The Rb+ content of lysate (A ) and fourth wash ( v )  
samples. Data expressed as means±SEM, (n=16).
212
5.4.7.2 BKOEtl mediated increases in Rb+ efflux from myocytes
The effect of BKOEtl on stimulating Rb+ efflux (10 min in KCI buffer) from rat
bladder myocytes was assessed. BKOEtl (0-100pM) evoked significant (One­
way ANOVA with Dunnett’s test, p<0.05) concentration-related increases in Rb+ 
efflux above vehicle control (Figure 5.11a). BKOEtl activated Rb+ efflux to a 
maximum (Emax) level of 124±16.35% , with a corresponding potency (EC4o%) of 
0.45±0.20pM and a Hill slope of 1.12±0.64 (Figure 5.11b).
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Figure 5.11: The concentration response effect of BKOEtl on stimulating
Rb+ efflux from rat bladder myocytes
Rat bladder myocytes were exposed to BKOEtl (0.1-100pM) for 10-minutes. 
The data was normalised as the percentage increase in Rb+ efflux above 
control achieved at each concentration tested (a). From which potency (EC4o%; 
defined as the concentration required to increase Rb+ efflux by 40%), efficacy 
(Emax; defined as the maximum increase in Rb+ efflux) and Hill slope was 
determined <b). Data presented as means±SEM (n=16-24). One-way ANOVA 
with Dunnett's test, *p<0.05, **p<0.01, indicate differences in Rb+ efflux at each 
concentration tested relative to control (OpM BKOEtl, KOI buffer + vehicle).
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5.4.7.3 Specificity of BKO Etl: Effect of K+ channel blockers
The specificity of BKOEtl to BKca channels was tested in myocytes by
examining its Rb+ efflux activation effects in the presence of different K+ channel 
blockers (Figure 5.12). All K+ channel blockers tested (in the absence of 
BKOEtl) did not lower Rb+ efflux below that achieved in the presence of KCI 
buffer alone. Addition of BKOEtl (100pM) alone to KCI buffer activated Rb+ 
efflux significantly (One-way ANOVA with Bonferroni’s, p<0.05) above that 
observed in the presence of vehicle alone (KCI buffer + DMSO 0.3%) reaching 
a level (102.2±12.4%) that had been demonstrated previously (Figure 5.11b).
The BKCa channel blocker pax (10pM) was able to significantly block BKOEtl 
mediated increases in Rb+ efflux (21.3±11.9%), however complete block to 
control levels was not achieved.
However, BKOEtl (100pM) mediated increases in Rb+ efflux were significantly 
blocked when co-applied with the non-specific channel blockers 4-AP (1mM) 
and TEA (10mM) to a level (5.2±9.7%) that was not significantly different from 
background (KCI + vehicle; 3.5±5.7%), (Figure 5.12).
In the presence of BKOEtl the SK channel blocker apamin (0.1 pM) significantly 
lowered (47.4±14.5%) efflux compared to when BKOEtl was tested alone; 
however it did not completely block Rb+ efflux to control levels. A lowered 
(64.8±15.9%) but not significantly different response to BKOEtl was observed 
in the presence of the IK blocker TRAM-34 (0.1 pM), (Figure 5.12).
In the presence of the Kv channel blocker marg (0.1 pM); the effect of BKOEtl 
was significantly lowered (53.1±21.6%), although marg did not completely block 
BKOEtl effects to control levels. In contrast, the K a t p  (10pM) channel blocker 
glib failed to modify (93.9±22.9%) the effect of BKOEtl on increasing Rb+ efflux 
(Figure 5.12).
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5.5 Discussion
5.5.1 Pharmacological properties of BKOEtl
BKca channel openers can be grouped into those with high or low affinity, high 
affinity compounds activate the channel with an EC50 within the sub-pM to nM 
range such as with DHS-1 (McManus et al 1993; Giangiacomo et al 1998) and 
di-CI-DHAA (Sakamoto et al 2006). BKOEtl can be regarded as a low-affinity 
BKCa channel opener with an EC50 (~1 0 pM) within the micro-molar range. This 
can be classed like other lower affinity BKCa channel openers including NS1619 
(10-30pM), (Olesen et al 1994b; Lee et al 1995b), KB130015 (20pM), (Gessner 
et al 2007), zonisamide (34pM) (Huang et al 2007), TBIC (8.9pM) (Ha et al
2006) and pimaric acid (1-1 OpM) (Imaizumi et al 2002).
The EC50 for BKca channel activation by BKOEtl was nearly identical when 
applied to either side of the channel. This property is similar to that 
demonstrated by NS1619, NS004 (McKay et al 1994; Hu et al 1996), BMS- 
204352/MaxiPost (Gribkoff et al 2001b) and pimaric acid (Imaizumi et al 2002). 
Other BKcaCO’s activate the channels at a site(s) located on the intracellular 
side of the channel such as with DHS-I (McManus et al 1993; Giangiacomo e ta l 
1998), maxiKdiol (Singh efa /1994 ) and L-735,334 (Lee et al 1995c). In addition, 
tamoxifen (Dick e ta l 2002), mallotoxin (Zakharov et al 2005; Wu e ta l 2007) and 
diosgenin (Wang et al 2006) are thought to activate BKca channels from a site(s) 
located on the extracellular side of the channel.
A Hill coefficient of around unity was determined for BKOEtl when applied to 
either the extracellular or intracellular aspect of the channel. This indicated 
binding of one BKOEtl compound molecule per channel (per tetrameric 
channel composition) was required for activation. A similar Hill co-efficient of 
around unity has been reported for EET, an endothelium derived factor that has 
shown to activate BKCa channels (Zhang et al 2001). In addition, LY-171,883, a 
leukotriene D4 antagonist that has been shown BKcaCO properties in GH3 cells 
(Li et al 2002) and certain benzofuroindole derivatives (Gormemis et al 2005) 
including TBIC (Ha e t a l2006) have revealed Hill co-efficient around unity.
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In contrast, compounds such as NS1619 (Lee et al 1995b; Khan et al 1998), 
KB130015 (Gessner e t a l2007), magnolol (Wu e t a l2002), cilostrazol (Wu e ta l 
2004) and DHS-1 (Giangiacomo et al 1998) have displayed Hill co-efficients 
greater than unity (2-3) suggesting that BKca channels contain more than one- 
binding site or potentially one binding site per a-subunit.
A number of explanations could be sought to determine potential sites of 
interaction. For example, BKOEtl could activate BKca channels at one site on 
the channel that is equally accessible to drug molecules from either side of the 
channel with equi-effectiveness. Alternatively there could be two sites on the 
channel one located extracellular and another intracellular with each site 
demonstrating similar Hill slope and potency values for BKOEtl. Further, the 
BKOEtl binding site could be formed by more than one subunit. A similar shift 
in V50 per e-fold change in concentration of BKOEtl was determined in both 
electrophysiology configurations, supporting one binding site that has a similar 
apparent equal affinity for BKOEtl when applied to the extracellular and 
intracellular aspect.
In both electrophysiology configurations BKOEtl activated BKca channels in a 
relatively rapid time (within 1 min of application). However, the time taken to 
‘wash off’ the effect of BKOEtl was much greater in whole-cell than in excised 
inside-out patches. This coupled to the relatively quick wash-off when BKOEtl 
was applied to the intracellular aspect would indicate either a transmembrane or 
an intracellular site of action (Data not shown). Another explanation could be 
the presence of a transmembrane binding site that would be equally accessible 
from either side of the channel. Furthermore, BKOEtl has a high degree of 
lipophilicity with a calculated value of LogP of 4 (See chapter 6, section 3.2) 
within the theoretical range for a molecule to be able to cross the lipid bilyaer; 
this property could account for the equal onset time observed in both 
electrophysiology configurations.
The most well known and characterised BKcaCO is NS1619. The effect of which 
was delayed in activation on-set time by 1-4 minutes in whole-cell configuration 
(McKay et al 1994; Olesen et al 1994a,b; Edwards et al 1996). In addition, 
NS1619 had a slow response to wash off as well as slow association of the
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drug for the channel in whole cell configuration (Olesen et al 1994b). 
Interestingly rapid activation of channels is apparent in excised membrane 
patches exposed to NS1619 (Olesen et al 1994b; Holland et al 1996). A similar 
observation to that determined for BKOEtl. Holland et al (1996) propose that 
this difference in time to activation may be due to the binding site of NS1619 to 
the channel being intracellular. Therefore, impairment across the membrane 
might be associated with the slow onset of action in whole cell mode. Holland et 
al (1996) suggest that this slow process of activation in whole cell verses inside- 
out is in part due to the availability and quickness of an effective NS1619 
concentration reaching the intracellular side of the cell. Although contradictory 
to this NS1619 has been shown to display high degrees of lipophilicity through 
lipid bi-layers.
A similar observation was made for the indole carboxylate CGS-7181 
developed by Novartis Pharmaceuticals that demonstrated a longer time to 
achieve a stimulatory response in whole cell (>5min) than in excised inside out- 
patch (2 min). In addition, it showed prolonged washout effects in whole cell (15 
min) than in excised out patches (3-5 min). This led the authors to speculate an 
intracellular activating site (Hu et al 1997).
BKOEtl (30 and 100pM) mediated activation of BKca channels in both whole 
cell and excised inside-out patches of BKCa a  cells was completely blocked by 
application of paxilline (10pM). Therefore it could be suggested that the site of 
action of BKOEtl is independent to that of paxilline, this could be confirmed by 
use of 125l-Paxilline binding assay or by further work investigating the kinetics of 
block by paxilline and determining whether BKOEtl affects the association rate 
of the blocker to the channel.
Further work would be required to investigate whether the binding site of 
BKOEtl is located intracellular, transmembrane or extracellular. This could be 
achieved by the use of either cell impermeable analogues of BKOEtl or via 
creation of radioactive or fluorescent labelled BKOEtl which could be used as 
tracer molecules to provide clues as to the site of action.
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5.5.2 The effect of BKOEtl on single BKCa channel properties
BKOEtl when applied to the internal face of the channel increased P0 rapidly 
producing an e-fold increase in P0 per ~5mV change in voltage, which was 
observed with all concentrations of BKOEtl tested. However, this value was 
significantly different to that obtained under control conditions with an ~15mV 
change in voltage per e-fold increase in P0. Therefore, BKOEtl affected the 
voltage sensitivity of the channel. A change in depolarising voltage of between 
10-20mV per e-fold increase in P0 has been reported for BKCa channels 
(Dichiara and Reinhart 1995; Diaz et al 1998; Cui and Aldrich 2000; Niu and 
Magleby 2002; Magleby 2003). Therefore, the voltage dependence of BKca 
channel activation reported here under control conditions (~15mV) falls within 
the range previously determined by others for the voltage dependence of BKca 
channel activation.
In contrast to BKOEtl, NS1619 does not affect the voltage sensitivity of BKca 
channels. Lee et al (1995b) reported that for an ~30mV change in membrane 
potential there was an e-fold increase in P0 and that this was un-affected in the 
presence of NS1619. Furthermore, mallotoxin does not affect the voltage 
dependency compared to that observed under control conditions with a reported 
e-fold increase in P0 per 10.6±0.5mV change in membrane voltage (Wu et al
2007). Further, TBIC has been shown to shift the conductance-voltage curve 
without affecting voltage sensitivity (Ha et al 2006).
The effect of BKOEtl on P0 was more pronounced at more positive voltages 
relative to that obtained under control conditions. This is similar to that observed 
for most BKcaCO’s including BMS-204352 (Gribkoff et al 2001b). Interestingly 
di-CI-DHAA and pimaric acid are the only two reported BKcaCO’s that 
demonstrate inversed potentiation of P0, in that bigger increases in P0 are 
observed relative to control at more negative voltages that become diminished 
at more positive voltages (Imazumi et al 2002; Sakamoto et al 2006).
A relatively quick onset time to activate BKca channels in whole-cell 
electrophysiology was observed for BKOEtl, and this coupled to the rapid 
increase in P0 demonstrated for a small change in voltage is in line with a 1:1 
stoichometry determined for BKOEtl based on Hill slope value.
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Single channel conductance was not altered by incubation with BKOEtl BKca 
channel openers identified to date have not affected the conductance of BKca 
channels. An exception is tamoxifen which has shown to cause a decrease in 
single channel conductance in BKca channels expressing BKca channel a and 
p1 subunits without affecting its ability to increase P0 (Dick et al 2001; Duncan 
2005; Coiret et a /2007).
5.5.3 The effect of Ca2+ on BKOEtl activation of BKCa 
channels
BKOEtl was able to activate BKca channels in the near absence of Ca2+, 
furthermore, its effects were not additive with increasing concentrations of 
intracellular Ca2+ in that BKOEtl was unable to further activate BKca channels 
above the level achieved with 10pM intracellular calcium. A possible 
explanation could be that BKOEtl binds to a site of Ca2+ interaction on the 
channel such as the Ca2+ bowl, RCK domains or other Ca2+ regulatory elements 
located on the channel (Magleby 2003). However, as suggested this is unlikely 
due to the equal affinity and potency observed when the compound is applied to 
either aspect of the channel. Therefore it is likely that the presence of 10pM 
Ca2+ would have opened all the channels and as a result BKOEtl (at the 
concentration used) could not activate the channel further. It would have been 
interesting to have used a higher concentration of BKOEtl (100pM). Although at 
+30mV membrane potential the P0 in 10pM Ca2+ was >0.8 therefore potentially 
not leaving a sufficient window to further increase channel activation.
BKcaCO’s have shown differential activating effects in the presence of Ca2+, for 
example, the openers KB130015 (Gessner et al 2007), tamoxifen (Dick et al
2001), NS1608 (Strobaek et al 1996; Siemer et al 2000), naringenin (Saponara 
et al 2007) and pimaric acid (Imaizumi et al 2002) have shown to activate BKca 
channels in the absence of Ca2+ whereas NS1619 (Lee et al 1995b) and DHS-1 
do not (Knaus et al 1993; Giangiacomo et al 1998). In addition, zonisamide was 
able to activate BKca channels 1.6 fold above that achieved in the presence of 
0.1, 1.0 and 10pM Ca2+ (Huang et al 2007) and NS1619 has been shown to
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activate BKca channels above the level observed in the presence of 10pM Ca2+; 
a feature not observed with BKOEtl (Olesen et al 1994b; Lee et al 1995b)
Furthermore, BMS-204352/MaxiPost demonstrated an additive effect, in that 
with increasing intracellular Ca2+ (across the physiological range) the greater 
the strength of BKca channel activation, this hence led to its subsequent clinical 
development for the treatment of stroke (Gribkoff et al 2001 b).
BKOEtl did not affect the level of intracellular Ca2+ in HEK293 cells, indicating 
that its mechanism of action does not occur secondary to an increase in 
intracellular Ca2+ either by release from stores or via VDCC activation. 
Stimulating channel activation by application of ryanodine and its subsequent 
release of Ca2+ from intracellular stores did lead to a significant increase in 
fluorescence above background, this is in line with previous observations that 
application of ryanodine to HEK293 cells resulted in an increase in Ca2+ 
concentration (of around 0.3-0.5pM), (Querfurth et al 1998). Furthermore, 
depolarising the cell with high K+ Krebs buffer resulted in an initial increase in 
fluorescence related to activation of VDCC and Ca2+ influx that subsequently 
declined over time; this in part could be due to repolarisation of the membrane 
by activation of BKca channels following VDCC channel activation, although 
50mM KCI is a strong depolarising stimulus. Calcium ionophore had the 
greatest effect upon fluorescence producing a 4-fold increase in fluorescence 
this is similar to the observations of Querfurth et al (1998) who demonstrated a 
4-fold increase in Ca2+ fluorescence in FIEK293 cells upon application of 
ionophore.
In this assay NS1619 did not affect the level of intracellular Ca2+, this is in 
contrast to the work of Yamamura et al (2001), who showed that NS1619, in 
porcine coronary smooth muscle cells, released calcium from 
caffeine/ryanodine-sensitive calcium storage sites and this partially contributed 
to activation of BKca channels leading to membrane hyperpolarisation. 
Furthermore, Khulmann et al (2004b) demonstrated that NS1619 induced Fura- 
2 fluorescence could be blocked by inhibition of lns(1,4,5)P3 induced Ca2+ 
release. The potential of NS1619 and BKOEtl to affect the level of intracellular
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calcium may have not been observed in BKca a cell line due to the absence of 
these cellular receptors in HEK293 cells.
A number of compounds, mainly from natural sources, have shown to activate 
BKCa channels indirectly. One such example is the plant steroid diosgenin (3b- 
hydroxyl-5-spirostene) which activated BKca channels as a consequence of 
increases in intracellular calcium resulting from VDCC channel activation (Wang 
et al 2006). Furthermore, Huang et al (2005) determined that the effect of 
thymol (2-isopropyl-5-methylphenol) a compound isolated from the plant oil of 
Thymus Vulgaris (Thyme) only activated BKca channel like diosgenin in cell- 
attached patches and not when applied to the intracellular aspect, they 
concluded that the effects of thymol were probably acting to activate ryanodine 
receptors in these cells.
5.5.4 Rubidium efflux studies: Characterising the effect of BKOEtl
on Rb+ efflux from myocytes
The specificity of BKOEtl to BKca channels was assessed by adapting the non­
radioactive Rb+ efflux assay to screen rat bladder myocytes. From which the 
potential of BKOEtl to activate K+ channels was examined by testing its effects 
on Rb+ efflux in the presence of different K+ channel blockers.
Rat bladder myocytes were chosen as they express a number of different K+ ion 
channel subtypes including BKca (Nakahara et al 2004; Malysz et al 2004), IK 
(Argentieri et al 2006), SK (Nakahara et al 2004), KAtp (Butera et al 2005; 
Argentieri et al 2006) and Kv channels (Ohya et al 2000). The bladder is 
composed of many different types of cell layers including smooth muscle, 
urothelium and fibroblast cells (Andersson and Arner 2004). A protocol for the 
dissociation of myocytes from rat bladder was optimised and to determine that 
the predominate cell types in culture were smooth muscle cells ICC was 
performed.
ICC demonstrated that cells stained positive with smooth muscle actin and not 
for the markers cytokeratin and vimentin. However, epithelial and fibroblast cells
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were not used as positive controls. As a result, the presence of other cell types 
can’t be ruled out completely. However, all cells in the field of view stained for 
smooth muscle a-actin as determined by a direct comparison with the pattern of 
DAPI staining. Therefore, it was likely that a homogenous population of rat 
bladder myocytes were obtained that were used for Rb+ efflux experiments.
Rb+ loading characteristics of myocytes were determined and the number of 
extracellular washes was optimised prior to efflux experiments. Rat bladder 
myocytes, as with BKca c l  cells, showed time dependent Rb+ loading reaching a 
maximum at around 4 hours, this was approximately twice as long (to reach 
peak loading) than in BKca cx cells. Furthermore, the amount of Rb+ loaded was 
approximately four-fold less than that achieved in HEK293 cells. Similar to BKca 
a cells four washes was sufficient to remove all extracellular Rb+
In rat bladder myocytes BKOEtl evoked significant concentration dependent 
increases in Rb+ efflux above control from which EC4o% and Emax values were 
calculated, these values were in line with those determined in BKca c l  cells, 
although there was greater variability in the data obtained from myocytes than 
from BKCa c l  cells.
The Rb+ efflux response from myocytes to BKOEtl was prevented by complete 
K+ channel block with 4-AP and TEA. Therefore, BKOEtl did not induce any 
non-specific Rb+ efflux from cells in that all Rb+ efflux (observed above control) 
can be attributed to K+ channel activation. The assay revealed that BKOEtl 
had a partial effect upon SK and Kv channels as it failed to activate Rb+ efflux 
to maximum levels (within Emax range) in the presence of apamin and 
margatoxin respectively. BKOEtl response was not affected by K a t p  channel 
blocker Glib or the IK channel blocker TRAM-34. BKOEtl mediated increases 
in Rb+ efflux were not completely blocked by pax. Therefore, BKOEtl could 
have ancillary pharmacology with Kv and SK channels. This would require 
further investigation using electrophysiology.
Ancillary pharmacology has been ascribed for numerous different synthetic 
BKcaCO's. For example, as' described previously (Chapter 1) NS1619 and 
NS004 have shown to activate numerous ion channels including CFTR-CI
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channel (Holland et al 1996; Patel et al 1998; Al Nakkash et al 2001). In 
addition, BMS-204352 has shown to have activated KCNQ/Kv7.x (Korsgaard et 
al 2005), di-CI-DHAA shown to suppress VDCC currents (Sakamoto et al 2006) 
and BMS-223131 has shown potent cytochrome P450 activating properties 
(Vrudhula et al 2005).
There has been no previous instance in the literature of using Rb+ efflux as a 
screening assay for K+ channel modulators on primary dissociated cells from a 
tissue. Although more traditional radioactive rubidium (86Rb) efflux assay has 
been used to assess the effect of K+ channel modulation and function from 
whole or tissue strips from aorta (Greenwood and Weston 1993; Linde et al 
1997), skeletal (Lindinger et al 2001) and bladder detrusor muscle (Edwards et 
al 1991; Trivedi et al 1994). In addition a non-radioactive, non- 96-well plate 
format Rb+ efflux assay has been used to asses the function of potassium 
channels in lymphocytes isolated from human blood (Raphael et al 2005). 
Therefore this a novel reporting of applying a medium-throughput 96-well plate 
assay using primary/dissociated cells from tissue to assess the activating 
properties of and the specificity of KCO’s.
5.6 Conclusions
BKOEtl is a novel compound that has shown to potently activate BKca channel 
currents in cloned cell lines expressing BKCa channel subunits and stimulate 
paxilline sensitive Rb+ efflux from rat bladder myocytes. BKOEtl affects the 
voltage sensitivity of BKca channels increasing open pore probability. An exact 
site of interaction remains unknown, although it could potentially act at a site on 
the channel associated with the a-subunit in the transmembrane or intracellular 
part of the channel particularly at a site associated with Ca2+ regulation of the 
channel. Further work with mutated BKCa channel cell lines would be of interest 
and could provide information regarding this question. The properties of 
BKOEtl as a BKcaCO’s are summarised in table 5.2. Molecular modelling 
could provide clues as to the chemical or structural features required for 
BKOEtl to be a BKcaCO (Chapter 6).
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Summary of the Properties of BKOEtl as 
a BKCa channel openers
A low-affinity activator of BKca channels whose effects are reversible upon 
washout and can be blocked with paxilline (Chapter 5.4.1 and 5.4.2).
Increases the voltage sensitivity of BKCa channels and produces large and 
significant shifts of V50 to more hyperpolarising potentials (Chapter 5.4.2).
Increases P0 rapidly for small increases in membrane voltage (Chapter 5.4.2).
Activatation is equally effective when applied to either aspect of the membrane 
with similar apparent affinity and potency (Chapter 5.4.1 and 5.4.2).
Does not affect single channel conductance (Chapter 5.4.3).
Does not affect time to reach peak current or the deactivation time constant as 
determined from whole cell recordings (Chapter 4.4.3).
Activate BKca channels in near absence of Ca2+ and its effects are not additive 
with increasing Ca2+ (Chapter 5.4.4).
Does not activate BKCa channels via a secondary effect by causing increases in 
intracellular Ca2+ or activation of VDCC (Chapter 5.4.5).
Hill slope of unity suggests one binding site per channel complex located on the 
a-subunit with a probable intracellular or transmembrane location (Chapter
5.4.1 and 5.4.2),
In Rb+ efflux assay, the effect of BKOEtl was not affected by co-expression of 
the (31-subunit (Chapter 3.4.2),
Stimulated paxilline sensitive Rb+ efflux from rat bladder myocytes (Chapter 
5.4.5.2).
Rb+ efflux studies identified that BKOEtl may activate Kv and SK channels 
(Chapter 5.4.7.3)
Table 5.2: Summary of the properties of BKOEtl as a BKCaCO
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Chapter 6
Pharmacophore modelling 
of benzanilides and general 
discussion
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6.0 Molecular Modelling
6.1 Introduction
A pharmacophore is defined as an ensemble of steric and electrostatic features 
of different compounds which are necessary to ensure optimal supramolecular 
interactions with a specific biological target structure to trigger or block a 
biological response (Langer and Wolber 2004). Pharmacophore modelling 
provides a powerful tool in the design of pharmaceutical compounds with 
improved potency, selectivity and/or pharmacokinetic properties (Li and Harte 
2002). The introduction of computer aided molecular design in the 
pharmaceutical industry has transformed the discovery and development of new 
classes of drugs. HTS bioassays produce a 0.1% ‘hit' rate; pharmacophore 
modelling has enabled improvement to this figure by providing insight into the 
interactions between a ligand and target using 3D pharmacophores (Langer and 
Wolber 2004).
The determination of 3D pharmacophores is dependent upon on the availability 
of the 3D structure of ligand and target binding site. Further, 3D 
pharmacophores can be built when only the structure of target is known (without 
a ligand interacting) using programs such as LigandScout (Wolber et al 2006; 
•Langer and Wolber 2004). However, if only ligand information is available the 
identification of pharmacophore relies upon the alignment of active molecules to 
identify common structural features and patterns. The Catalyst program by 
Accelrys Inc is the most common program used for this application (Langer and 
Wolber 2004).
Building of 3D pharmacophores for ligand-ion channel interaction is difficult. 
This is in part due to the complexities of ion channel structure and the dynamics 
of the gating process. This deems building realistic models that reflect the effect 
of binding of a ligand to a receptor unrealistic (Li and Harte 2002).
Neuronal sodium channel blockers have received the most investigation in 
terms of structure activity relationship (SAR) studies for ion channels; these
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have been formulated by using data provided by Na+ flux assays or by 
measuring the affinity of peptide blockers for the channel (Li and Harte 2002).
The lack of a protein structure of BKca channels limits the ability to generate 3D 
pharmacophores of ligand-protein interaction. Pharmacophore models have 
been used for data mining and design of combinatorial libraries for ion channel 
interacting compounds for example with the identification of flavanoids as 
BKcaCO’s (Li et al 1997). Further modelling of a series of carbonic anhydrase 
inhibitors has revealed the properties required for them to exhibit BKcaCO 
properties (Tricarico et al 2004).
Using a molecular mechanic approach benzanilides and NS1619 were 
examined for various molecular properties that could be used in determining the 
discriminate ability of certain compounds to activate BKca channels. Further, to 
provide information on suggested pharmacophore features of this series of 
compounds and to use this information to guide the synthesis of further 
compounds.
Molecules were energy minimised and then aligned to identify structural 
differences or commonalitites between them. The pharmacodynamic profiles, 
electrostatic potentials and hydrogen bonding (H-bond) ability were determined. 
Compounds BKPr2-BKPr3-BKPr4 and BKMe1-BKH1-BKOEtl are grouped as 
two sub-series for comparison.
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6.2 Molecular modelling methods
Molecules were built using the molecular modelling package Chem3D Ultra 
version 10 (CambridgeSoft, Cambridge, U.K). The minimum energy 
conformation and most plausible geometry of each compound was searched 
using the AM1 mathematical algorithm method with a closed shell wavefunction 
and a eigenvector following (EF) routine geometry optimiser. This was 
performed in the semi-empirical program, molecular orbital PACkage (MOPAC) 
2002 (CambridgeSoft, Cambridge, U.K). The convergence criterion for the 
energy gradient was <0.1 kcal mol'1 and to stimulate physiological conditions 
optimisation of the geometry was performed in the presence of a 1.4A layer of 
water. All calculations were performed on a Viglen desktop PC.
Energy minimised and geometry optimised molecules, where appropriate, were 
aligned and overlayed. Three sites were chosen as points of alignment and 
included the amide linker and to a point on each ring system. Molecules were 
overlaid using Chem3D ultra 'fast overlay1 algorithm to a 0.01 kcal mol'1 A'2 
gradient and 0.1 RMS error.
For the optimised geometry of each molecule different molecular electronic 
properties were calculated. The Wang-Ford parametric electrostatic potential 
(PMEP) method of MOPAC.was used to calculate the charge distribution 
accross the molecule.
Also with the MOPAC interface the octanol-water partition coefficient (LogP) 
was calculated using the clogP driver. In addition, intramolecular hydrogen 
bonding (H-bond) were searched and their lengths were determined as a 
measure of validity.
Inter-molecular hydrogen bond (H-bond) sites of interaction were determined 
using the theoretical hydrogen-bond donor/acceptor (HBDA) calculator plug-in 
of the Marvin web-tool provided by the Chemaxon Company (Chemaxon, 2007). 
Those moieties available for H-bonding at at pH 7.2 were calculated.
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In addition, this web-tool was also used to calculate theoretical pKa (logarithm 
of acid dissociation constant) values.
Total polar surface area (TPSA) and molecular volume (Van der Waals volume 
A 3) was assessed by use of Molinspiration chemoinformatics web-tool 
(Molinspiration 2007).
Data tables and graphs of selected data were constructed using Graphpad 
Prism 4 and Microsoft word respectively. Data, where appropriate is displayed 
as means±SEM. Pictures of molecules were directly exported from Chemdraw 
Ultra.
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6.3 Results
6.3.1 Energy minimisation and alignment
6.3.1.1 BKPr2, BKPr3 and BKPr4
Alignment of energy minimised molecules BKPr2, BKPr3 and BKPr4 was 
performed to reveal structural differences or commonalities that could be related 
to differences in efficacy of compounds. BKPr3 and BKPr4 were equally 
effective in electrophysiology screening whereas BKP2 was significantly less 
effective (Chapter 4.4.4).
Comparison of structures of the BKPr series indicates that the overall shape of 
these molecules are generally similar particulary with the N-benzyl ring 
alignment. However further examination of the linker region and the N-phenyl 
ring reveal structural differences that could account for the decreased efficacy 
of BKPr2 (Figure 6.1).
The NH group of the amide linker of BKPr2, BKPr3 and BKPr4 could act as a 
potential H-bond donor site. The overlay revealed a similar location of this group 
therefore differences in efficacy between the compounds cannot be attributed to 
the location of this H-bond site (Figure 6.1; Table 6.2). The carbonyl group of 
the amide linker could act as an H-bond acceptor site for compounds BKPr2, 
BKPr3 and BKPr4. The overlay for this group (Figure 6.1) showed that the 
carbonyl group was orientated differently with each compound and so its 
positioning is less critical for BKcaCO properties (Figure 6.1).
The nitrogen atom of the pyridine ring is positioned differently between the BKPr 
series (Figure 6.1) with BKPr2 the pyridine nitrogen is located closer to the 
amide NH group of the linker (2.4 A) compared to that of BKPr3 (3.8 A) and 
BKPr4 (4.2 A) which are located towards the end of the ring. Therefore, with 
BKPr3 and BKPr4 it could allow an interaction with a H-bonding amino acid in 
the BKCa channel protein. The closeness of the pyridine nitrogen of BKPr2 to 
the amide NH of the linker could promote an interaction so that the NH group 
would appear less available for hydrogen bond interaction and thus affect the H- 
bonding ability of the amide linker. There factors may account for the decreased 
efficacy observed for BKPr2.
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a) Energy minimisation and alignment of BKPr series
BKPr4
BKPr3
BKPr2
N-benzyl ring Amide linker N-phenyl ring
a) Expanded view of the linker b) Expanded view of the N-phenyl ring
f  Similar positioning of
'  NH group for all BKPr
Spacing of carbonyl compounds
groups
Pr2
Amide NH
Pyridine N located 
at end of molecule
Figure 6.1: Overlaying of molecules BKPr2, BKPr3 and BKPr4
(a) Molecules were built and energy minimised using Chem3D Ultra with 
MOPAC and overlaid using ‘fast overlay’ algorithm. Also shown are expanded 
areas of the amide linker (b) and the N-phenyl ring (c, hydrogen atoms are not 
shown for clarity) to highlight structural differences. Nitrogen atoms are 
highlighted in blue and oxygen atoms in red.
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6.3.1.2 BKH1, BKMel and BKOEtl
BKOEtl was the most effective benzanilide tested and was 2-fold more 
effective than any other compound tested in this series. To assess whether any 
structural differences between BKOEtl, BKH1 and BKMel could account for 
differences in efficacy, energy minimisation using MOPAC and alignment of 
these molecules using ‘fast overlay’ algorithm (Figure 6.2) was performed.
All three compounds share an overall similar shape. The major difference in the 
conformation of these compounds is the extension of an ethoxy group on the 
benzyl ring of BKOEtl.
All three compounds in this series display a site for intramolecular H-bonding 
provided by the hydroxyl group of the N-phenyl ring and the amide NH of the 
linker (Table 6.2). In BKOEtl a second site of potential intramolecular H- 
bonding can form between the oxygen of the ethoxy group and the amide NH of 
the linker. However, the oxygen atom of the ethoxy moiety is located in the 
same position as the methyl or hydrogen of BKMel and BKH1 respectively 
(Figure 6.2). Consequently, the overall shape of these three molecules at the 
benzyl ring suggested that the second intramolecular H-bond of BKOEtl may 
not be important in the shape or positioning of an ethoxy group.
However, examination of the electrostatic potential profiles demonstrated that 
the presence of the ethoxy oxygen increases the region of negative charge 
compared to BKH1 and BKMel that may account for a stronger association of 
BKOEtl with an area of positive charge on the channel (Figure 6.5). In addition, 
the presence of the ethoxy oxygen could provide an H-bond acceptor site. 
Therefore the presence of an oxygen group could be important for an 
electrostatic or H-bond interaction with the channel that is absent in BKH1 and 
BKMel (Table 6.2).
In addition to the oxygen atom the extension of an ethyl group (CH2CH3) on this 
structure seems to be important for improved efficacy. This contributes by 
increasing the cLogP value of BKOEtl and hence hydrophobicity compared to 
BKH1 and BKMel (Figure 6.4c). This may increase the transport of compound 
(if required) to a potential receptor site within the transmembrane region of the
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channel. From electrophysiology studies (Chapter 5) it was proposed that the 
site of action of BKOEtl could be within the transmembrane region of the 
channel. To test whether the oxygen or increased hydrophobicity is important 
to this pharmacophore compounds bearing either ethyl or propyl or with 
methoxy or propoxy would provide evidence to which feature is important.
Extension of an ethyl group of BKOEtl
Methyl group of BKH1
Ethoxy oxygen atom of BKOEtl
Hydroxyl group 
/
N-benzyl ring Amide linker N-phenyl ring
Figure 6.2: Overlaying of molecules BKH1, BKMel and BKOEtl
BKFI1 (pink), BKMel (blue) and BKOEtl (orange) molecules were built and 
energy minimised using Chem3D Ultra with MOPAC and overlaid using ‘fast 
overlay’ algorithm. Nitrogen atoms are highlighted in blue and oxygen atoms in 
red.
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6.3.1.3 BKOEtl vs NS1619
An overlay of BKOEtl and NS1619 (Figure 6.3) was performed to determine if 
any commonalities or differences exist in the alignment of these two compounds 
that could account for similarities and differences in BKcaCO properties 
determined for these compounds.
A good overlap in the N-phenyl ring is observed and indicated an essential 
requirement for a hydroxyl with a halogenated group in the para position for 
both these compounds to display BKcaCO properties (Figure 6.3). In contrast 
the N-benzyl ring of BKOEtl has a dissimilar structure and conformation to 
NS1619.
The mechanism of BKca channel activation by BKOEtl is different to NS1619 as 
this reference BKcaCO has different channel activation properties to BKOEtl. It 
was demonstrated that BKOEtl affects the channels voltage-sensitivity 
(Chapter 5) whereas NS1619 has been shown not to demonstrate this property 
(Lee et al 1995b). In addition, NS1619 had different affects on 
activation/deactivation kinetics of the channel compared to BKOEtl assessed 
using whole cell electrophysiology (Chapter 4).
The similarity in the N-phenyl ring may form a ‘molecular region’ that could be 
important in affinity and/or specificity of these compounds to a receptor site on 
the channel. This is supported by experimental data in that BKOEtl has a 
similar potency, affinity and co-operativity in activation to NS1619. In addition, 
both compounds activate the compound equally effectively when applied to 
either aspect of the channel with similar onset times. Furthermore, both 
compounds have similar cLogP values (Figure 6.4c).
Therefore, a similar N-phenyl ring arrangement could confer a similar receptor 
site on the channel for both compounds but with BKOEtl activating the channel 
via a different mechanism to NS1619. The difference in the mechanism of 
activation could be attributed to the structural differences in the benzyl ring 
(Figure 6.3).
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Side view
of
N-benzyl ring linker N-phenyl ring
Flipped view (horizontal by 180°)
Ethoxy group of
BKOEtl Hydroxyl groups of NS1619 and BKOEtl
5’-CF3 groups of 
NS1619
Cl group 
BKOEtl
The N-phenyl ring 
of both
compounds is 
located in a similar 
spatial location. 
Both rings could 
interact with the 
channel at a 
similar site.
The benzimidazolone ring (grey) of NS1619 and the linker and 
N-benzyl ring of BKOEtl (orange) have different orientations 
and occupy different spaces relative to each other
Figure 6.3: Alignment of NS1619 and BKOEtl
NS1619 (grey) and BKOEtl (orange) molecules were built and energy 
minimised using Chem3D Ultra with MOPAC and overlaid using ‘fast overlay’ 
algorithm. Shown are the side view orientations. Fluorine atoms are highlighted 
in green, chlorine in yellow, oxygen is red and nitrogen atoms are blue.
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6.3.2 Physiochemical properties
The effect of different physiochemical properties such as cLogP, total polar 
surface area (TPSA) and molecular volume (Van der Waals volume) was 
determined for each benzanilide and NS1619 and correlated with efficacy. 
Efficacy was defined as the shift in V50 from control of the G-V curve in the 
presence of each benzanilide (30pM), (Chapter 4, section 4.4).
Total polar surface area (TPSA) is a measure of the sum of surface 
contributions of all polar atoms in the molecule and has been shown to be a 
useful measure in drug transport properties. A TPSA of >140 A2 are molecules 
with poor membrane penetration and compounds with a TPSA <60 A2 are 
required for blood brain penetration (Ertl et al 2000). TPSA values were within a 
narrow range with values for benzanilides (except B KW ) and NS1619 between 
50-60 A2 and consequently there was no correlation with efficacy. However, a 
high value of TPSA was not favourable for increased BKcaCO properties as 
B K W  (95.2 A2) was less effective.
Lipophilicity is a major determinant in the biological activity of certain drugs a 
measure of this is the partition coefficient (logP) which is a ratio of compound in 
aqueous phase to the concentration in an immiscible solvent (neutral molecule), 
(Mannhold and Van de Waterbeemd 2001). This was calculated using cLogP 
program using Chem3D Ultra 10 which is a fragmentation system that 
generates theoretical values based on octanol/water partition coefficient 
(Mannhold and Van de Waterbeemd 2001). LogP values provide information of 
compounds ability to be formulated, dosing and sites of optimal penetration 
within the body. Medium values of logP, in the range of 2.5 to 3.5, were 
calculated for the least potent benzanilides; interestingly the most lipophilic 
compounds were the most potent. BKOEtl and NS1619 demonstrated high 
values of clogP (4-5). Therefore, the ability of benzanilides to be available to 
activate BKca channels could be due to the relative differences in lipophilicity.
Molecular volume (Van der Waals volume) is the volume of the union of 
overlapping spheres generated from the Van der Waals radii for each atom of a 
molecule. This is employed as a measure of molecular similarity between 
molecules and is used to help understand the steric requirements of a receptor
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site to a particular ligand. The strongest correlation between BKcaCO’s and 
activity was observed with molecular volume. This suggested that molecular 
size is a key determinant for activity of benzanilides. BKOEtl had a similar 
molecular volume (250.7 A 3) to NS1619 (259.4 A 3) whether this size is 
important for access to and occupation of the same site for both molecules on 
the receptor is unknown.
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Figure 6.4: The physiochemical properties of benzanilides
The efficacy was determined as the shift in V50 relative to control for each 
compound (at 30pM) from WCR. This was correlated with either molecular volume 
(a), total polar surface area (TPSA) (b) or cLogP (c) determined using either 
ChemDraw 3D or for molecular volume using Molinspiration chemoinformatics web- 
tool. Data expressed as means±SEM. Data points were fitted by linear regression 
(y= mx + C) analysis, r2 values are displayed.
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6.3.3 pKa determination
pKa (logarithm of acid dissociation constant) values were determined to indicate 
whether compounds could act on intracellular sites as ionised molecules are 
less able to cross biological membranes compared to non-ionised compounds. 
Therefore, pKa was examined for benzanilides. Although a variety of pKa 
values were determined there was no correlation between pKa and BKcaCO 
ability. For example BKH1, BKMel and BKOEtl had the same pKa values. 
NS1619 had a similar pKa value in the range of that for BKOEtl, BKH1 and 
BKMel. Although there was more variability in pKa for compounds BKPr2, 
BKPr3 and BKPr4 with BKPr2 from this series having a much lower pKa value. 
However at pH 7.4, the value for the physiological buffers used in 
electrophysiology, all compounds (except BKW ) had the same degree of 
ionisation. Therefore, most compounds exist as neutral molecules and would be 
available for H-bond interaction with the channel and they could transverse 
biological membranes. Interestingly, B K W  at pH 7.4 was much more ionised 
(51.81%); this may afford an ionic or dipole-dipole interaction with the channel.
NS1619 8.3111.74 7.25
BKPr2 9.83a 0.24
BKPr3 9.80a 1.17
BKPr4 10.20a 1.26
BKH1 8.22a11.54b 8.73
BKMel 8.20a11.66b 8.70
BKOEtl 8.20a11.13b ' 9.00
B K W 7.17a 9.70b 51.81
Table 6.1: pKa values determined for benzanilides and NS1619 and the % 
ionisation of compounds at pH 7.4
a= pKa values for phenol; OH ^  O' + H+
b= pKa values for amide; N+H2 — NH + H
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6.3.4 Hydrogen bonding properties of benzanilides
The number of potential H-bond donor and acceptor sites on the compounds 
was determined (Table 6.2). The locations of intramolecular H-bond were 
examined and distances were determined as a measure of validity in the 
strength of bonding. An intramolecular hydrogen bond has a typical distance of 
between 1.8 A to 3.5 A. Intermolecular H-bond distances for benzanilides were 
between 2.2 to 2.3 A. Jeffrey (1997) describes H-bonds with donor-acceptor 
distances of 2.2 to 2.5 A as strong, mostly covalent interaction, and therefore 
this can be applied to all H-bonds measured. The most active compounds; 
NS1619 (10 sites), BKOEtl (6 sites) and B K W  (6 sites) have more sites of 
potential H-bond interaction than other benzanilides (<5 H-bond sites). BKOEtl 
compared to BKH1 and BKMel has one additional H-bond acceptor site 
provided by the ethoxy group.
NS1619 OH to C=0(2.2A) OH and NH C=0, O-H & 2x (CF3)
BKPr2 NH O-CH3 , C=0, -CI& Not pyridine
BKPr3 NH to O-CHa(2.3A) NH
O-CH3 , C=0, -Cl & 
N of pyridine
BKPr4 NH to 0-CH3
(2.3 A)
NH 0-CH3,C=0, -Cl & N of pyridine
BKH1 NH to OH
(2.3 A)
OH and NH C=0, O-H & -Cl
BKMel NH to OH{2.2k) OH and NH C=0, O-H & -Cl
BKOEtl
NH  tn D H
(2.3A)
N H tn O -F t
(2.2k)
OH and NH C=0, O-H, -Cl & O-Et
BKW OH and NH C=0, O-H & 2x(N-0)
Table 6.2: Hydrogen bonding properties of benzanilides
BKPr2, BKPr3 and BKPr4 have the same number of H-bond donors and 
acceptor sites therefore this is not a distinguishing feature for differences in 
efficacy. However, as regards intramolecular H-bonds, BKPr3 and BKPr4 have 
one intramolecular H-bond site where as BKPr2 does not display an interaction.
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6.3.5 Molecular electrostatic potential profiles
The electrostatic profile of NS1619 demonstrated three distinct negatively 
charged areas, Two are formed from the CF3 groups and a third larger region 
formed from the carbonyl oxygen of the benzimidazolone ring and the hydroxyl 
group of the N-phenyl ring (Figure 6.5). This observation has previously been 
determined for NS1619 (Tricarico et al 2004; Calderone et al 2007).
Common to all the benzanilides is a large region of negative charge. For the 
BKPr series it is formed between the carbonyl oxygen of the amide linker and 
the oxygen of the methoxy group. In addition, for BKH1, BKMel and BKOEtl 
the region is formed between the amide linker and the hydroxyl group of the N- 
phenyl ring. In addition, B K W  has one large area of negative charge that 
envelopes over the amide linker and the nitro group. Therefore an area of 
negative charge may be a fundamental requirement for compounds to display 
BKcaCO properties.
In total BKH1, BKMel and BKOEtl display two regions of negative charge. 
However, comparable to NS1619; BKPr2, BKPr3 and BKPr4 display three 
distinct negative charge regions. One as described above and a second 
associated with the chlorine and a third area whose location is dependent upon 
the positioning of the pyridine nitrogen. For BKPr2 this charged region occurs 
nearer to the amide NH group than in BKPr3 and BKPr4 and as suggested this 
charged area could affect the electronic properties of the amide NH. Due to the 
commonalities and differences in the electrostatic profiles between the BKPr 
compounds and NS1619 It would be of interest to perform further 
electrophysiological studies to evaluate whether these compounds activate the 
channel with similar or distinct properties to either BKOEtl or NS1619.
BKH1, BKMel and BKOEtl display a similar negative electrostatic potential 
profile across the molecules. However, BKOEtl provides an extension of bulky 
non-polar ethoxy group in ortho position of the ring that occupies an empty 
space. This could promote a favourable interaction with hydrophobic residues 
on receptor site of channel. This compared to an absence of this moiety with the 
less effective BKH1 and BKMel. Therefore, BKOEtl has a bulky non-polar 
group essential for interaction (Figure 6.5). The addition of bulky non-polar
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group could be required for hydrophobic interaction with a receptor site on the 
channel or it could promote an increase in molecular volume that is required for 
optimum fit to receptor site. The addition of ethoxy group could induce an 
increase in logP and lipophilicity thus enabling easier access to the receptor site 
compared to BKH1 and BKMel which are less lipophilic.
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6.4 A confirmatory pharmacophore for benzanilides?
A generalised pharmacophore pattern has been previously proposed that could 
form the basis to guide the design of new molecules demonstrating BKcaCO 
properties as discussed in chapter 1, section 14 (Figure 1.26). This pattern is 
represented by two multiple substituted phenyl rings an ‘A ’ and ‘B’ ring, that are 
structurally attached by a linker region (Coughlan et al 2001; Calderone et al 
2005a,b; Nardi et a /2007).
Benzanilides share a similar pattern to this generalised pharmacophore 
template and represent the first group of compounds to be reported that are 
separated by an amide linker introducing a three bond spacer between two 
phenyl rings.
The presence of hydroxyl groups has been shown to be important in the design 
of many BKcaCO’s including benzimidazolones (Meanwell et al 1996), 
triazolones (Romine et al 2002) and oxadiazolones (Hewawasam et al 2003). 
Further, a carboxylic acid group is also a feature for a number of different 
BKcaCO's including acrylamides (Lennox et al, Wyeth 1999; Lennox et al, 
Wyeth, 2000), fenamates (Ottolia and Toro 1994; Wu et al 2001) and 
benzofuroindoles (Butera et al 2001; Ha et al 2006), positioned homologous to 
the hydroxyl group of the benzimidazolones. Whether the whole carboxylic acid 
moiety, the hydroxyl group or oxygen atoms are important remains unknown. 
However, other BKcaCO’s including flavanoids and phenols rely upon the 
presence of hydroxyl groups for activity.
For benzimidazolones it was proposed that the phenolic OH and carbonyl 
oxygen could act as a mimic of a carboxylic acid (Meanwell et al 1996; Li et al 
1997). Further, the amide hydrogen and amide carbonyl could also act as a 
surrogate carboxylic acid. These were essential features for BKcaCO properties 
of the benzimidazolones (Meanwell et al 1996). The benzanilides; BKH1, 
BKMel, BKOEtl and B K W  have an oxygen containing group provided by a 
hydroxyl or methoxy group that occupies a similar position to the hydroxyl group 
of the benzimidazolones. It is unlikely that the hydroxyl and the carbonyl group
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of the benzanilides would act as a mimic of a carboxylic acid due to the distance 
of separation. Furthermore, the NH and carbonyl group within the linker could 
not mimic a carboxylic acid due to the orientation of these groups relative to 
each other.
Modelling studies for triazole compounds revealed that the relationship between 
the carbonyl group and the phenol was not important for BKcaCO activating 
properties. However, the relationship and distance between the oxygen of 
phenol and the amide hydrogen of the triazole ring was important (Romine et al 
2002). This observation can be made for benzanilides as the presence of an NH 
group in relation to an oxygen containing moiety on the ‘A ’ ring was important 
for the introduction of an intramolecular H-bond.
In addition removal of NH from triazoles while retaining the carbonyl group led 
to inactive compounds; therefore a H-bond donor or protonated N in the 
heterocycle was thought to be essential for these compounds (Romine et al
2002). The presence of this intramolecular H-bond was a feature present for all 
benzanilides; BKPr2 lacked this feature and consequently was the least 
effective benzanilide. This could be verified by synthesising a BKOEtl 
compound without an NH group in the linker, and this would help elucidate the 
importance of an NH proton donating group in the linker region.
It has also been suggested that the amide NH of benzimidazolones acts as a 
weak acid and that this acidity is increased by the attachment of EWG to the 
heterocyclic nucleus (Li et al 1997). Li et al (2003) determined that addition of 
halogens to bisphenols increased the acidity of the hydroxyl groups and those 
with a pKa value of less than 8 were the most active BKcaCO’s. However there 
was no correlation between pKa determined for the benzanilides and their 
effectiveness as BKca channel openers.
The compounds BKPr2, BKPr3 and BKPr4 have a methoxy in place of a 
hydroxyl group in a comparable location with NS1619 and the other 
benzanilides. The similarity in efficacy between BKH1, BKM el, and the BKPr 
series revealed that the hydroxyl function may not be important for activation 
properties. Substitution of hydroxyl groups with methoxy groups has been
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shown to retain BKcaCO activity, for example with Maxipost (Gribkoff et al 
2001a), 3-aryloxindoles (Hewawasam et al 1997) and triazoles (Biagi et al
2000). The presence of an oxygen containing moiety at this position introduced 
an intramolecular H-bond site which is found as a feature in all benzanilides 
except BKPr2 which was the least effective. Therefore, the presence of this 
intramolecular H-bond is a favourable feature for BKcaCO properties of 
benzanilides.
Another common feature for BKcaCO is the presence of a halogen group in the 
para position to the OH or methoxy function. All benzanilides (except BKW) 
had Cl atom in the para position to the respective function. However, B KW  
displayed similar efficacy without Cl in para position to hydroxyl group therefore 
halogenations of this ring are probably less important than the hydroxyl or 
methoxy function.
Alignment of BKOEtl and NS1619 showed that there was a degree of overlap 
between the N-chlorophenol moiety of BKOEtl and the trifluoromethyl-phenol of 
NS1619. For both compounds this ‘A ’ ring adopted a planar conformation. 
However, there was more flexibility in ‘B’ ring of BKOEtl than NS1619 which 
adopted a co-planar alignment across the whole molecule.
Examination of the ‘B’ rings of BKOEtl and NS1619 revealed significant 
differences in structure between the two molecules. Whether this can account 
for differences in mechanism of action of these compounds remains unknown. 
However, it does open up the structure of BKOEtl and induce more flexibility.
Investigation of structural similarity between benzofuroindole and acrylamides 
by over-lapping of the two structures revealed that the right hand side of the 
overlap demonstrated good overlay with a common polar feature. In contrast, 
the left hand side of the rings demonstrated poor overlap showing that these 
structures had tolerance to different types of subsituents in this side of the 
molecule; this led to pharmacophore probing of these compounds (Nardi et al 
2006; Nardi et al 2007)
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For benzanilides the positioning of an ethoxy group (as with BKOEtl) on the ‘B’ 
ring increased hydrophobicity of the molecule and significantly increased its 
efficacy. Further probing of this ring with other hydrophobic residues such as 
trifluoromethyl, methoxy, propoxy or the addition of benzyl/phenyl rings could 
help to further probe the pharmacophore of benzanildes.
The ethoxy group of BKOEtl does not have steric effects on the molecule as it 
retains the same shape as BKH1 and BKMel. Further it does not affect the 
electronic properties of this ring and the molecules as all three compounds 
share similar negative electrostatic potential profiles. Flowever, the ethoxy 
moiety does increase molecular volume and projects out hydrophobic residues 
to occupy a space not observed with BKH1 and BKMel.
The addition of non-polar or hydrophobic groups to the ‘B’ ring such as methyl 
or benzene rings has shown to increase potency and efficacy. For example, 
Ohwada et al (2003) determined for DFIAA derivatives that the addition of 
hydrophobic groups increased potency and efficacy of the template molecule. 
Moreover, studies from the same researchers revealed that small differences in 
the extension and direction of hydrophobic residues at C13 of PiMA derivatives 
was important for activity and that these groups bind to a common hydrophobic 
site of the a-subunit. Further, examination of tamoxifen derivatives has shown 
that addition of hydrophobic groups is critical for activity (Sha et al 2005). 
Moreover, the addition of hydrophobic groups has shown to increase potency of 
triazolyl -benzotriazoles and -benzimidazolones (Baragatti et al 2000; Biagi et al
2001) and hydroxyalkyl quinolin-2-ones/BMS223131 (Flewawasam et al 2003).
The addition of non-polar groups to BKCaCO molecules could have potential 
steric or electronic effects on the molecule; this has been suggested previously 
for the addition of halogens and hydrophobic groups to phenyl rings of different 
classes of BKcaCO’s including triazoles (Calderone et al 2005b) and 2-amino-4- 
azaindoles (Turner et al 2003) but the effects of these subsituents have not 
been modelled. In addition, Ottolia and Toro (1994) proposed that the 
fenamates (niflumic and flufenamic acid) bind to a receptor confined to a 
hydrophobic pocket within the cytosolic side of the channel.
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. Duncan (2005) proposed that due to the lipophilic nature of tamoxifen that it 
could result in channel activation via mechanical stresses it exerts on the 
membrane bilayer rather than directly binding and activating the channel. 
Further a similar feature has been shown to occur with cholesterol in that 
increases in membrane content of cholesterol caused a decrease in BKca single 
channel conductance and mean open time (Chang et al 1995). Therefore, 
lipophilic drugs such as the benzanilides may activate the BKca channel through 
indirect non-specific effects on the properties of the lipid bilayer.
The pKa values determined revealed that the benzanilides remain in neutral 
form in the pH of buffers used, therefore this coupled to the relatively high clogP 
values determined indicated that the benzanilides could readily cross the 
plasma membrane. This supports the finding that BKOEtl activated, in 
electrophysiology, the channel with apparent equal affinity when applied to 
either aspect, so could be concluded that there is a site located in the 
transmembrane region of the channel.
Further examination of the allosteric sites of interaction on the a-subunit in 
addition to investigating differential effects in different tissues needs to be 
investigated to identify specificity of BKOEtl. Further exploration of this could 
be achieved by expressing mutant BKCa channel a-subunits and using Rb+ 
efflux assay as a screening tool to assess differences in potency, and efficacy.
Slight differences in the structure of BKPr2, BKPr3 and BKPr4 had pronounced 
effects on channel activation. This is a common feature for BKcaCO as minor 
variations and structural isomer of PiMA (Imaizumi et al 2002), ketoconazole 
derivatives (Power et al 2004) and thymol (Huang et al 2005) have shown to 
have marked effects on the compounds ability to activate the channel. Further, 
alterations to template structures can also switch specificity of compounds as 
displayed by 3-fluorooxindoles (BKca to Kv7), (Korsgaard et al 2005) and 
acrylamides (BKca to KCNQ), cyclobut-3-ene-1,2,-diones ( K a t p  to BKca), 
(Butera et al 2005) and tetraycle compounds ( K At p  to BKca) , (Butera et al 2001).
Therefore, caution should be taken when making changes to the template 
structures of benzanilides as small changes in addition to having beneficial
250
effects on increasing efficacy can also switch specificity. The effect of BKOEtl, 
when tested on rat bladder myocytes was sensitive to the SK and Kv channel 
blockers apamin and margatoxin. Genetically and to a certain extent 
functionally BKca channels in some aspects are closer to Kv channels rather 
than KCNN (SK and IK) channels in particular due to the presence of the 
voltage-sensor domain (Vergara et al 1998). Therefore, as BKOEtl has a 
predicted transmembrane binding site and interacts with the channel to increase 
voltage sensitivity then examination of the Kv channel activating properties of 
BKOEtl would be useful.
Unlike that reported for other BKca channel openers some compounds of the 
benzanilide series including BKPr2, BKPr3, BKPr4, and BKH1 displayed 
specificity to BKCa channels expressing BKca oc subunit only. These compounds 
could form the basis of a pharmacophore for investigating agents with 
differential selectivity profiles.
Benzanilides display particular physiochemical properties, for example the most 
effective benzanilides (and NS1619) had a molecular volume >240A3 and a 
clogP value of >4.0 with a 50-60 A2 range in TPSA. In addition, the presence of 
at least one intramolecular H-bond site seems to be a requirement for all 
compounds. Further, two intramolecular H-bond sites was also tolerated and 
could improve efficacy as with BKOEtl (two sites) compared to BKH1 and 
BKMel (one site). This series of benzanilides contained at least five sites of H- 
bond interaction the importance of which remains undetermined but it seems at 
least two H-bond donor sites are required. Therefore, these factors are key to 
consider in the design of BKcaCO’s based on a benzanilide template.
All benzanilides tested fall under the requirements of Lipinski's rule of five which 
are molecular properties important for drugs to display suitable pharmacokinetic 
properties in-vivo and include no more than 5 H-bond donors, 10 H-bond 
acceptors and a molecular weight not greater than 500 or clogP greater than 5 
(Lipinski e ta l  2001).
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Therefore the properties of this series of benzanilides confirm some of the 
pharmacophore properties suggested for other reported BKcaCO’s. To retain 
potent BKcaCO properties compounds require two substituted phenyl rings, the 
presence of an oxygen containing group, an amide group provided by the linker 
region and hydrophobic moieties. Further refinement of the generalised 
pharmacophore model can be achieved by proposing a confirmatory 
pharmacophore based on the results presented here for the benzanilides 
(Figure 6.6).
The 2’ acidic function is thought to either impart an H-bond donor site with the 
channel. In addition, the ionic form of this group such as with the hydroxyl 
subsituent (O') could promote a dipole interaction with the channel. 
Replacement of an acidic moiety with a methyoxy group is also tolerated but in 
certain compounds resulted in less active openers. Whether these 
discrepancies are due to the steric ‘bulk’ effect on the compound or whether it 
affects the type of interaction with the linker region or the affinity to the channel 
remain un-resolved.
It can be concluded that the TV ring and the linker region could act as the 
‘molecular region’ that is important for binding, affinity and apparent specificity 
of molecules to BKca channels. Where as the ‘B’ ring is important for the 
activation properties of compounds. Further that the subsituents of the ‘B’ ring 
could also affect the transport properties of drugs across the membrane. In 
addition, the composition of the ‘B’ ring could affect the steric conformation of 
the molecule affecting the type of interaction and mechanism of activation of the 
channel.
Synthetic molecules that open BKca channels offer a novel therapeutic 
approach for controlling cellular excitability. The benzanilides studied could 
provide potential therapeutics for un-met clinical conditions and be useful in the 
understanding of the structure and physiological functions of BKca channels.
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